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Mitotic division. I to III, prophase; IV, metaphase; V and VI, anaphase; VII and VIII, telophase. 
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Glossary 
Germline mutation 
Mutation that is present in the sperm or egg cell and is inherited to the 
offspring, who will then have the mutation in all the cells of its 
organism. 
Somatic mutation 
Mutation that occurs in a somatic cell in an organism, that is any cell of 
the organism other than the gametes. Somatic mutations are not 
inherited to the offspring. 
Postzygotic mutation 
Mutation that arises in a cell of an organism in the first few cell 
divisions after fertilization. 
Mosaicism 
Presence of more than one genetically distinct cell line in a single 
organism deriving from one zygote. 
Chimerism 
Presence of more than one genetically distinct cell lines in an organism 
deriving from different zygotes. 
Primordial germ cell 
Cell set aside early in embryogenesis that serves as a progenitor to the 
germ cells which eventually give rise to the sperm or egg cell. 
Germ layer 
Layer of cells formed during embryonic development by gastrulation. 
Vertebrate embryos have three germ layers: ectoderm, mesoderm and 
endoderm. 
Germline mosaicism 
Presence of mosaicism in the gonads, with some germ cells having a 
mutation while others do not. 
Somatic mosaicism 
Presence of mosaicism in an organism, excluding the gonads. Some 
cells in the organism have a mutation, while others do not. 
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DNA holds information that is essential for life  
Every living organism on Earth carries in each of its cells the genetic 
information needed for its development, growth and maintenance.1 In humans, 
this information is stored in the form of deoxyribonucleic acid (DNA), which 
provides cells with the instructions needed to produce all the building blocks 
necessary for life. Additionally, DNA allows for genetic information to be 
transmitted from a cell to its daughter cells, but also from an organism on to its 
progeny. 
DNA is composed by long chains of nucleotides which consist of a sugar 
molecule and one of four bases: adenine (A), cytosine (C), guanine (G) or 
thymidine (T). DNA is most often found in the form of a double helix, which results 
from the binding of two nucleotide chains to one another.2 Nucleotides are 
complementary and pair in only two ways: A with T and C with G.3 Base-pair 
complementarity implies that the sequence of nucleotides in a single strand of 
DNA is sufficient to copy and transmit all genetic information. DNA can be 
replicated by separating a double stranded molecule of DNA and using each 
strand as a template to which complementary base pairs are added by a DNA 
polymerase to form a second strand of DNA.2,4 Based on the sequence of the 
nucleotides in each strand, DNA encodes the genetic information that serves as 
the template to make proteins.5 
A genome is the complete set of genetic information of an organism, 
including both nuclear or genomic DNA (gDNA) and mitochondrial DNA. In 
humans, each cell contains approximately 6 billion base pairs of gDNA (6x109 bp), 
which would equal roughly 3 meters long if extended.6 However, gDNA is tightly 
packaged by wrapping itself around proteins to form chromatin (Figure 1), which 
is then stacked and compacted to form chromosomes.7 Humans have 46 
chromosomes forming two sets of 23 chromosomes, of which one pair 
corresponds to sex chromosomes that differ between the sexes: XX in women and 
XY in men. In contrast, the remaining 22 pairs, also called the autosomes, are 
present regardless of the sex. Almost all cells in the human body are diploid: they 
contain two sets of 23 chromosomes in their nucleus of which one set is inherited 
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from the mother and one from the father. Germ cells, such as the sperm or egg 
cells, are an exception as they have a single set of chromosomes and are therefore 
haploid.  
 
The central dogma of molecular biology: DNA to RNA to protein 
Chromosomes contain genes, which are segments of gDNA with genetic 
instructions to make a functional RNA molecule or a protein. As of 2016, the 
human genome is estimated to contain approximately 20,000 protein-coding 
genes, accounting only for 1% of the human genome.6 Base-pair 
complementarity is also fundamental for the expression of information contained 
in DNA. Gene expression begins with the separation of double stranded DNA in 
two strands, one of which is then used as a template for the addition of 
nucleotides by an RNA polymerase to form messenger RNA (mRNA).8 This process 
of forming an mRNA molecule by copying a gene is termed RNA transcription and 
is similar to DNA replication, except that thymine is replaced with uracil, which 
also pairs with adenine. The mRNA transcript is then processed by the splicing 
machinery in the cell nucleus to remove the introns, which are regions of a gene 
that are transcribed from DNA into mRNA but are not included in the mature 
mRNA. The exons, which are the regions of a gene remaining after splicing, are 
then joined to form mature mRNA.1 
Mature mRNA is exported from the nucleus to the cytoplasm or to the 
membrane of the rough endoplasmic reticulum, where the sequence of 
nucleotides is read and translated into protein by the ribosome. The genetic code 
is the basis for translation of the mRNA transcript into protein; each codon, or 
combination of three successive nucleotides, encodes for one of 20 different 
amino acids or for one of three signals to stop translation of the mRNA into 
protein (stop codon).1 RNA consists of four different nucleotides (A, C, G and U) 
which give rise to 64 different codons. Transcripts are read by dividing the 
sequence of DNA into triplets of nucleotides which match one of the 64 codons. 
Any transcript can be read in three different frames, beginning from each of the 
three nucleotides composing a triplet. Usually, only one reading frame leads to 
the correct production of a protein (the open reading frame). Since there are only 
20 different amino acids, there is redundancy in the genetic code and different 
codons can code for the same amino acid (synonymous codons). The transcript is 
therefore read one codon at a time, deciphered and the corresponding amino 
acid is incorporated into the protein before moving on to the next codon. 
Different amino acids have distinct chemical properties and the interaction 
between the side chains of a sequence of amino acids within a protein determines 
how the translated protein folds to form protein secondary structures, such as 
alpha helixes and beta sheets. Proteins then fold into a three dimensional 
structure which is necessary for its correct function.9 Proteins can be modified by  
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Figure 1. Depiction of a cell and multiple DNA structures. DNA is formed by four base pairs (A, C, G 
and T) which are complementary to each other and form chains of nucleotides.  DNA is wrapped 
around proteins to form nucleosomes. Nucleosomes are packaged together to form chromatin, 
which is in turn compacted with scaffolding proteins into solenoid loops. During cell division, 
chromosomes become more condensed to make chromosome segregation possible.  
 
 
addition of chemical molecules such as a phosphate group or a saccharide during 
or after protein synthesis in the cell. 
DNA that does not code for proteins (non-coding DNA) may still be 
functional; it may contain regulatory elements such as enhancers, repressors, 
silencers, promoters and transposons that are not transcribed into RNA.10 
Additionally, non-coding DNA may also include genes that are transcribed into 
RNA molecules which are functional by themselves, such as ribosomal RNA or 
microRNA.11 
 
Genetic variation is at the origin of evolution, diversity and genetic 
diseases 
Genetic information is encoded in DNA by the sequence of nucleotides; 
the genome of an individual organism dictates not only the general 
characteristics of its species but also the personal variation pertaining to that 
specific individual. The human reference genome is a digitally built DNA 
sequence representing the genome of the human species (Homo sapiens). The 
human reference genome differs substantially in size and in sequence from the 
reference genome of other organisms, such as the thale cress (Arabidopsis 
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thaliana)12 or the mouse (Mus musculus).13 However, there are also many 
differences in the sequence of nucleotides in the genome of any human being 
when compared to the human reference genome.  
The sequence of nucleotide bases in the genome can mutate, due to 
errors in the normal mechanism by which genomes are copied or repaired when 
damaged. Alterations in the nucleotide sequence resulting from these mutations 
can become permanently fixed in a genome sequence, giving rise to variation 
within a genome. Mutations leading to genetic variation can occur at the level of 
a single nucleotide, in which case they are called single nucleotide variants (SNVs), 
or they can affect multiple bases. One or several nucleotides can be inserted or 
deleted in a fragment of DNA, which is known as an indel if the size of the insertion 
or deletion is less than 1000 bp or 1 kb. Variation affecting DNA fragments larger 
than 1 kb is known as structural variation (SV) and includes insertions and 
deletions but also duplications, inversions and translocations.  
Differences in the sequence of A, C, G and T lead to variation in the 
information encoded genetically; if a SNV occurs in the coding region of a gene, 
it may affect translation of the protein which may have consequences on the 
functionality of the protein. For instance, a SNV in a codon can lead to the 
incorporation of a different amino acid during translation (missense mutation). A 
SNV replacing a T for a G resulting in a change in the codon from UUG to UGG 
would lead to the substitution of the encoded residue from leucine to tryptophan. 
Because of the different chemical properties of leucine and tryptophan, this 
missense mutation can have important consequences on the structure of the 
protein and its function. On the other hand, because of the redundancy of the 
genetic code, a SNV may not lead to any changes in the sequence of amino acids 
(synonymous mutation). A substitution of a G to an A leading to a codon change 
from UUG to UUA would not have an effect on the translation of the protein, since 
UUG and UUA both code for leucine. A SNV can also lead to the substitution of a 
codon by a stop codon (nonsense mutation). For example, a change of a T to an 
A leading to a codon substitution of UUG for UAG would be read by the ribosome 
as an indication to stop translating the transcript into protein, which leads to a 
truncation in the amino acid sequence. Finally, because the translation occurs 
codon by codon, the insertion or deletion of a base pair may change the entire 
reading frame of the transcript (frameshift mutation). This can ultimately also lead 
an early truncation of the protein or the translation of a protein that is not 
functional. 
Two unrelated humans share approximately 99.9% of their genome 
sequence. The remaining 0.1% of the human genome that is variable between 
individuals includes both common and rare variants. A typical human genome 
varies at 4.1 to 5.0 million positions compared to the human reference genome.14 
The vast majority of genetic variation observed in a typical human genome is 
common and shared by more than 0.5% of the population as a result of having 
been recombined, selected and passed on for many generations.14 On the other 
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hand, a typical human genome contains 40,000 to 200,000 rare variants that are 
observed in less than 0.5% of the population.14 A recent analysis of the coding 
sequence of 60,000 individuals showed that 99% of all variants identified in 
humans have a population frequency of less than 1%.15 This study identified 7.4 
million common and rare variants in the coding sequence of the human genome, 
which corresponds to one variant every 8 bp of coding sequence.15 A gene may 
have different mutations throughout its sequence and each alternative form of a 
gene or a genetic locus is known as an allele. Genes occur in pairs in the human 
genome because we have two sets of chromosomes, implying that humans have 
two alleles for each gene. If both alleles of a particular gene are identical in an 
organism, then the organism is said to be homozygous for this allele. 
Alternatively, if the two alleles are different, then the organism is heterozygous 
for said allele.  
Genetic variation in functional regions of the genome may cause changes 
in gene expression or in the sequence and structure of these encoded RNA or 
protein molecules, which in turn leads to differences in their function. Changes in 
the function of a specific RNA or protein molecule can result in variation in a trait, 
a specific feature which may range from a molecular aspect, such as intolerance 
to certain types of food because of an enzymatic defect, or to a physical 
characteristic, like hair color. Seemingly small genetic changes may give rise to 
significant physical or physiological differences. For instance, a single nucleotide 
change in a non-coding region of the human genome associated with blonde hair 
color in European populations was recently shown to disrupt the expression in 
hair follicles of KITLG, a gene involved in migration, survival and proliferation of 
melanocytes.16,17 
Genetic variation, together with the environment, determine the sum of 
an organism’s traits, or its phenotype. Phenotypes in humans are incredibly 
diverse and can vary both in physiologic and pathogenic ways. Genetic and 
phenotypic variation can affect the fitness of an organism, which is the likelihood 
of an organism to survive and reproduce in a given environment. The 
environment is often changing and the fitness of a given allele is likely to be 
unstable and fluctuate through time in response to the environment.18 Natural 
selection is the process by which a certain trait results in differences in fitness in 
individuals with this trait, leading to differential survival and reproduction of the 
allele responsible for the trait.19 
Mutations with a survival or reproductive advantage spread rapidly 
through a population.  Recent studies in human populations living in extreme 
environmental conditions or with significant dietary changes have shown 
evidence of natural selection for specific alleles and traits.20 For instance, genetic 
variation in a transcription factor involved in response to hypoxia shows a strong 
signal for natural selection in ethnic Tibetans living at high altitudes, suggesting 
adaptation to the low oxygen found in this environment.21 Similarly, strong 
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Inheritance 
pattern 
Mechanism Examples 
Autosomal 
recessive 
The phenotype is caused by the presence 
of a disease-causing allele in both copies of 
a gene, either with the same allele on both 
copies or a different allele in each copy. 
Cystic fibrosis (CFTR)35 
Autosomal 
dominant 
The phenotype is caused by the presence 
of a disease-causing allele in one copy of a 
gene. 
Marfan syndrome 
(FBN1)36 
X-linked 
The phenotype is caused by the presence 
of a disease-causing allele on the X 
chromosome.a 
Duchenne’s muscular 
dystrophy (DMD)37 
Germline de 
novo mutations 
The phenotype is caused by a germline 
mutation in the affected individual which 
was not inherited from the parents and 
thus likely occurred during gametogenesis. 
Bohring-Opitz 
syndrome  
(ASXL1)26 
Postzygotic de 
novo mutations 
The phenotype is caused by a mutation in 
the affected individual which occurs in the 
first few cell divisions after fertilization. 
Proteus syndrome 
(AKT1)38 
Digenic or 
oligogenic 
The phenotype is caused by damaging 
variants in two or more genes. 
Bardet-Biedl 
syndrome  
(BBS2, BBS6)39 
Imprinting 
disorders 
The expression of the phenotype depends 
on the parent of origin of the pathogenic 
allele due to parent-specific gene 
expression. 
Beckwith-Wiedemann 
syndrome 
(BWS)40 
Complex 
disorders 
The phenotype is caused by the 
combination of a multigenic component 
and environmental factors. 
Alzheimer’s disease 
(APOE)41 
Repeat 
expansions 
Expansion of repeats of trinucleotides due 
to genetic instability. 
Huntington’s disease 
(>40 CAGs in HTT)42 
Mitochondrial 
genetic disease 
Mutations in genes within the 
mitochondrial genome. 
Leigh disease  
(MT-ATP6)43 
Table 1. Mendelian and non-Mendelian modes of inheritance. a X-linked disorders can also be 
recessive or dominant, depending on whether the presence of a wild-type allele in females with two 
X chromosomes can rescue the effect of the disease-causing allele. 
 
 
selection for alleles resulting in the persistence of lactase activity in adulthood 
have been identified in European population, where additional nutrition from 
dairy consumption may have given a selective advantage.22 However, high 
frequency of a mutation within a population does not always entail that it is under 
positive selection; most genetic variation is neutral and does not result in 
phenotypic differences. In these cases, the frequency of a neutral allele can 
change simply because of chance, without undergoing natural selection, an effect 
known as genetic drift.19 
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Genetic variation can result in deleterious traits and phenotypes which 
may be disadvantageous in the context of a specific environment or which 
constitutively impair the normal functioning of an organism. From the 
perspective of evolution, individuals with deleterious traits have decreased 
survival or reproductive success, which progressively leads to the elimination of 
damaging mutations from the population. This phenomenon is known as 
purifying selection and in the most extreme cases, an affected individual may die 
without producing progeny, entirely removing the damaging mutation from the 
population. From a medical perspective, an individual with mutations in DNA 
disrupting his or her development, physiology or anatomy is considered to have 
a genetic disease. Some genetic diseases are thought to result from the 
interaction of variation in several genes together with lifestyle and environmental 
factors. These disorders, for which no clear inheritance pattern has been 
identified, are therefore known as multifactorial or complex disorders (Table 1). 
On the other hand, some genetic disorders have been established to be caused 
by mutations in one gene or genetic locus. These diseases often affect many 
members within a family and are known as monogenic or Mendelian disorders. 
 
Monogenic disorders are a prominent cause of human disease 
Monogenic disorders are individually rare; the most common monogenic 
disorder in Northern European population is cystic fibrosis, a disease caused by 
mutations in CFTR and found in 1 in 2000 births.23 Collectively, however, 
monogenic disorders are estimated to affect approximately 0.4% of live births,24 
representing a substantial part of human disease and placing an important 
burden on healthcare systems worldwide. 
Like all genetic information, damaging mutations leading to genetic 
disorders can be inherited from parents to offspring and monogenic diseases can 
be classified as recessive or dominant disorders according to their mode of 
inheritance. Diploid cells have two copies of each gene and, for most genes, loss 
of function in one of the copies due to a damaging mutation can be compensated 
by the presence of a normal allele on the other chromosome. Thus, the function 
of most genes is only disrupted if both copies harbor mutations, either because 
the same mutation is found homozygously or if different mutations are present 
on each copy (compound heterozygous). Monogenic disorders requiring the 
presence of homozygous or compound heterozygous mutations are recessive 
disorders (Table 1 and Figure 2A).  
Dominant diseases arise in the presence of only one mutated allele and 
their molecular mechanism of disease is variable. In some cases, the loss or 
damage to one copy of the gene cannot be compensated by the remaining one 
due to a dosage problem (haploinsufficiency). In other instances, the mutated  
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Figure 2. A. Family tree showing the transmission of an autosomal dominant pathogenic allele. 
Individual I-1 carries a pathogenic allele and is affected, transmitting the allele and the disease to 
his daughter II-2, who in turn transmits it to her son III-2. B. Family tree showing the transmission of 
an autosomal recessive pathogenic allele. Individual I-1 carries the pathogenic allele but is not 
affected by the disease. He transmits the pathogenic allele to his daughter II-2 who has children 
with another unaffected carrier (II-1). Among her three children, one is affected due to inheritance 
of both pathogenic alleles (III-2) and one is an unaffected carrier (III-3). C. Family tree showing the 
transmission of an X-linked pathogenic allele. Individual I-2 carries the allele but does not display 
the phenotype. She transmits the pathogenic allele to her daughter II-2 who is unaffected, but who 
in turn transmits the allele to her son III-2, who is a carrier of the allele and displays the phenotype. 
 
 
allele may interfere with the function of the normal allele, causing dysfunction of 
both copies (dominant negative mutation). Finally, other mutations may change 
the function of the allele (gain-of-function mutation), which cannot be 
compensated by the normal allele. Dominant disorders are usually transmitted by 
an affected parent in which the mutation is present heterozygously (Table 1 and 
Figure 2B). However, dominant disorders can also be caused by de novo 
mutations, which are mutations arising in the germline for the first time. De novo 
mutations have been recently recognized as an important cause of dominant 
disorders, particularly in sporadic cases. 
In broad terms, genetic disorders caused by mutations in genes located 
on the autosomes occur independently of the sex of the individual. However, 
because some genes are found on the sex chromosomes, the inheritance of 
monogenic diseases can also be linked to the sex of an individual. The vast 
majority of disease genes in the sex chromosomes are found on chromosome X. 
Genetic disorders caused by mutations in these genes are said to have X-linked 
inheritance and rarely affect women, as the presence of a second copy of 
chromosome X in women often rescues a pathogenic mutation. On the other 
hand, as a result of having a single copy of the X chromosome, men are more 
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Figure 3. Family tree showing germline de novo occurrence of a mutation. Both parents have wild-
type alleles and have two children with wild-type alleles and one with a constitutive de novo 
mutation.  
 
 
susceptible to X-linked disorders and are usually more severely affected (Table 1 
and Figure 2C). Few disease genes, implicated for the most part in infertility, have 
been identified in chromosome Y and consequently only affect men.  
Many disorders with a clear genetic component do not follow Mendelian 
inheritance patterns. A prominent example of this are some genetic disorders 
with sporadic appearance, where both the disease-causing allele and the 
phenotype are present in the offspring but absent in the parents. As a result, the 
main mechanism for these disorders is the de novo occurrence of a pathogenic 
mutation in the offspring, leading to the disease phenotype (Figure 3). Some 
sporadic diseases caused by de novo mutations may not affect fertility and 
affected individuals can transmit the mutation and the disorder to their offspring 
as an autosomal dominant disease.25 Other phenotypes, however, occur 
exclusively due to de novo mutation because the phenotype entails decreased 
fitness and fertility, which precludes the transmission of the pathogenic  
allele.26–28  
 
The origin and role of de novo mutations in human biology and disease 
are reviewed in more detail in Chapter 2. A few additional examples of disorders 
with non-Mendelian segregation, such as somatic mutations, complex diseases 
and mitochondrial genetic disorders are summarized in Table 1.  
 
The next generation sequencing (NGS) revolution 
Many genetic techniques have been developed to detect genetic 
mutations, including karyotyping, microarray technology, Sanger sequencing 
and more recently, next generation sequencing (NGS). An important distinction 
between these methods is their level of resolution, which is the minimal size of 
the alteration that can be detected using this technique. Genetic disease in 
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humans can be caused by mutations ranging from an alteration in a single 
nucleotide to the involvement of an entire chromosome. Consequently, an 
appropriate genetic technique with the right level of resolution must be selected 
to be able to detect each of these types of variation (see Table 2). For instance, 
karyotyping can only visualize aneuploidies and large chromosomal aberrations, 
while Sanger sequencing can detect small indels and SNVs at known loci.  
In contrast with these methods, NGS has the capacity to detect all kinds 
of genomic variation. NGS is based on the massive sequencing of millions of DNA 
fragments in parallel, offering an unprecedented output of genetic information 
at the base pair level in a single experiment. Many different high throughput 
sequencing methods exist based on distinct principles to generate millions of 
sequence reads in parallel. Currently, the sequencing methods most commonly 
used generate short sequencing reads of 35 to 700 base pairs. These are based 
mainly on two principles: sequencing by synthesis (with cyclic reversible 
termination as used by Illumina or single nucleotide addition such as in 
semiconductor sequencing in the Ion Torrent system and pyrosequencing in the 
454 Pyrosequencing, both by Life technologies) and sequencing by ligation (used 
by Life technologies in the SOLiD systems and by Complete Genomics in DNA 
nanoball sequencing).29,30 Single molecule real time sequencing (used by Pacific 
Biosciences) and nanopore sequencing (used by Oxford Nanopore Technologies) 
are two promising sequencing methods producing long reads of up to 200 kb29. 
In addition to the sequencing approach and read length, these NGS methods 
have different accuracy, throughput, costs and, therefore, applications. The 
increased accuracy of NGS-based approaches relies on high sequencing 
coverage, which is the number of individual reads covering a genomic region.  
Despite the fact that the advent of NGS entails an exponential increase in 
the sequencing throughput of these platforms, sequencing of entire eukaryotic 
genomes is not yet routinely feasible due to costs and time. Whole genome 
sequencing (WGS) of one human genome at 30x coverage represents 180 Gb of 
sequencing, which until relatively recently required several sequencing runs and 
thousands of dollars in costs.31 As a result, a lot of effort has been placed in 
developing methods to target regions of interest within a genome for 
sequencing. Specific genomic regions can be enriched by multiplexed PCR, 
capture by molecular inversion probes (MIPs) and hybrid selection either in 
solution or in an array.31 For instance, whole exome sequencing (WES) is a method 
to enrich for the exome, that is all the exons of the genome which represent 
approximately 1% of the genome. In order to enrich for this fraction, genomic 
DNA is randomly sheared into smaller fragments which are subsequently 
hybridized to a biotin-labelled probe that is specific to the region targeted. 
Streptavidin is then used to pull out the biotinylated probes and extract the 
bound DNA fragments. These enriched regions are then processed into a 
sequencing library that is read by a NGS platform of choice. Thus, for a single  
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 Karyotype Microarray Sanger sequencing NGS 
Basis of 
the 
technique 
Staining of 
chromosomes 
and observation 
under a light 
microscope 
DNA 
hybridization 
onto a 
microarray with 
large insert 
clones or 
oligonucleotide 
probes 
PCR amplification of 
a target sequence 
incorporating 
fluorescent 
dideoxynucleotides 
that terminate DNA 
synthesis  
Massive parallel 
sequencing of 
millions of DNA 
fragments by 
amplification, 
ligation or other 
sequencing 
principles 
Genome-
wide or 
targeted 
technique 
Genome-wide Genome-wide Targeted 
Genome-wide or 
targeted 
Resolution 
of the 
technique 
Aneuploidies 
and 
chromosomal 
aberrations 
 (>5 Mb) 
1 to 100 kb, 
depending on 
the array 
Single nucleotide 
Single 
nucleotide 
Type of 
variation 
that can 
be 
detected 
Gains, losses, 
rearrangements 
Gains, losses SNVs, indels 
Gains, losses, 
indels, SNVs 
Example 
of genetic 
alteration 
that can 
be 
detected 
Trisomy 21 in 
Down’s 
syndrome44 
8q12 
microdeletion in 
CHARGE 
syndrome45 
Inherited FGFR3 
point mutation in 
achondroplasia46 
De novo SNVs, 
indels, copy 
number 
variations and 
chromosomal 
rearrangements 
in intellectual 
disability47 
Comment 
Limited 
resolution 
Fails to detect 
balanced 
rearrangements 
Low throughput, 
time-consuming and 
expensive 
High 
throughput, 
need for 
bioinformatics 
infrastructure, 
challenges in 
variant 
interpretation. 
Table 2. Comparison of techniques to detect genetic alterations. 
 
 
individual, exome-wide variation can easily be detected by WES. On the other 
hand, MIPs represent a capture method that allows multiplexing and scaling so 
that one can target a set of genomic regions of interest and easily sequence them 
in hundreds of samples in a single NGS platform run. In addition to enrichment 
methods, the protocol for library preparation can be modified in order to examine 
other aspects of cell biology, such as the transcriptome, the epigenome or even 
study single cells. 
 
NGS allows for genome-wide detection of genetic variation at nucleotide 
level. As a result, NGS has fueled a revolution in human genetics, particularly 
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within fields of research that had been previously limited by the available 
technology.  For instance, traditional disease gene identification methods are 
based on Sanger sequencing to identify disease-causing mutations in candidate 
genes. This approach relies on the identification of candidate genes by positional 
mapping of loci in large pedigrees with multiple members affected or based on 
previous knowledge of the biological or genetic aspects of the disease.32 On the 
other hand, WES and WGS provide the possibility to perform an untargeted and 
therefore unbiased exome- or genome-wide analysis in a single affected 
individual. 
 
In the first 5 years of widespread availability of WES, more than 500 genes 
associated with monogenic disorders have been identified by WES and WGS, of 
which an important proportion involve de novo mutations arising for the first 
time.24,32,33 Trio-based sequencing represents one of the stepping stones for 
discovery of de novo mutations and identification of candidate disease-genes. 
Trio-based sequencing consists of performing WES or WGS in an individual and 
both his or her parents. This allows the identification of mutations that were not 
inherited but occurred de novo and are thus are present in the offspring while 
absent in the parents.32 This approach relies heavily on the quality of the 
sequencing method and the accuracy of the software used to call variants.32 A 
large fraction of mutations identified as de novo by trio-based sequencing are in 
fact sequencing artifacts or inherited mutations missed in one or both parental 
samples.34 
 
The generation and role of de novo mutations in human health and 
disease is a fundamental topic in my thesis and, as such, Chapter 2 serves as an 
in-depth introduction to this topic. Additionally, in this chapter, I provide 
additional insights into NGS and somatic mutations. 
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Aims and scope of this thesis 
 
The introduction and expansion of the use of NGS to study the genetics 
of human disease in the last years swiftly removed the restrictions imposed by the 
limitations of previous technologies. These developments have led to significant 
progress in the study of de novo mutations as a cause for sporadic human disease. 
This includes both de novo germline mutations, which often play a crucial role in 
the developmental disorders, and new somatic mutations, which often drive 
different forms of cancer. Remarkably, some germline mutations causative for 
developmental disorders have been shown to arise in the same genes as somatic 
mutations driving cancer. While mutations disrupting the same gene can cause 
both types of disease, the downstream effects of the mutation and the expression 
of the phenotype are likely modulated by the type and timing of the mutation. 
Therefore, the aim of this thesis is to study the timing of de novo mutations in 
human physiology and human disease, particularly for mutations which may 
result either in developmental disorders or in cancer. 
In Chapter 2, I describe the causes and mechanisms of de novo mutations 
and expand on their role in human biology and disease. 
Chapter 3 presents an instance in which the application of NGS led to the 
identification of the disease-causing gene for a sporadic phenotype caused by de 
novo mutations. In this chapter, I describe how we applied exome sequencing to 
detect de novo mutations in THRA as the cause of a novel thyroid hormone 
resistance syndrome. 
Chapter 4 shows that the use of NGS can expand beyond novel disease-
gene identification, by offering insight into the timing de novo mutations. By 
analyzing the variant allele fraction of de novo mutations sequenced using NGS 
methods, we detect de novo mutations which actually occurred as postzygotic 
events. 
In Chapter 5, we investigate the timing of novel mutations throughout 
adult life by using human hematopoiesis as an in vivo model. 
Chapter 6 explores the differences in timing and functional 
consequences of overlapping germline and somatic SETBP1 mutations involved 
in a rare developmental disorder and in leukemia, respectively. 
Chapter 7 provides the general discussion of this thesis and implications 
for future research on the topic.  
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Abstract 
Aside from inheriting half of the genome of each of our parents, we are 
born with a small number of novel mutations that occurred during 
gametogenesis and postzygotically. Recent genome and exome sequencing 
studies of parent-offspring trios have provided the first insights into the number 
and distribution of these de novo mutations in health and disease, pointing to risk 
factors which increase their number in the offspring. De novo mutations have 
been shown to be a major cause of severe early-onset genetic disorders such as 
intellectual disability, autism spectrum disorder and other developmental 
diseases. In fact, the occurrence of novel mutations in each generation explains 
why these reproductively lethal disorders continue to occur in our population. 
Recent studies have also shown that de novo mutations are predominantly of 
paternal origin and that their number increases with advanced paternal age. In 
this chapter, we provide an overview of recent literature on de novo mutations, 
covering their detection, biological characterization and medical impact.
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Introduction 
Upon fertilization, a human zygote inherits half of its genome from the 
mother via the oocyte and the other half from the father through the sperm. In 
addition to the genetic information passed on from generation to generation, 
each of us is born with a small number of novel genetic changes, de novo 
mutations, that occurred either during the formation of the gametes or 
postzygotically.1,2 Additionally, novel mutations continue arising throughout 
post-natal and adult life both in somatic and germ cells. Only mutations present 
in the germ cells can be transmitted to the next generation.3 
There is a long-standing interest in the study of the frequency and 
characteristics of de novo mutations in humans, as these are crucial to the 
evolution of our species and play an important role in disease. A typical human 
genome varies at 4.1 to 5.0 million positions compared to the human reference 
genome.4 The vast majority of genetic variation observed in a typical human 
genome is common and shared by more than 0.5% of the population as a result 
of having been recombined, selected and passed on for many generations.4 On 
the other hand, a typical human genome contains 40,000 to 200,000 rare variants 
that are observed in less than 0.5% of the population.4 All of this genetic variation 
must have occurred as a de novo germline mutation in an individual at least once 
in human evolution.5  Historically, the germline mutation rate in humans has been 
calculated by analyzing the incidence of genetic disorders; in 1935, Haldane 
estimated the mutation rate per locus per generation based on the prevalence of 
hemophilia in the population.6,7 More recently, in 2002, Kondrashov accurately 
calculated the de novo mutation rate in humans by examining the mutation rate 
at known disease-causing loci.8 Nowadays, next generation sequencing (NGS) 
approaches in parent-offspring trios can be used to directly study the occurrence 
of all types of de novo mutations throughout the genome, from single nucleotide 
variants (SNVs) to small insertions-deletions (indels) and larger structural 
variations. Genome-wide NGS studies place the germline de novo mutation rate 
for SNVs in humans at 1.0 to 1.8 ×10-8 per nucleotide per generation,1,9–13 with  
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Figure 1. Mechanisms of de novo mutations. De novo mutations may arise because of static 
properties of the genome, such as the underlying sequence (deamination of methylated CpGs, 
transitions versus transversions) or due to erroneous pairing of nucleotides during DNA replication. 
However, de novo mutations may also occur in relation to cell-specific properties such as chromatin 
state, transcriptional status and gene expression levels. Mutational hotspots for genomic 
rearrangements are largely determined by the underlying genomic architecture. One such example 
is given for Non-Allelic Homologous Recombination. Arrows represent the influence of each feature 
on the de novo mutation rate. Green upwards arrows indicate elevated mutability; red downwards 
arrows indicate lower mutability. 
 
 
substantial variation among families.11,13,14 This number translates into 44 to 82 de 
novo single nucleotide mutations in the genome of the average individual, with 
1 to 2 affecting the coding sequence.9,10,12,13,15 These state-of-the art genomic 
approaches allow us to determine additional characteristics of de novo 
mutations, such as the parental origin and whether they occurred in the germline 
or postzygotically. We now know that the majority of germline de novo mutations 
have a paternal origin and that a higher paternal age at conception results in an 
increase in the number of de novo mutations in the offspring.15–18 Furthermore, 
the study of large cohorts of parent-offspring trios provides insight into the 
distribution of mutations throughout the genome, the genomic context in which 
they arise and possible underlying mechanisms (see Figure 1 for an overview of 
different mechanisms resulting in de novo mutations).11–13 
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Mutations conferring a phenotypic advantage propagate rapidly through 
a population,19–21 while neutral mutations may disseminate merely as a result of 
genetic drift.22 However, damaging mutations resulting in deleterious traits 
before or during the reproductive phase undergo purifying selection and their 
spread through the population is averted.23 This entails that de novo mutations 
are genetically distinct from inherited variants, as they represent the result of the 
mutagenic processes taking place between one generation and the next, prior to 
undergoing selection (see Table 1). Loss or acquisition of traits at the population 
level drives evolution of a species whereas, at the level of an individual, loss or 
acquisition of traits may result in disease.  
Germline de novo genetic alterations have been implicated in human 
disease for decades. Virtually all disease-causing aneuploidies arise as de novo 
events. The best-known example for this is trisomy 21, identified in 1959 as the 
cause of Down syndrome.24 In the beginning of this millennium, genomic 
microarray technology provided insight into the role of de novo copy number 
variations (CNVs) in disease.25 Even though large CNVs occur at a very low rate, 
arising at a frequency of only 0.01 to 0.02 events per generation,25–27 they 
contribute significantly to severe and early-onset neurodevelopmental disorders 
and congenital malformations due to their disruptive effect on many genes.28 The 
magnitude of the contribution of de novo genetic alterations to human disease, 
however, has only recently become fully apparent now that NGS approaches 
allow the reliable and affordable detection of all types of de novo mutations.25 
Damaging de novo point mutations and indels affecting important genes in 
development have been established as a prominent cause of both rare and 
common genetic disorders.29–35 
In this chapter, we first touch on the biological aspects of de novo 
mutations in humans, such as their origin, distribution throughout the genome 
and factors related to their occurrence and timing. Later, we discuss the 
increasingly recognized role of de novo mutations in human disease and other 
translational aspects. Throughout this chapter, we focus mostly on de novo SNVs 
and refer to previous work from others for more information on the role of de 
novo CNVs and other structural genomic variation in human disease.36,37 
 
Causes of de novo mutations 
Mistakes during DNA replication can give rise to de novo mutations as a 
result of the erroneous incorporation of nucleotides by DNA polymerases.38 DNA 
polymerases ε and δ catalyze replication predominantly in the leading and 
lagging strand, respectively. Both polymerases integrate nucleotides during 
polymerization in a highly selective way, with an average of one mismatch per 
104-105 bp in vitro.39,40 A proofreading subunit present in both polymerases  
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 Inherited Variants De novo mutations 
Single Nucleotide Variants (SNVs) 3.5 to 4.4 million4 44 to 82 9,10,12,13,15 
Number of coding SNVs 22,186 10 1-2 25 
Insertions and deletions  
(indels <50 bp) 
~550,000 4 2.9 - 9 26,81 
Large indels (50 – 5,000 bp)a ~1000 4 0.16 26 
Copy Number Variations (CNVs) ~160 4 0.0154 26, b 
Selection pressure in previous 
generation(s) 
High None 
Damaging capacity of variants 
Majority with small 
effect 
High 
Differences in population Yes None 
Parental/Paternal age effect None Strong 
Detection of variants Imputable Not imputable 
Amenable to positional cloningc Yes No 
Table 1. Comparison of inherited and de novo variants. a Due to technical limitations, the number 
and mutation rate for large indels ranging between 50 and 5000 bp remains uncertain. Novel 
sequencing approaches will likely provide more accurate estimates (see Chaisson et al.237). b per 
generation for CNVs larger than 100 kb. c Positional cloning by linkage analysis or homozygosity 
mapping. 
 
 
subsequently verifies the geometry of the paired nucleotides to ensure that the 
incorporated base is correct.38 Single or multiple base-pair mismatches may cause 
alterations in the structure of the replicating DNA and can be restored by the 
mismatch repair (MMR) pathway.41 The MMR pathway is highly efficient, which 
explains why the amount of mutations generated during DNA replication is much 
lower than the polymerase error rate. The frequency at which specific base-pair 
substitutions arise may be different from the speed at which they are repaired, 
which defines the mutation rates for specific base-pair substitutions.41 Incomplete 
repair can lead to single or multiple base-pair substitutions or indels. Additionally, 
damaged nucleotides can be incorporated during replication, leading to 
mispairings and base substitutions.42 
DNA lesions may also appear spontaneously as a consequence of 
exogenous or endogenous mutagens; UV or ionizing radiation and DNA-reactive 
chemicals are an example of the former, while reactive oxygen species belong to 
the latter.38 Prior to replication, these spontaneous lesions are repaired mainly by 
the nucleotide excision repair system and base excision repair pathways.43 
However, inefficient repair of pre-mutations before a new round of DNA 
replication may lead to the mutation becoming permanently fixed in either one 
or both daughter cells.44 If mutation repair fails, DNA replication may also be 
completely arrested and ultimately lead to cell death.44 
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The difference between the rate at which pre-mutagenic damage appears 
in DNA and the rate at which it is repaired defines the rate at which de novo 
mutations arise. It is often assumed that germline de novo mutations originate 
from errors in DNA replication during gametogenesis, particularly in sperm cells 
and their precursors (see paragraph on parental origin of de novo mutations). 
However, inefficient repair of spontaneous DNA lesions may also give rise to de 
novo mutations during spermatogenesis, as continuous proliferation and short 
periods between cell divisions may translate into less time to repair these 
lesions.44,45 In oogenesis, spontaneous DNA mutations coupled to inefficient 
repair mechanisms may play a more prominent role.44 Therefore, while the de 
novo mutation rate is a reflection of the replication error rate and the number of 
mitoses a cell has undergone, this number is also influenced by the amount of 
time between mitoses and the efficiency of the DNA repair.44 
 
Distribution of de novo mutations in the genome  
While the average human mutation rate is 1-1.8 × 10-8 per nucleotide per 
generation,1,9–13 mutagenesis does not occur completely at random across the 
genome.9 Variation in mutability across different areas of the genome can be 
explained by intrinsic characteristics of the genomic region itself, related to its 
sequence composition and functional context.46 Certain factors playing a role in 
the mutability of the genomic region are predicted to be shared by all cell types 
in the human organism. These include the local base pair context, recombination 
rate and replication timing.9,13,47 Replication timing refers to the order in which 
different areas of the genome are replicated during the S-phase of the cell cycle. 
Genomic regions which are replicated late display more genetic variation than 
regions that are replicated early.47 It has been suggested that this may be due to 
a higher mutability that is secondary to depletion of dNTP at the end of 
replication, although other changes such as alterations in polymerase activity and 
decreased MMR repair activity have also been implicated.38,48,49 
Other factors influencing mutability may vary from cell to cell, depending 
on the transcriptional activity and chromatin state.50–52 In addition, recent whole 
genome sequencing (WGS) studies have revealed the presence of so-called 
“mutational clusters” and “mutational hotspots”. Mutational clusters correspond 
to the observation of multiple de novo mutations in very close vicinity in a single 
individual, while multiple de novo mutations occurring at the same location in 
several individuals are an indication of the existence of mutational hotspots.53 
 
Nucleotide differences: transitions, transversions and CpGs 
The molecular events underlying transitions occur more frequently than 
those leading to transversions, resulting in a two-fold rate of transitions over 
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transversions across the genome.27,38 Transitions arise predominantly as a result 
of C>T mutations, which is at least partially explained by the mutability of CpG 
dinucleotides.54 The cytosine in a CpG dinucleotide often undergoes methylation 
at the 5th position of the 6-atom ring leading to 5-methylcytosine (5-mC). In 
humans, methylated CpG dinucleotides are known to be chemically unstable and 
highly mutable due to deamination of 5-mC at CpG dinucleotides resulting in G:T 
mismatches.12 Indeed, the mutability of CpG dinucleotides is approximately ten 
to eighteen times higher than that of other dinucleotides27 and, as a result, CpG 
dinucleotides are found at only a fraction of their expected frequency in the 
human genome.54 The high de novo mutation rate at CpG sites is also illustrated 
by the recent work of the Exome Aggregation Consortium (ExAC). Through the 
work of this consortium, exome data from more than 60,000 individuals without 
severe pediatric disease is currently available. Analysis of the data in ExAC shows 
that the discovery of new mutations at CpG dinucleotides reaches saturation at 
20,000 exomes.55,56 This emphasizes that identical CpG mutations do not 
necessarily reflect an ancestral event but are likely the result of independent de 
novo mutations. 
Remarkably, the mutability of CpG dinucleotides is lower in genomic 
regions enriched for CpG and with higher GC content than in the rest of the 
genome.44 In fact, the mutation rate for CpGs in the GC-richest regions of the 
genome are two to threefold lower than in the rest of the genome.44,48 This could 
be the result of lower methylation levels, the effect of selection because the 
regions play a role in gene regulation or secondary to stronger binding between 
DNA strands impeding separation and spontaneous deamination.38,44,57 
 
Mutational signatures underlying specific mutational processes 
While errors in DNA replication, exposure to mutagens or failure to repair 
DNA damage can all result in mutations, there are differences in the pattern of 
mutations arising from each of these processes. A “mutational signature” has 
been defined as a pattern of mutations which is specific to a mutational process 
occurring in a cell, tissue or organism.58 A recent study based on the analysis of 
4.9 million somatic mutations in more than 12,000 cancer genomes defined 21 
mutational signatures associated with mutational processes active in somatic 
cells (termed signature 1 to 21).58 Detailed descriptions of each signature are 
available at http://cancer.sanger.ac.uk/cosmic/signatures. Each of these millions 
of mutations is placed into one of 96 possible mutation types based on six 
possible base pair substitutions (C>A, C>G, C>T, T>A, T>C and T>G) and one of 
four possible base pairs adjacent to the mutation both at the 5’ and at the 3’ 
position of the mutation. Concisely, each mutation type is a trinucleotide in which 
the middle base pair is mutated to a specific nucleotide and each mutational 
signature is defined by the frequency of each mutation type observed.59 
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A recent study showed that the mutational spectrum of germline de novo 
mutations correlated best with two of these previously described mutational 
signatures, currently known as signature 1 and 5.11,13 This suggests that the 
mutational processes associated with these signatures in somatic cells may also 
be active in germ cells although the mechanisms underlying the processes 
remain elusive. Mutational signature 1 represents close to 25% of de novo 
germline mutations and is characterized by a high proportion of C>T transitions 
at CpG dinucleotides, which is associated with deamination of methylated 
cytosine.11,58 Mutational signature 5, which corresponds to the remaining 75% of 
de novo mutations, is characterized mainly by A>G transitions.11 While the 
mechanism underlying this signature remains unclear,  the mutations observed 
as part of this signature may be secondary to spontaneous deamination of 
adenine to hypoxanthine, which is then read as guanine.60 This mutational 
signature is associated with transcriptional strand bias, suggesting that some of 
these mutations arise from adducts subject to transcription-coupled repair.60 
 
Mutational clusters and hotspots 
De novo mutations occur throughout the human genome but 
occasionally several mutations may arise at a closer distance than expected by 
random distribution.9 The term “mutational clusters” refers to the occurrence of 
de novo mutations in an individual at a closer distance than expected, with 
multiple de novo mutations within regions ranging from 10 to 100 kb.9,12,13,53 
Mutational clusters display a unique mutational spectrum with a lower rate of 
transitions and a large proportion of C>G transversions.13 This phenomenon has 
been described to arise in somatic cells in the context of cancer, where it is known 
as “kataegis”, and is linked to APOBEC enzymes.53,58 It has been suggested that 
clusters involving C>G transversions could be related to the formation of single 
stranded DNA in diverse cellular processes, such as double-strand breaks and 
dysfunctional replication forks.61 Single stranded DNA may be mistaken for 
retroelements and attacked by APOBEC enzymes, which convert cytosine to 
uracil.53 The mutations are then repaired via base-excision repair and subsequent 
translesional DNA synthesis with error-prone polymerases.38 Indeed, mutational 
clusters have been described to be reminiscent of APOBEC-mediated mutations 
albeit with a different sequence context.12,13 The occurrence of mutational clusters 
has been found to correlate with increased parental age.13  
Another origin for some of these clusters could be chromosomal re-
arrangements. It has been shown that the mutation rate for SNVs is elevated and 
SNVs can cluster in proximity of the breakpoints of de novo CNVs.62,63 This is likely 
the result of the replicative CNV mechanism in which a low-fidelity, error-prone 
DNA polymerase is used during repair of DNA. Indeed, work performed in yeast 
supports the observation that double-strand break-induced replication is a 
source of mutation clusters.61 
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In contrast to the mutation clusters that occur within one individual, 
mutational hotspots are considered overlapping loci that are found to be 
mutated more frequently than expected in different individuals. Recent research 
based on WGS datasets and modeling has identified such hotspots in coding 
sequences.9 Furthermore, the existence of these mutational hotspots has been 
recently confirmed in a larger study which showed specific bins of 1 Mb within 
the human genome with elevated mutation rates.13 Interestingly, in this study, 
two bins including genes CSMD1 and WWOX were shown to have a higher 
maternal than paternal mutation rate. The mechanism for this is still largely 
unknown, but the latter is a well-known fragile site within the human genome.64 
Other sites of the human genome that are especially prone to de novo mutations 
include rDNA gene clusters,65 segmental duplications66 and microsatellites67 with 
mutation rates three to four orders of magnitude higher than average.68 
 
Timing of de novo mutations  
De novo mutations occur predominantly in the egg or sperm cell 
resulting, upon fertilization, in a zygote with a constitutive germline mutation 
present in all of the cells of the organism. The advent of NGS allowed scientists to 
demonstrate that de novo mutations occur as non-germline events more often 
than previously estimated.3,69–71 Mosaicism, which is the existence of two or more 
genetically distinct cell populations in an individual developing from a single 
fertilized egg,72 is the norm rather than the exception. Postzygotic mutations, that 
is mutations arising in the first few cells divisions after fertilization, can lead to 
high level mosaicism and be present in many different tissues of an organism. 
Mutations that arise later in development or post-natal life, on the other hand, can 
remain restricted to a single tissue or even to a small number of somatic cells (see 
Figure 2). Although mutations which occur in somatic cells during post-natal and 
adult life are conventionally not considered de novo mutations, they are included 
in this section as they represent the end of the spectrum of timing in which novel 
mutations may arise. 
 
De novo mutations arising during gametogenesis 
In human embryos, the primordial germ cells (PGCs) emerge from the 
epiblast, 8 to 14 cell divisions after fertilization.73 In these first cell divisions, the 
mutation rate appears to be similar in male and female embryos (approximately 
~0.2-0.6 mutations per haploid genome per cell division, according to models 
estimating the mutation rate during gametogenesis).11 After their specification, 
PGCs expand to form the pool of spermatogonial stem cells and the complete 
population of primary oocytes in male and female embryos, respectively.11,73 
Despite differences in the expansion of PGCs to oogonia or spermatogonia, the 
mutation rate during this step is similar in both sexes with approximately 0.5 to 
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0.7 mutations per haploid genome per cell division, according to computational 
modeling.11 However, after puberty, the processes involved in spermatogenesis 
and oogenesis diverge further. Spermatogonial stem cells divide by mitosis 
approximately every 16 days, maintaining the spermatogonial stem cell pool 
while generating differentiated spermatogonial cells which produce sperm cells 
through an additional round of mitosis followed by meiosis.74 In contrast, each 
menstrual cycle, a few oocytes escape from meiotic arrest and complete the first 
meiotic division. After ovulation, the oocyte becomes arrested once more until 
fertilization, when it completes the second meiotic division. Thus, after PGC 
expansion in embryogenesis, oocytes only undergo one additional round of DNA 
replication in their evolution to a mature ovum. In contrast, spermatogonial cells 
may undergo hundreds of rounds of DNA replication and cell division before their 
maturation to sperm cells.  
Approximately 80% of all de novo germline point mutations arise on the 
paternal allele and advanced paternal age at conception has been established as 
the major factor linked to the increase in the number of de novo mutations in the 
offspring, both at the population level and within the same family (see Figure 
2).11,13,15 Spermatogonial cells continue to divide throughout life, which is likely to 
allow the progressive accumulation of mutations due to errors during DNA 
replication but also as a result of failure to repair non-replicative DNA damage 
between cell divisions.44 Furthermore, the efficiency of endogenous defense 
systems against radical oxygen species and of DNA repair mechanisms may also 
decline with age.75,76 De novo mutations in children of young fathers show a 
different signature and localize to later-replicating regions of the genome 
compared to children of old fathers, suggesting that additional factors contribute 
to de novo mutations with age.12,13 It has been calculated that 1 to 3 de novo 
mutations are added to the germline mutational load of the offspring for each 
paternal year at conception, but this effect varies considerably between 
families.11,13 This variability has been suggested to be due to individual differences 
in the rate of mutagenesis, in the frequency of spermatogonial stem cell division 
and even to genetic variation in DNA mismatch repair genes.11 Indeed, one could 
speculate that deleterious variation in genes involved in replication and repair 
could predispose to elevated de novo mutation rates not only in somatic cells but 
also in the germline, as has been observed in mouse models lacking exonuclease 
activity in DNA polymerase δ.77 
 
The effect of increased maternal age is well established for errors leading 
to chromosomal nondisjunction involved in aneuploidies,78,79 but less so for de 
novo point mutations. The fixed number of mitoses required for oogenesis would 
entail that maternal age would not be linked to an increase in DNA replication-
associated mutations. However, an effect of maternal age on the number of de 
novo mutations has been reported recently,13,80 likely reflecting an excess of non-
replicative DNA damage that is not properly repaired.44 This maternal age effect  
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Figure 2. Timing of de novo mutations. Sperm cells have undergone approximately 100 to 150 
mitoses in a 20-year-old man while oocytes have gone through 22 mitoses in a woman of the same 
age (left). As a result of errors in replication and repair of DNA damage occurring during parental 
embryogenesis, gametogenesis or as postzygotic events in the offspring, de novo mutations 
(DNMs) arise in each new generation. Advanced parental age is associated with an increase in the 
number of de novo mutations (right). The male germline adds 23 mitoses per year, entailing that a 
spermatogonial stem cell in a 40-year-old man has undergone more than 600 cell mitoses. Each 
additional year in paternal age at conception adds 1 to 3 de novo mutations to the genome of the 
offspring. Oogenesis has a fixed number of mitoses, but mutations accumulate over time possibly 
due to failure to repair DNA damage. The increase in number of de novo mutations with maternal 
age is lower: 0.24 extra de novo mutations for each additional year of maternal age at conception. 
Cell lineages modified from Scally.236 Somatic cells are showed in orange, the male germline is 
shown in blue and the female germline is shown in purple. Blue stars represent postzygotic 
mutations present in the germline and in somatic cells; yellow stars represent mutations arising 
exclusively in the germline; red stars represent somatic mutations arising during embryonic 
development or post-natal life and are absent from germline cells. 1 The ratio of paternal to maternal 
mutations originating from parental gonosomal mosaicism is 1:1; 2 the ratio of paternal to maternal 
germline de novo mutations is 4:1; 3 the ratio of paternal to maternal postzygotic de novo mutations 
is 1:1; 4 this range is based on the average number of de novo mutations published in Michaelson et 
al.9, Gilissen et al.10, Francioli et al.12, Goldmann et al.13 and Kong et al.15, regardless of parental age. 
 
 
was initially reported in a study analyzing de novo mutations in WGS data from a 
large cohort of parent-offspring trios, in which maternal age correlated with the 
total number of de novo mutations after correcting for paternal age.80 A more 
detailed analysis of the same cohort confirmed a subtle but significant increase in 
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the number of maternal de novo mutations with advancing maternal age, 
 consisting of 0.24 additional de novo mutations per extra year of maternal age at 
conception.13 Previous studies had failed to identify a maternal age effect on the 
number of de novo mutations.12,15 This may be explained by differences in the 
parental age distribution between cohorts or due to lack of statistical power to 
detect this subtle effect for which paternal age is a confounder.80 The increase of 
de novo mutations with advanced paternal and maternal age support the 
possibility that the accuracy of DNA repair mechanisms in germ cells decreases 
with age.76 
 
De novo mutations arising postzygotically 
Approximately 7% of seemingly de novo mutations are present in blood 
as high level mosaic mutations, having likely occurred as early postzygotic 
events.70,71,81 Considering an average of 44 to 82 de novo mutations in our 
genome,9,10,12,13,15 it is likely that each of us carries between 8 and 15 early 
postzygotic de novo mutations in our organism. This, together with the 
observation that chromosomal instability and structural rearrangements are 
common in cleavage-stage human embryos, has led to the suggestion that early 
embryogenesis may be a period of high mutability.82,83 Prior to the initiation of 
transcription and translation in the zygote, human embryos rely on maternal 
proteins contributed by the oocyte,84 which could lead to shortage of proteins 
involved in DNA replication and repair, resulting in genomic instability.3 
Recent studies in zebrafish have shown that the majority of cells in each 
organ derive from a small number of progenitor cells,85 while research in mouse 
embryos suggests that an individual progenitor cell can contribute unequally to 
multiple tissues.86 Therefore, depending on the timing at which a de novo 
mutation arises during embryonic development, it may be present at different 
levels in multiple tissues or can be organ-specific.87 A recent study examined 
multiple samples from the same individual and showed the widespread presence 
of postzygotic de novo mutations in tissues of different embryonic origin, 
including somatic and germ cells.88 Furthermore, mutations may arise in the germ 
cell lineage after the specification of PGCs during early embryonic development, 
remaining isolated from somatic cells.3 Although these mutations are 
undetectable in sampled tissues such as blood or buccal swabs, they can be 
transmitted to the offspring as germline events. 
 
Somatic mutations arising during postnatal and adult life 
Studies in mouse models have shown that the mutation frequency is 
higher in somatic cells than in germ cells,89,90 a finding supported by the 
comparison of the somatic and germline mutation rate in humans.76 Indeed, 
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somatic cells have been shown to accumulate hundreds of mutations throughout 
post-natal and adult life.91 Large chromosomal abnormalities have been observed 
in many tissues in the human body92 such as the blood, where the presence of 
these lesions increases with age.93–95 For instance, loss of chromosome Y in blood 
cells has been described as a frequent event in aging males, affecting over 15% of 
men of 70 years of age or older.96,97 Somatic mutations resulting in low level 
mosaicism are prevalent in healthy tissues,98 including the brain,99 blood100–102 and 
skin, where the somatic mutation burden has been calculated at two to six SNVs 
per Mb of coding sequence per cell.103 
The increased mutation frequency observed in somatic tissues may 
partially be explained by differences in the efficiency of DNA replication and 
repair mechanisms in germ and somatic cells.76 However, the number and type of 
mutations observed in different somatic tissues in the human organism is highly 
variable.104 This is likely due to disparities in the type of environmental factors that 
cells are exposed to,58 as well as the number of stem cell divisions per tissue.105 
Indeed, exogenous factors such as radical oxygen species related to diet and/or 
lifestyle have been shown to be a major source of DNA damage in adult tissues.106 
Different tissues are subjected to different mutagens. For instance, skin is exposed 
to ultraviolet light, which contributes substantially to the mutations observed in 
this tissue,103 while factors such as tobacco and alcohol consumption are 
important sources of mutations in the esophagus.107 
As for differences in the number of stem cell divisions per tissue, a careful 
balance between cell proliferation, differentiation and apoptosis is necessary for 
the maintenance of developed tissues in adult organisms. Adult stem cells are 
multipotent cells that divide to sustain their own population and differentiate to 
generate specialized cells which usually form the bulk of adult tissues. 
Differentiated cells undergo different degrees of turnover; some tissues in the 
human organism undergo constant renewal, such as the lining of the gut,108 while 
others, like the frontal lobe of the brain, do not go through any turnover. Stem 
cells in tissues with constant renewal undergo more cell divisions than those of 
tissues that do not105 and are therefore more likely to acquire mutations 
associated to DNA replication. Because stem cells are long-lived, mutations 
arising in stem cells can persist in the tissue for years and accumulate dozens of 
mutations over the course of time. 
 
De novo mutations in human disease 
The effects of de novo mutations encompass a wide spectrum, ranging 
from beneficial to an organism to lethal. Within this phenotypic spectrum, de 
novo mutations can cause many types of human disease including severe 
congenital disorders and late-onset diseases. The medical relevance of de novo 
mutations has only recently been fully appreciated, mainly because advances in 
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sequencing technology have allowed a comprehensive analysis of these 
mutations.25 NGS techniques such as whole exome sequencing (WES) or WGS now 
provide the possibility to detect most, if not all, genetic variation present in a 
patient. To this end, trio-based WES or WGS has been instrumental in detecting 
and characterizing de novo mutations in patients with a wide variety of 
diseases.25,35 
 
De novo mutations in pediatric disease 
De novo mutations are now well known to play an important role in 
severe early-onset diseases, which for the most part arise sporadically because of 
their impact on fitness; due to the severity of the phenotype in which they often 
result, an individual with a deleterious de novo mutation will not produce 
offspring and the phenotype therefore only arises through de novo mutations. 
In the first 5 years of widespread availability of WES, more than 500 novel 
disease-gene associations have been identified, with the strongest increase in 
sporadic diseases caused by de novo mutations.35,109,110 Recent studies applying 
exome sequencing in the clinic have shown that of all sporadic cases who 
received a molecular diagnosis through clinical exome sequencing, between 60% 
and 75% could be explained by de novo mutations.111,112 De novo mutations 
affecting the coding region have also been established as an important cause of 
common neurodevelopmental disorders such as autism,29,30 epilepsy31 and 
intellectual disability,33,34 which affect over 1% of the population.113,114 Clearly, 
these common genetic disorders are not explained by de novo mutations 
affecting the same locus in every patient. Instead, an extreme genetic 
heterogeneity is observed and patients with common genetic disorders carry de 
novo mutations in many different genes. The population frequency of a disorder 
caused by de novo mutations is determined in large part by the number of genes 
or genetic loci that can result in this disorder when mutated, which we have 
referred to previously as the mutational target.25 Rare disorders are most often 
caused by mutations in a single gene or a small number of genes, while common 
genetic disorders usually have a large mutational target often consisting of 
hundreds to thousands of genes or genetic loci.25 As an example, more than 700 
genes have now been identified to cause autosomal dominant intellectual 
disability when mutated,113 and this number is rapidly increasing since the 
widespread application of NGS technology. Based on these sequencing studies, it 
appears that the majority of the most severe neurodevelopmental phenotypes, 
such as severe intellectual disability with an IQ below 50, are the consequence of 
damaging de novo germline mutations in the coding region.10 An enrichment for 
damaging de novo mutations has also been observed in individuals with milder 
phenotypes such as autism spectrum disorder without cognitive 
deficits.16,18,29,30,115 For these milder phenotypes which have less impact on fitness, 
the exact contribution of de novo mutations to the disease burden is not yet 
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firmly established and inherited variation is likely to be at least as important in the 
expression of the phenotype.116–118 Next to neurodevelopmental disorders, de 
novo mutations also play a prominent role in pediatric diseases such as congenital 
heart defects (CHD).119–121 In agreement with the observation made in 
neurodevelopmental disorders, recent studies found the highest contribution of 
de novo mutations to disease in individuals with the most severe and syndromic 
forms of CHD.119,121 Finally, it is essential in large-scale sequencing studies to 
formally test whether the recurrence of de novo mutations in a gene exceeds the 
number of observations expected by chance.122 
The vast majority of pathogenic de novo mutations are involved in 
dominant genetic disorders. This appears logical, as a single damaging de novo 
mutation can be sufficient to cause these kinds of disorders. However, there are 
examples of recessive disorders which can be caused by the combination of an 
inherited mutation on one allele and the occurrence of a de novo mutation on the 
other.33 In a cohort of 100 trios with severe ID, we identified one case of autosomal 
recessive intellectual disability due to the inheritance of one pathogenic allele 
and a de novo hit in the other33 and similar observations in the context of late-
onset disease are described below. Furthermore, there are reports of cases with a 
merged phenotype composed of two clinically distinct disorders of which either 
one or both are caused by a pathogenic de novo mutation.111 Phenotype-based 
and classic genetic approaches are insufficient to diagnose individuals with this 
kind of combined disease, illustrating the power of an unbiased genotype-first 
approach. Additionally, this approach reduces the need for clinical homogeneity 
for disease-gene identification studies as was required for phenotype-first 
approaches.123,124 
 
De novo mutations in late-onset disorders 
Few studies until now have addressed the role of de novo mutations in 
late-onset diseases. The role of de novo mutations is likely to be smaller in late-
onset disorders than in pediatric disorders given the effect of de novo mutations 
on reproductive fitness. Still, genes involved in adult-onset disorders are just as 
likely to be affected by de novo mutations as genes involved in pediatric 
disorders. A complicating factor in these late-onset disorders, however, is the 
collection of parental samples for the study of de novo mutations.125 Despite this 
obstacle, recent publications have suggested a link between de novo mutations 
and late-onset neurological and psychiatric disorders: Parkinson’s disease, 
amyotrophic lateral sclerosis, schizophrenia and bipolar disorder have been 
associated with de novo SNVs and CNVs.126–133 For example, one study found that 
10% of individuals with sporadic schizophrenia have a rare de novo CNV 
compared to 1.26% of controls.128 Exome sequencing of a cohort of 623 
schizophrenia trios identified an enrichment for de novo point mutations in genes 
encoding synaptic proteins in cases compared to controls.126 A large meta-
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analysis recently identified both an excess of loss-of-function mutations in 
SETD1A and an excess of de novo occurrence of these mutations in individuals 
with schizophrenia compared to controls.134 Recent studies have exposed a 
genetic overlap between neurodevelopmental disorders and schizophrenia, with 
de novo mutations in the same gene being involved in both early and late-onset 
disorders.134–136 While de novo mutations have been firmly linked to 
neurodevelopmental disorders, their involvement in late-onset psychiatric 
phenotypes is more controversial. This may be the result of a more complex 
underlying genetic architecture,137 together with a more prominent role for 
environmental factors in the expression of the phenotype.138 Furthermore, based 
on the high degree of mosaicism observed in a normal human brain, it has been 
suggested that that pathogenic postzygotic and somatic mutations could 
contribute to psychiatric disorders.139,140 
Cancer, particularly in relatively young individuals without relevant family 
history, has been associated with de novo mutations in genes involved in cancer 
predisposition syndromes. For example, at least 7% of germline mutations in TP53 
in individuals with Li-Fraumeni syndrome occurred de novo,141 and a similar 
proportion has been identified for mutations in APC involved in familial 
adenomatous polyposis.142 Nevertheless, the rate of de novo mutations in genes 
involved in other cancer predisposition syndromes, such as BRCA1 and BRCA2143 
or in DNA mismatch repair genes (MLH1, MSH2, MSH6 and PMS2)144 has been 
reported to be much lower. Postzygotic de novo mutations have been implicated 
in early-onset cancer145,146 and could well represent an early mutational event in 
the development of cancer in the general population.147 
Interestingly, de novo mutations have also been identified as causative 
mutations in genetic disorders which are typically inherited, such as hereditary 
blindness. For instance, the rate of causative de novo mutations among sporadic 
cases within a cohort of patients with Retinitis Pigmentosa was close to 10%,148 a 
result which was later confirmed by an independent study.149 Although for the 
majority of this group, the de novo mutation represented a single dominant hit 
causative for the phenotype, in one case the de novo mutation was in fact the 
second hit in an autosomal recessive form of Retinitis Pigmentosa. Similarly, in a 
cohort suffering from mild to moderate sensorineural hearing loss, de novo 
mutations were identified in 2 out of 11 sporadic cases,150 also suggesting a role 
for de novo mutations in this heterogeneous disorder.  
As de novo mutations are known to play an important role in disorders 
that affect fitness, it may also be very relevant to investigate their role in disorders 
linked to fertility, such as male infertility. Both de novo chromosome Y deletions 
as well as de novo point mutations in a few genes have been found to cause this 
disorder,151,152 but a systematic screen is lacking so far. 
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The role of timing of de novo mutations in human disease 
As a consequence of technological improvements allowing the detection 
of (low level) mosaic mutations at a genome-wide scale, mosaicism has been 
recognized to have an important role in human biology and disease. Postzygotic 
and somatic mutations have been recently implicated in several human diseases, 
ranging from developmental disorders153–155 to cancer.145–147 A lesson derived from 
these discoveries is that the timing of a pathogenic de novo mutation can have 
an important influence on the expression of the phenotype.  
 
Mutations arising during gametogenesis 
Pathogenic de novo mutations arising during gametogenesis cause a 
clinical phenotype in the offspring in whom they are present as a constitutive 
event. However, the consequences of these mutations may not be limited to the 
next generation, but could also affect the cells in which they arise. Thus, certain 
de novo mutations arising during gametogenesis may also have an effect on 
cellular behavior in spermatogonial stem cells or oogonia in the parent of origin 
for the mutation. 
 A small subset of de novo mutations which are highly recurrent and 
localize to specific nucleotides in the genome have been observed to have a 
striking increase with paternal age. These de novo mutations are thought to grant 
spermatogonial stem cells a growth advantage, leading to clonal expansion of 
mutated cells in the testis.156 For instance, gain-of-function mutations in genes in 
the RAS/MAPK pathway have been shown to cause clonal expansion of mutant 
spermatogonial stem cells due to proliferative selective advantage.156,157 
Computational modeling suggests that this would result from a slightly increased 
ratio of symmetric versus asymmetric divisions in mutant spermatogonial stem 
cells, favoring the production of two mutated spermatogonial stem cells 
compared to a single mutated stem cell and one differentiated spermatogonial 
stem cell harboring the mutation.158,159 Therefore, over time, spermatogonial stem 
cells carrying these mutations undergo positive selection due to higher self-
renewal than surrounding wild-type cells and expand clonally in the testis.160 The 
occurrence and enrichment of mutations in spermatogonial stem cells is thought 
to take place in all men and would entail that the testes of older men contain a 
higher number of clones of mutant spermatogonial stem cells.156,157 
Interestingly, the first mutations implicated in clonal expansion in 
spermatogonial stem cells were initially shown to cause developmental disorders 
such as Noonan and Costello syndrome (caused by PTPN11 and HRAS mutations, 
respectively),157,160,161 Apert, Crouzon and Pfeiffer syndromes (FGFR2),160,162 
achondroplasia, Muenke syndrome and thanatophoric dysplasia (FGFR3)160,161 and 
multiple endocrine neoplasia (RET).163 Mutations which are positively selected at 
the spermatogonial stem cell level but are detrimental at the organism level have 
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been termed to behave selfishly and are therefore referred to as “selfish 
mutations”.161 Due to the expansion of mutant cells over time, the incidence of 
these developmental disorders shows an exponential increase with paternal age 
at conception, well beyond the increase observed for other disorders caused by 
de novo mutations.164 Appropriately, these disorders are known as recurrent, 
autosomal dominant, male-biased and paternal age effect disorders (RAMP) or, 
simply, paternal age effect disorders (PAE).45,157 Because of the selfish selection of 
mutant spermatogonial cells, PAE disorders have an incidence up to 1000-fold 
higher than expected based on the mutational target size and the average 
mutation rate.45,164 It has been hypothesized that “selfish mutations” with a 
weaker effect on spermatogonial stem cell behavior could be involved in more 
common phenotypes such as intellectual disability, autism or epilepsy.165 
Furthermore, “selfish” behavior is a characteristic of certain mutations driving 
cancer, as they lead to positive cellular selection despite being harmful for the 
organism. Predictably, several mutations behaving selfishly in spermatogonial 
stem cells have also been identified as somatic events driving clonal growth in 
tumorigenesis.161 
Following the identification of genomic regions enriched for maternal de 
novo mutations,13 the possibility of selfish mutations in the maternal germ line 
has also been put forward.76 It appears these genomic regions harbor genes with 
a role in tumor suppression and some de novo mutations could speculatively 
provide mutant oocytes in aging women with a survival advantage over wild-type 
ones.76 
 
Postzygotic mutations 
Regardless of whether they occur in the germline or postzygotically, some 
de novo mutations lead to a single Mendelian phenotype in which the mosaic and 
constitutive form are part of the same clinical spectrum.166 For example, 
pathogenic mutations in genes involved in epileptic encephalopathies167 and 
cerebral cortical malformations168 have been shown to cause similar phenotypes 
when they arise either in the germline or as postzygotic de novo mutations 
leading to mosaicism in the brain. However, in some of these cases, mosaicism 
may cause a milder clinical phenotype than a constitutive mutation.169,170 
De novo mutations can also result in different phenotypes when they are 
present in the germline or arise postzygotically.171 Some de novo mutations lead 
to developmental disorders only if the de novo mutation occurs postzygotically, 
as the constitutive presence of the mutation is suspected to be lethal.172,173 
Examples of this include Proteus syndrome (caused by AKT1 mutations),153 
Sturge-Weber syndrome (GNAQ)154 and CLOVES syndrome (PIK3CA).174 A 
common feature to these disorders is that they are caused by mutations known 
to lead to activation of cellular proliferation pathways and overgrowth. The 
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mutations with the strongest effect generally result in more severe 
developmental alterations,175 suggesting that the type of de novo mutation 
influences the expression of the phenotype. Remarkably, the mutations with the 
strongest effect on activation have also been observed as somatic events in 
cancer,175 for which constitutive activation of cellular proliferation pathways is a 
major hallmark.176 This finding supports that not only the type, but also the time 
at which a pathogenic mutation occurs is crucial in defining its consequences.  
The timing of a postzygotic mutation determines the percentage of 
affected cells in the organism and the type of tissues involved.72,154 For instance, 
the same genetic alteration in genes in the RAS/MAPK pathway can result in very 
diverse phenotypes depending on the timing at which they arise.171,177,178 
Mutations in HRAS mutating codon G12 of the HRAS protein have been identified 
in Costello syndrome when present in the germline,179 but postzygotic and 
embryonic occurrence of mutations in this residue has been observed in 
Schimmelpenning syndrome,171 sebaceous nevus,171 keratinocytic epidermal 
nevi180 and in early-onset bladder cancer145,181. Furthermore, identical mutations 
in PIK3CA can cause different phenotypes ranging from different overgrowth 
syndromes155 to lymphatic182 and venous malformations183 depending on the 
tissue distribution. Therefore, the timing of a pathogenic de novo mutation is 
likely instrumental in defining its phenotypic consequences as it determines the 
burden placed by the mutation upon the organism, including the type of tissues 
affected and the percentage of cells in which the mutation is present.72,154 
An important characteristic of postzygotic mutations is that they generate 
genetically distinct populations of cells that coevolve within a single organism. As 
such, mosaicism may lead to differences in cell fitness which could result in 
competition between the mutant and wild-type cells in the developing human 
embryo. Indirect or classic cell competition is the context-dependent elimination 
of cells with reduced metabolism in a developing embryo; “fit cells” induce 
apoptosis of cells that are less fit but otherwise viable and proliferate to occupy 
their place.184 Classic cell competition was originally described in Drosophila as a 
mechanism to eliminate suboptimal cells during embryogenesis and ensure 
fitness of the cells from which the organs and the multicellular organism would 
develop.185 Classic cell competition was recently shown to also take place during 
early mammalian embryogenesis.186,187 
Another possible consequence of postzygotic de novo mutations is that 
genetically different cells in a developing organism may fail to coordinate due to 
heterogeneous responses to stimuli. This phenomenon was first observed in the 
context of mutations in EFNB1 in craniofrontonasal syndrome and PCDH19 in 
epileptic encephalopathy.188–190 The proteins encoded by EFNB1 and PCDH19  
play a role in forming topologically-defined tissue domains. Consequently, 
cellular mosaicism for these proteins leads to abnormalities in cellular 
determination and migration, alterations in the formation of compartments and 
mosaic tissue segments. In both conditions, females present a severe phenotype 
De novo mutations in health and disease | 51 
 
while male carriers are asymptomatic or mildly affected. This is explained by 
random inactivation of the X chromosome in females leading to mosaicism in the 
cellular expression of the genetic mutation, causing discordant cellular responses 
and resulting in alterations in tissue organization. On the other hand, cells of 
hemizygous carrier males express the genetic mutation uniformly and 
compensate through the use of highly homologous receptors which allows 
signaling to bypass the mutated protein. Remarkably, mosaicism for pathogenic 
mutations in these genes has been identified in clinically affected males, for 
whom the molecular mechanism of disease is similar as for females with random 
X inactivation. 
Finally, pathogenic de novo mutations arising postzygotically and leading 
to gonadal or gonosomal mosaicism may be clinically silent in an individual. 
Nevertheless, this person has increased risk of transmitting this pathogenic 
mutation to the next generation as a constitutive event, resulting in a clinical 
disorder in his or her offspring.191 
 
Somatic mutations  
 Pathogenic mutations arising somatically can have an effect on cell 
behavior. Depending on their effect, these mutations can promote their own 
disappearance or propagation; while cells acquiring deleterious mutations are 
likely to die, some mutations may grant cells an advantage and promote their 
survival or replication.192 Clonal expansion is a phenomenon by which a single cell 
forms groups of identical daughter cells. Clonal expansion can be the result of a 
stem cell favoring proliferation over its differentiation, as is thought to occur with 
spermatogonial stem cells harboring ‘selfish’ mutations. Another mechanism by 
which clonal expansion may occur is by escaping quiescence or having increased 
survival in comparison to other cells, as in revertant mosaicism in individuals with 
genetic diseases. In these individuals, clones of wild-type cells are occasionally 
observed in tissues such as skin or blood, due to correction of the deleterious 
alleles by spontaneous mutation and subsequent selection for wild-type cells in 
the context of pathogenic cells.193–196 
 Certain recurrent mutations arising somatically have been shown to be 
implicated in the clonal expansion of mutated hematopoietic stem cells 
detectable in circulating blood cells or “clonal hematopoiesis”. Somatic mutations 
involved in clonal hematopoiesis most commonly affect DNMT3A, TET2 and 
ASXL1.101 These somatic mutations are found in blood-derived DNA at allelic 
fractions ranging from 2 to 10%, suggesting thereby that between 4 and 20% of 
nucleated cells in blood derive from mutated hematopoietic stem cells.102 
Previous work has shown that DNMT3A and TET2 mutations involved in clonal 
hematopoiesis impair the differentiation of hematopoietic stem cells and increase 
self-renewal capacity, leading to a clonal expansion of these cells in the bone 
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marrow.100,197 Loss of ASXL1 leads to aberrant gene expression and epigenetic 
alterations secondary to loss of gene repression.198 Clonal hematopoiesis is rarely 
observed in individuals younger than 50 years but increases in frequency with 
age, affecting up to 10% of individuals older than 65.100,102,199 It has been suggested 
that the aging cellular background plays an important role in the selection and 
expansion of hematopoietic stem cells carrying mutations.200 Aging leads to a 
decline in the function of hematopoietic stem cells199 and myeloid bias201 as well 
as modifications in the bone marrow niche.202 It is therefore possible that certain 
mutations provide a cellular advantage in the context of the aging bone marrow, 
allowing for clonal expansion.200 
 Most mutations involved in clonal expansion have been identified with 
several types of tumors and are classified as oncogenic.45 Indeed, the selective 
advantage granted to mutant stem cells and resulting in clonal expansion could 
contribute to the formation of tumors: spermatocytic seminomas in the testicle, 
in the case of spermatogonial stem cells45 or to leukemia, in the case of 
hematopoietic stem cells.100,203 However, these mutations are not sufficient to 
cause cancer; the transformation of a normal somatic cell into a cancer cell has 
been suggested to require at least six genetic mutations (granting self-sufficiency 
for growth signals, insensitivity to growth-arresting signals, evasion of apoptosis, 
ability to replicate without limits, sustained angiogenesis and tissue invasion and 
metastasis).202 Adult stem cells have a long life span, which allows them to 
progressively accumulate the necessary genetic mutations to pave the way for 
tumorigenesis.202 However, the acquisition of mutations is not linear, as cells 
acquiring advantageous mutations can also be eliminated due to stochasticity 
within the organism.204,205 
 
De novo mutations in clinical practice 
The recent recognition of the importance of de novo mutations in human 
disease has many implications on routine genetic testing and clinical practice. 
Germline de novo mutations are now established as the cause of disease in a large 
fraction of patients with severe early-onset disorders ranging from rare congenital 
malformation syndromes206,207 to more common neurodevelopmental disorders, 
such as severe forms of intellectual disability,33 epilepsy31 and autism.29 Together, 
these disorders represent a substantial proportion of all patients seen at 
neuropediatric and clinical genetics departments around the world.  
Pinpointing the genetic cause of a disorder caused by a de novo mutation 
in an individual can be challenging from the clinical point of view because of 
pleiotropy as well as genetic heterogeneity underlying a single phenotype. For 
instance, intellectual disability can be caused by de novo point mutations, indels 
or CNVs in any of hundreds of genes.113 This obstacle to providing a clinical 
diagnosis strongly argues for a reliable and affordable genomics approach which 
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can be used to detect these de novo mutations in large groups of patients. Exome 
and genome sequencing (which additionally offers the possibility of accurate 
detection of structural variation) of patient-parent trios is ideal for this and will 
soon become the first-tier diagnostic approach for these disorders. A key 
advantage of this trio-based sequencing approach is that it helps prioritize 
candidates by de novo occurrence, allowing clinical laboratories to focus on the 
most likely candidate mutations for follow-up and interpretation.208 
Although identifying de novo mutations is becoming increasingly easy, 
interpreting them (i.e. linking them to a phenotype) often remains challenging.209 
Clinical interpretation of de novo mutations requires evaluation at the level of the 
affected locus or gene, as well as at the variant level.210 The interpretation of 
candidate de novo mutations can be guided by the use of in silico prediction 
programs like SIFT, PolyPhen, MutationTaster and CADD.210–213 Large scale 
databases of genetic variation can be used to see whether a gene or gene region 
shows constraint against variation in controls, as the frequency of a mutation in 
the population is often a good indirect estimation of its pathogenicity.212 To this 
end, RVIS and selective constraint scores have become routine in the 
interpretation of de novo variants both in research and in the clinic.122,214 
Population databases such as ExAC are expected to be depleted of de novo 
disease-causing mutations for severe and early-onset disorders.55 Given that de 
novo mutations are the rarest type of variation, the absence of a mutation from 
the ExAC database is not in itself sufficient evidence for its pathogenicity. On the 
other hand, the presence of a mutation in ExAC does not automatically entail that 
the mutation is not disease-causing. Pathogenic mutations involved in dominant 
disease are present in ExAC,55 which may be explained by variable penetrance for 
these variants,215 the presence of false-positive variants in the control database,216 
undiagnosed disease in control individuals or late-onset of disease. Possible other 
explanations for these observations could be the presence of these mutations as 
somatic events in control individuals100–102 or resilience to disease in few selected 
individuals.217  
In the context of research, evidence linking a gene or a mutation to a 
phenotype is traditionally established experimentally,210,212 although functional 
validation is laborious and the necessary assays may differ per gene and per 
mutation. Many recent developments can support the interpretation of de novo 
mutations in human disease. For instance, to study the consequences of a 
mutation, induced pluripotent stem cells from patient-derived samples can be 
differentiated into cell types relevant for the respective disease.218 Furthermore, 
as a robust method for in vitro and in vivo genetic manipulation, CRISPR/Cas9 can 
be used to establish cell and animal models for functional studies.219,220 Other 
CRISPR/Cas9-based methods, such as Saturation Genome Editing, hold promise 
for the evaluation of hundreds of mutations in a single assay,221 allowing the 
interpretation of de novo mutations to keep pace with their discovery in the 
genomics era. 
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The impact of mosaicism in human disease is not yet fully appreciated, 
possibly because postzygotic mutations often remain undetected. In comparison 
with germline de novo mutations, postzygotic mutations are more challenging to 
identify as they are only present in a small percentage of cells and may resemble 
false-positive artefacts in sequencing data. The detection of postzygotic 
mutations can be improved by using higher sequencing coverage and 
implementing technological improvements such as single molecule tracing, 
which is based on the incorporation of unique molecular identifiers to each DNA 
molecule during capture.70,222 It is to be expected that our understanding of 
postzygotic mutations will increase rapidly in the coming years due to this and 
other improvements, as well as access to DNA from other (affected) tissues. 
Sequencing of cell-free DNA in plasma is currently being explored as a source of 
DNA from multiple tissues.223–225 
The identification of a de novo mutation as the cause of disease in a 
patient has several implications for the patient and his or her family. First, the 
detection of the genetic defect underlying the phenotype establishes a genetic 
diagnosis which can be used to provide a prognosis based on data from other 
patients with similar mutations,226 information about current treatment options227 
and, in the future, to the development and application of personalized 
therapeutic interventions.228 Furthermore, the identification of a de novo 
mutation offers the parents of the affected patient an explanation as to why the 
disorder occurred and may help deal with feelings of guilt.229,230 In terms of family 
planning, the identification of a de novo mutation as the cause of disease in a 
child may be positive news with regard to recurrence risk, as it is much lower than 
for recessive or dominant inherited disorders (slightly above 1% versus 25 and 
50%, respectively).11,191 However, the recurrence risk is strongly dependent on the 
timing of the mutation as parental mosaicism for the mutation increases the risk 
of recurrence.191 Approximately 4% of seemingly de novo mutations originate 
from parental mosaicism detectable in blood11 and recent work suggests that 
transmission of parental mosaicism could explain up to 10% of de novo  
mutations in autism spectrum disorder.231 This entails that a fraction of de novo 
mutations has an estimated recurrence risk above 5%.191 Furthermore, close to 7% 
of seemingly de novo mutations arise as postzygotic events in the offspring.70,71,81 
Parents of an individual with a postzygotic mutation have a low risk for recurrence 
of the mutation in an additional child, estimated to the same as the population 
risk.72 Targeted deep sequencing of a disease-causing mutation can be performed 
to test for its presence in parental blood and detect mosaicism in the offspring. 
Although it is not yet offered on a routine basis, this kind of testing can provide a 
personalized and stratified estimate of the recurrence risk based on the presence 
or absence of mosaicism in the parents or in the offspring. 
Finally, it is impossible to prevent de novo mutations from arising in the 
germline of each new generation but attention must be brought to the factors 
that increase the number of de novo mutations in the offspring. The single most 
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important risk factor is advanced paternal age at conception,15 which is of great 
importance from an epidemiological perspective since most couples in Western 
countries are having children at later ages. In fact, this increase in de novo 
mutations with paternal age at conception may explain epidemiological studies 
that link increased paternal age to increased risk of neurodevelopmental 
disorders in offspring.232 A recent population genetic modeling study, however, 
indicated that de novo mutations may not explain much of the increased risk of 
psychiatric disorders in children born to older fathers.118 While this may be the 
case for relatively mild and late-onset phenotypes such as schizophrenia, de novo 
mutations are responsible for the majority of the most severe pediatric disorders 
arising in outbred populations.10,233 At present, most attention, advice and 
guidelines are focused on advanced maternal age as a public health issue. It is 
evident from current work on de novo mutations that advising the public, 
including policy makers, on potential risks of advanced paternal age and the 
burden it may bring on society, is crucial. An extreme solution if reproduction is 
to be postponed may be to promote cryopreservation of oocytes and sperm,234 a 
measure under much debate that has been termed “social freezing”. 
 
Conclusions and future directions  
Advances in sequencing technologies have provided us with the ability 
to systematically identify most if not all de novo mutations in a genome. This has 
boosted fundamental research into the evolution of our genome by providing 
insight into the mechanisms that play a role in mutagenesis, the origins of these 
mutations and their distribution throughout the genome. While most of this 
research has been focused on germline mutations, we now see a shift towards the 
detection and study of somatic de novo mutations also for non-cancer 
phenotypes, greatly facilitated by more accurate and deeper coverage 
sequencing technologies. Next generation sequencing has also boosted research 
and diagnostics on sporadic diseases. The routine detection of de novo  
mutations by trio-based sequencing of patients and their unaffected parents in 
research as well as in diagnostics will soon allow the identification of most 
disease-causing genes involved in sporadic monogenic disorders. This will allow 
for the classification of different developmental and neurodevelopmental 
disorders based on the underlying genotype rather than solely on the phenotype. 
In turn, this offers the possibility of targeted medical consultations and 
interventions, engagement in gene-specific patient groups and, in some cases, in 
treatment. The study of de novo mutations will shift more and more towards the 
detection and characterization of non-coding de novo mutations in disease. 
Although a phenomenal challenge that will require large study cohorts and 
detailed functional validation, the limited number of de novo mutations per 
genome reduces the search space for pathogenic non-coding mutations, as was 
recently shown for non-coding de novo CNVs.235 
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Abstract 
Resistance to thyroid hormone is characterized by a lack of response of 
peripheral tissues to the active form of thyroid hormone (triiodothyronine, T3). In 
about 85% of cases, a mutation in THRB, the gene coding for thyroid receptor β 
(TRβ), is the cause of this disorder. Recently, individual reports described the first 
patients with thyroid hormone receptor α gene (THRA) defects. We used 
longitudinal clinical assessments over a period of 18 years at one hospital setting 
combined with biochemical and molecular studies to characterize a novel thyroid 
hormone resistance syndrome in a cohort of six patients from five families. Using 
whole exome sequencing and subsequent Sanger sequencing, we identified 
truncating and missense mutations in the THRA gene in five of six individuals and 
describe a distinct and consistent phenotype of mild hypothyroidism (growth 
retardation, relatively high birth length and weight, mild to moderate intellectual 
disability, mild skeletal dysplasia and constipation), specific facial features (round, 
somewhat coarse and flat face) and macrocephaly. Laboratory investigations 
revealed anemia and slightly elevated cholesterol, while the thyroid profile 
showed low free thyroxine (fT4) levels coupled with high free T3 (fT3), leading to 
an altered T4:T3 ratio, along with normal thyroid-stimulating hormone levels. We 
observed a genotype-phenotype correlation, with milder outcomes for missense 
mutations and more severe phenotypical effects for truncating mutations. In 
patients with clinical symptoms of mild hypothyroidism without confirmation in 
endocrine studies, a molecular study of THRA defects is strongly recommended. 
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Introduction 
Thyroid hormones (THs, comprising triiodothyronine – T3 and thyroxine 
– T4) have diverse actions, which include the regulation of skeletal growth, 
maturation of the central nervous system, cardiac and gastrointestinal function 
and energy homeostasis.1 Thyroid hormones exert their effects through alpha 
(TRα) and beta (TRβ) receptors,1 which belong to the nuclear receptors 
superfamily including receptors for gluco- and mineralocorticoids, estrogens, 
progesterone and vitamin D. TRα and TRβ are encoded by two genes (THRA and 
THRB), each of which undergoes alternate splicing to generate receptor subtypes 
(TRα1, TRα2, TRβ1, TRβ2, and TRβ3) with distinct tissue distribution.1 TRα1 and 
TRα2 are located mainly in bones, digestive tract, cardiac and skeletal muscle and 
central nervous system.2 Three subtypes of TRβ are mainly expressed in the liver, 
kidney, hypothalamus and pituitary, where they regulate the release of 
thyrotropin, subject to the current concentration of THs in blood and in the 
thyroid gland.3,4 
Resistance to thyroid hormone (RTH) is characterized by a lack of response 
of peripheral tissues to the active form of thyroid hormone (T3). Two forms of 
inheritable RTH have been described, leading to clinically distinct phenotypes: 
RTH β and α. In more than 85% of the cases, RTH β is caused by a mutation in 
THRB, the gene coding for TRβ. This disorder affects 1 per 50,000 live births and 
can appear both sporadically, as well as in an inherited autosomal recessive or 
dominant manner.5 Affected individuals clinically present with goiter, short 
stature, decreased body mass, enlarged heart and mild psychomotor retardation. 
Furthermore, the disruption of TRβ function in the hypothalamus, pituitary and 
thyroid gland results in a loss of the negative feedback in this axis. This is reflected 
in the thyroid function tests in affected individuals, which show increased levels 
of T4 and T3 coupled to inappropriately normal levels of thyroid-stimulating 
hormone (TSH).6 Approximately 15% of patients with RTH do not harbor a 
mutation in the THRB gene, which has led to the suspicion that this disorder may 
be caused by alterations in other thyroid hormone receptor-related genes. These 
candidate genes include co-regulators, co-activators and co-repressors 
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regulating TRβ function. However, efforts to screen individuals with RTH for 
mutations in these genes have failed so far.7 
Particularly, the absence of mutations in THRA in patients with RTH has 
been met with puzzlement, leading to speculation that mutations in this gene 
could be extremely rare or undiagnosed. Recently, three case reports described 
the first patients with heterozygous truncating mutations in the last exon of THRA 
presenting clinical features suggestive of thyroid hormone resistance, however 
different from RTH β.1,5,8,9 
Here, we present the clinical and laboratory features of five pediatric 
patients (one male and four females, age 4 to 18 years) as well as one adult patient 
(age 39 years) with RTH α, a novel thyroid hormone resistance syndrome due to 
truncating and missense THRA mutations. To our knowledge, this is the first study 
with a larger number of patients and a description of a distinct and consistent 
phenotype of mild hypothyroidism, associated with macrocephaly, specific facial 
features, skeletal abnormalities and altered T4:T3 ratio, along with normal TSH 
levels. 
 
Results 
Clinical syndrome 
The clinical syndrome was similar in all patients and occurred due to de 
novo mutations or was transmitted as a dominant trait in one family 
(Supplementary Figure S1). Supplementary Table S1 summarizes the clinical data 
for the six patients studied. All patients presented with a similar clinical outcome 
and phenotype which comprises growth retardation (with relatively short limbs, 
hands and feet, and long thorax), mild to moderate intellectual disability, mild 
skeletal dysplasia, constipation, deep voice and specific facial features 
(round/puffy, somewhat coarse, flat face, flat nasal bridge, upturned nose, 
hypertelorism,) with relative macrocephaly (Figure 1 and 2). Other changes 
included puffy hands and feet, club feet, tortuosity of arteries of the dorsal area of 
the feet and hands, and skin with rough and doughy texture (Figure 3). In two 
patients with more pronounced clinical features mild cardiomyopathy was also 
noted. From infancy, all patients presented mild to moderate motor and mental 
retardation, deep voice and constipation. 
The developmental phenotype was characterized by delayed delivery 
after week 40, relatively high birth weight and length, large head circumference 
relation to the chest circumference and floppiness (Supplementary Table S1). 
Newborn screening allowed exclusion of hypothyroidism. From the age of 2 
years, the height gain became slower, leading to the marked short stature at the 
later age. Growth retardation was disproportionate, affecting the lower segment 
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more than the upper segment. The Polish reference charts for sitting height are 
available for children aged >4 years. The following indexes were calculated:  
 
1. Trunk-lower extremities index (according to Giuffrida-Ruggeri) using the 
following formula:   
 ℎℎ
	
 ℎℎ
 ×100 
2. Skelic index (according to Manouvrier) using following formula:  
 
	
 ℎℎ −  ℎℎ
 ℎℎ
 ×100 
 
Trunk-lower extremities index in all patients except one (patient 1 after 
puberty had skeletal deformity) revealed long trunk. Skelic index revealed all 
patients to be hyperbrachyskelic.  
 
 
Figure 1. Progression of facial features in five patients with a novel thyroid hormone resistance 
syndrome due to truncating mutations in THRA. Patient 1, aged 2, 2, 7 and 18 years, respectively (1), 
patient 2, aged 2.5 and 15 years, respectively (2); patient 3, aged 18 months, 4 and 6 years, 
respectively (3); father of patient 3, aged 39 years (F); patient 4, aged 2 and 5 years (4); patient 5, 
aged 3 months, 2, 4 and 5 years, respectively (5). Note the characteristic facial traits such as 
macrocephaly, round/puffy, somewhat coarse and flat face, flat nasal bridge, upturned nose and 
hypertelorism.  
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Figure 2. Photo gallery of five patients with a novel thyroid hormone resistance syndrome due to 
truncating mutations in THRA. Patient 1, aged 2 (1) and 18 (1a) years; patient 2, aged 2.5 years (2); 
patient 3, aged 6 years (3); father of patient, aged 39 years (F); patient 4, aged 5 years (4) and patient 
5, aged 5 years (5). Note the short stature, relatively short limbs, hands and feet and long thorax. 
 
 
 
 
Figure 3. Hands and feet in a novel thyroid hormone resistance syndrome due to truncating 
mutations in THRA. Please note puffy hands and feet, club feet, tortuosity of arteries of the dorsal 
area of the feet and hands and skin with rough and doughy texture. 
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Laboratory investigations revealed anemia (low red blood cells and 
hemoglobin level), slightly elevated creatine kinase and cholesterol. The thyroid 
profile showed low free thyroxine (fT4) levels coupled with high free T3 (fT3), 
leading to an altered T4:T3 ratio, along with normal TSH levels (Supplementary 
Table S1 and S2). 
X-ray examination revealed ovoid immature form of the vertebral bodies, 
anterior superior ossification defect in the lower thoracic and upper lumbar 
bodies, and hypoplasia of the acetabular and supraacetabular portions of the ilia 
and coxa vara. X-rays of hands showed minimal changes in the tubular bones of 
the hands, which became abnormally short, wide and deformed. A consulting 
radiologist suggested similarities to the radiological characteristics of 
hypothyroidism (Supplementary Figure S2).  
 
Management 
Attempts to treat affected patients with levothyroxine at standard doses 
did not improve any of the clinical symptoms.  
 
Genetic studies 
The two patients with the most severe phenotype were selected for 
exome sequencing (patient 1 and 2, Supplementary Table S1). Both affected 
individuals were found to have heterozygous stop mutations in the last exon of 
the coding sequence for THRA isoform 1 (RefSeq NM_199334; c.1176C>A, 
[p.C392X] in patient 1 and c.1207G>T, [p.E403X] in patient 2. These mutations 
were absent in in-house exomes (2,094 exomes), as well as 6,500 public exomes 
from Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS). Truncating 
mutations in the last exon of THRA isoform 1 were previously reported to cause a 
similar phenotype in three individuals from two families.1 We validated these 
mutations by Sanger sequencing and confirmed that they had occurred de novo 
in the patients. Using Sanger sequencing, we screened the rest of our cohort for 
mutations in the coding regions of THRA. We identified a heterozygous missense 
mutation in the last exon of THRA isoform 1 in two additional unrelated 
individuals (c.1207G>A, [p.E403K] and c.1193C>G, [p.P398R] in patient 3 and 4, 
respectively). The mutation in patient 3 was inherited from the father, who was 
also affected, while the mutation in patient 4 occurred de novo. All of these 
mutations cluster to the C-terminus of the TRα1 protein, leaving TRα2 unaltered 
(Supplementary Figure S3), which is consistent with the previous case reports.1,8 
Despite sharing the same clinical features, no mutations in THRA were 
found in patient 5 after screening by Sanger sequencing. We performed 
additional genetic studies to identify the disease-causing genetic lesion in this 
individual, including exome sequencing and a high-resolution microarray CNV 
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analysis. The absence of mutations in the THRA gene was confirmed by exome 
sequencing and no potentially pathogenic variants were identified in any 
candidate genes (including genes coding for TR co-factors and other proteins 
involved in thyroid hormone metabolism and function). Furthermore, a high-
resolution microarray failed to show potentially pathogenic copy number 
variations. Therefore, despite genome-wide screening by different methods, we 
failed to identify the disease-causing genetic hit in patient 5.  
 
Discussion 
 We describe a novel clinical and biochemical phenotype associated with 
truncating mutations in the THRA gene. While THRS due to mutations in THRB 
gene is a well known disorder, patients with THRS caused by mutations in THRA 
had not, until recently, been identified. As no patients with classic THRS have been 
found to have mutations in THRA, it has been often suggested that mutations in 
THRA may be extremely rare or clinically unrecognized. However, our study 
suggests that milder clinical features and thyroid profile in patients with this novel 
form of RTH α may be the major cause. This discrepancy is most likely due to the 
differences in tissue expression of THRA and THRB; THRA is expressed in the 
cardiac and skeletal muscle, digestive tract, bones and brain, while THRB  is found 
in the liver, kidneys, hypothalamus, hypophysis and thyroid gland. In both forms 
of RTH, organs expressing a dysfunctional thyroid hormone receptor will respond 
in a tissue-specific way to the lack of thyroid hormone stimulus. Mutations in THRB 
lead to selective pituitary resistance to thyroid hormone, releasing the negative 
feedback in the hypothalamic-pituitary-thyroid axis, which finally results in an 
increase in production of thyroid hormone by the thyroid gland. The clinical 
picture of individuals with RTH β often includes a mixture of features of 
hyperthyroidism, such as tachycardia or weight loss, and of classic 
hypothyroidism (for instance, delayed growth or alterations in bone ossification). 
Interestingly, in RTH α, although the uptake of thyroid hormones is altered in 
several target organs, the signalling in the hypothalamus-pituitary-thyroid axis is 
preserved because of the regular function of TRβ2 in the hypothalamus and 
pituitary gland. As a result, despite the deprivation of thyroid hormone stimulus 
on peripheral tissues, the concentration of TSH in these individuals is found within 
the normal range. Despite normal/high T3 blood serum concentration, the 
patients present symptoms of hypothyroidism as the result of an impaired TRα 
function in T3 target tissues. All patients described so far with RTH α presented 
with clinical features resembling those of untreated mild congenital 
hypothyroidism such as mild to moderate intellectual disability, short stature, 
alterations in bone ossification, macroglossia and chronic constipation.1,8,11 Our 
study revealed additional hallmark features of RTH α such as macrocephaly, 
specific facial features, skeletal abnormalities (planovalgus foot, sandal gap 
deformities, club foot or spine deformities), mild features of skeletal dysplasia 
characteristic for hypothyroidism, anaemia, elevated creatine kinase and 
De novo mutations in THRA cause a thyroid hormone resistance syndrome | 75 
 
moderate hypercholesterolemia. Additionally, our findings suggest a certain 
degree of correlation between the genotype and phenotype, as patients with 
nonsense mutations have intellectual disability, while patients with missense 
mutations show low IQ levels that are still within normal ranges. In line with this, 
the only inherited disorder was due to a THRA missense mutation, while all other 
mutations leading to more severe outcome were due to de novo mutations.  
Although the clinical picture of RTH α reminds of hypothyroidism, the 
laboratory data in these patients is inconsistent. The results of laboratory analyses 
in the study group are not typical for hypothyroidism. Despite a low fT4 level, the 
concentration of fT3, physiologically the strongest of the thyroid hormones, is 
high. Such correlation between the free thyroid hormones results from a TRα 
mutation, which prevents complete utilisation of thyroid hormones at the cellular 
level. Free thyroid hormones fall within a broad, normal range. This results in a 
thyroid laboratory profile, which without detailed analysis, is unremarkable for 
thyroid disease and thus, hampers the correct diagnosis in these patients. The 
above may lead to a discontinuation of attempts to find causes of hypothyroidism 
and a misdiagnosis. However, if results of thyroid hormone investigations show 
normal levels of TSH with low-normal T4 and high-normal T3 resulting in a low 
T4/T3 ratio, the possibility of deficit of TRα should be taken into consideration. 
Newborn screening for hypothyroidism, which is run in many countries does not 
reveal TRα deficit. We strongly recommend that patients with some clinical 
signs/symptoms of hypothyroidism and without confirmation in routine 
endocrine studies should have a molecular study of THRA defects.  
The clustering of all the mutations identified to the last exon of THRA 
supports that the mechanism through which this mutation leads to pathogenicity 
is by acting as a dominant-negative TRα1 protein constitutively binding a co-
repressor.1 Remarkably, one of the missense mutations identified in our cohort, 
TRα1 P398R, corresponds to a mutation of the homologous residue in TRβ1 
(P452R), which has been previously identified to lead to RTHβ.12 The presence of 
equivalent pathogenic mutations in both TH receptors points to a common 
molecular mechanism underlying RTH in RTHα and RTHβ. Regarding the stop 
mutations in THRA, their localisation to the last exon allows them to avoid mRNA 
nonsense-mediated decay, permitting transcription of the protein. In our cohort, 
the two patients with nonsense mutations in THRA had the most severe clinical 
phenotypes accompanied by the largest deviations from the norm in the results 
of thyroid-related laboratory tests. At the same time, these two patients are the 
oldest in the observed group and their clinical symptoms seem to be intensifying 
with age. However, one can speculate that, despite the wide spectrum of clinical 
expression in dominant inheritance, we observe a genotype/phenotype 
correlation in our cohort. 
Despite presenting with the same clinical phenotype, the absence of 
mutations in THRA in one patient in our cohort suggests genetic heterogeneity in 
this syndrome. Additional genome-wide studies failed to identify the genetic 
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lesion responsible for the phenotype in this patient. This is reminiscent of RTH β 
in which 85% of affected individuals have mutations in THRB, whilst mutations in 
this gene have been excluded in the remaining 15% without thereby identifying 
the disease-causing genetic lesion.7 It has been hypothesized that individuals 
with so-called non-TR-RTH may have a mutation in a gene involved in TR function 
or TH metabolism. We speculate that this may also be the case for RTH α; a 
mutation or small deletion in a gene involved in TR function or TH metabolism 
may be the cause of the disease in patient 5. Our results suggest that this novel 
syndrome of thyroid hormone resistance is genetically heterogeneous and there 
may be additional genes involved in the pathogenesis of this disorder. 
The results from studies performed on mutant Thra mouse models 
suggest that the recruitment or action of co-regulators, mainly co-repressors, on 
TRα1 could be a target for treatment in individuals with THRA mutations.12 A 
better understanding of the role that TRα1 co-regulator dysfunction plays in this 
genetic syndrome is necessary. However, pharmaceutical compounds targeting 
such nuclear receptor co-regulators could be a promising treatment, not only for 
rare genetic syndromes such as RTH, but also for hormone-dependent cancers.13 
 
Conclusions 
1. Truncating mutations in the THRA gene lead to RTH α, a distinct and 
consistent phenotype of mild hypothyroidism associated with 
macrocephaly, specific facial features and skeletal abnormalities.  
2. THRA mutations may be more common than expected and may escape 
standard laboratory/hormone level tests. 
3. In patients with clinical signs/symptoms of mild hypothyroidism, without 
confirmation in endocrine studies, a molecular study of defects in THRA is 
recommended. 
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Materials and methods 
Patients 
All patients (n=6, age range 2 to 39 years, mean age 16, median age 11.5) 
were admitted and followed at The Children’s Memorial Health Institute (Warsaw, 
Poland). All five pediatric patients were selected based on strikingly similar 
dysmorphic features along with developmental and metabolic alterations, 
suggestive for a common underlying genetic defect.  
 
Molecular genetic studies 
Blood and/or saliva samples from the patients and their parents were 
obtained, from which DNA was extracted and purified. Exome libraries were 
prepared using a SureSelect human exome v2 kit (Agilent, Santa Clara, USA) and 
sequencing was performed on patient DNA on a SOLiD4 platform (Life 
Technologies, Foster City, USA). Reads were mapped to the hg19 reference 
genome and variant calling was done with Lifescope software v2.1 (Life 
Technologies, Foster City, USA), Variant annotation, filtering and prioritization 
was performed as described previously.10 Sanger sequencing was performed to 
validate candidate variants and prove de novo occurrence or show segregation. 
 
Ethical considerations 
The protocol was approved by the human-subjects institutional review 
board at the Children’s Memorial Health Institute. The study was designed and 
conducted in compliance with the principles of the International Conference on 
Harmonisation of Technical Requirements for registration of Pharmaceuticals for 
Human Use Guidelines for Good Clinical Practice. Written informed consents for 
the genetic investigations and picture publication were provided by the parents 
or legal guardians. 
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Web resources 
Exome Variant Server:  http://evs.gs.washington.edu/EVS/  
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Supplementary data 
 
Supplementary materials 
Based on the similarity and severity of their clinical features, two affected 
individuals were selected for exome sequencing. Blood samples were taken and 
DNA was extracted and purified using the QIAamp genomic DNA kit (Qiagen, 
Hilden, Germany). Exome libraries of patients 1 and 2 were prepared using the 
SureSelect v.2, 50Mb kit (Agilent) and sequenced on a SOLiD™4 platform (Life 
Technologies, Foster City, USA. The sequence reads were aligned to the hg19 
reference genome resulting in 2.9 Gb of mapped sequences in both cases which 
correlates to 58-fold and 59-fold average coverage respectively (see 
Supplementary Table S3). Variants were called and annotated using Lifescope 
v.2.1. software. Called variants were prioritized based on the quality of the 
sequencing of each called base pair, on the predicted consequences at the 
protein level and taking into consideration the overlap with common variation 
(in-house variant database consisting of 2,094 exomes, dbSNP v.132, 1000 
Genomes project and the exome variant server (EVS); Supplementary Table S4). 
After these prioritization steps, we performed an overlap analysis to determine in 
which genes were private variants identified in both of the sequenced individuals 
(Supplementary Table S5). In the exome data, we identified in each individual a 
truncating variant in THRA in each individual (Supplementary Figure S1 and 
Supplementary Table S5) and a private missense mutation in KRT2 (which was 
shown to be false-positive by Sanger sequencing). We performed Sanger 
sequencing of the THRA gene from genomic DNA of the affected individuals and 
their parents, to check for segregation of the mutations (Supplementary Figure 
S1). All primers were obtained from IDT and their sequences are provided in 
Supplementary Table S6. 
 
The exome of patient 5 was prepared using SureSelect v.4 (Agilent) and 
sequenced on a SOLID™ 5500XL Platform (Life Technologies, Foster City, USA). 
Mapping and variant calling was done as mentioned previously. Called variants 
were filtered based on the quality of the sequencing (more than 3 variant reads 
and variant present in more than 20% of the reads), the frequency of the variant 
in sequencing databases (minor allele frequency less than 0.1% and found in less 
than 5 samples from our in-house database) and the predicted consequences at 
the protein level (conserving missense and truncating coding mutations and 
mutations affecting the canonical splice sites). No mutations were seen in the 
THRA gene, in genes coding for known co-factors, co-regulators or co-repressors 
of the THRA protein nor in the genes coding for deiodinases.   
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Supplementary figures 
 
 
 
 
      
 
Supplementary Figure S1. Pedigrees of the different families, showing sequencing data from 
exome sequencing and capillary electrophoresis. A c.1176C>A mutation in THRA was identified by 
exome sequencing in the index case from family 1 (marked with an arrow). This truncating mutation 
in THRA [p.C392X] was found to be de novo. Mutation c.1207G>T in the index case of family was 
also identified by exome sequencing. Capillary electrophoresis shows that this truncating mutation 
occurred de novo in the affected individual. The mutation in the index case of family 3, THRA 
c.1207G>A [p.E403K] was inherited from the father, who was also affected. This mutation was 
identified by screening through capillary electrophoresis. Screening for mutations in THRA by 
capillary electrophoresis also revealed a missense mutation (THRA c.1193C>G [p.P398R]) in the 
index case of family 4. The mutation in this patient occurred de novo.  
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Supplementary Figure S2: Radiologic finding in a novel thyroid hormone resistance syndrome due 
to truncating mutations in THRA gene. a: ovoid (immature) form of the vertebral bodies, 
anterosuperior ossification defect in the lower thoracic and upper lumbar bodies. b: Hypoplasia of 
the acetabular and supraacetabular portions of the ilia; coxa valga. 
 
  
a b 
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Supplementary Figure S3. Diagram of THRA isoform 1 mRNA (a) and protein (b) showing the 
mutations at the cDNA and protein level, which are only found in THRA isoform 1 and not in THRA 
isoform 2 (c and d, for mRNA and protein level respectively). Truncating mutations are shown in red 
triangles and missense mutations are shown in pink triangles. Dark blue rectangles represent exons 
that are found both in THRA isoform 1 and 2, while light blue rectangles represent exons that are 
differentially spliced in each isoform. Important domains in the THRA protein are shown 
in color with green representing the nuclear receptor domain and purple represents the ligand-
binding domain. 
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Supplementary tables 
 
Patients 
 1 2 3 4 5 
Mutation 
(cDNA) THRA C1176A THRA G1207T THRA G1207A THRA C1193G Not identified 
Substitution 
(protein) THRA C392X THRA E403X THRA E403K THRA P398R Not identified 
Inheritance de novo de novo inherited de novo - 
Age 18 14 12 8 5 
Dysmorphic features 
Macrocephaly + + + - + 
Coarse face + - - - - 
Wide forehead + + - + - 
Hypertelorism + + + + + 
Palpebral 
ptosis + + + - + 
Low or flat 
nasal bridge + + + + + 
Micrognatia + - + - - 
Macroglossia - + - - - 
Short neck + - + - + 
Growth and skeletal abnormalities 
Delayed 
growth + + - + - 
Short stature + + + - + 
Elongated 
thorax + + + + - 
Lumbar 
kyphosis + + - - - 
Short limbs + + + + + 
Developmental abnormalities 
Intellectual 
disability Severe Moderate Mild Normal Normal 
IQ 22 70 80 95 110 
Delayed 
speech 
development 
+ - - + - 
Psychomotor 
alterations + + + + - 
Gestational 
age at birth 41 weeks 42 weeks 42 weeks 42 weeks 40 weeks 
Birth weight 
4200g 
 (90th perc) 
3950g  
(90th perc) 
3650g 
 (>75th perc) 
3450g  
(>50th perc) 
3920g 
 (>75th perc) 
Birth length 
56cm 
 (>98th perc) 
50cm  
(>50th perc) 
55cm  
(>98th perc) 
55cm  
(>98th perc) 
51 cm  
(>75th perc) 
Head 
circumference 
37cm  
(>98th perc) 
39cm  
(>98th perc) 
39 cm 
 (>98th perc) 
35 cm  
(>75th perc) 
36 cm  
(>98th perc) 
Thyroid laboratory tests 
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Patients 
 1 2 3 4 5 
Mutation 
(cDNA) THRA C1176A THRA G1207T THRA G1207A THRA C1193G Not identified 
Substitution 
(protein) THRA C392X THRA E403X THRA E403K THRA P398R Not identified 
Inheritance de novo de novo inherited de novo - 
Age 18 14 12 8 5 
Other characteristics 
Deep or hoarse 
voice + + + + + 
Pale and 
doughy skin 
+ + - - - 
Constipation + + + + + 
Anemia + + + + + 
High 
cholesterol + + + + - 
Thyroid laboratory tests 
fT4 Low Low/Normal Low/Normal Low/Normal Normal 
fT3 
High/Upper 
limit 
Upper limit Upper limit Upper limit Upper limit 
TSH Normal Normal Normal 
Low/ 
Normal 
Normal 
Other thyroid 
function 
features 
Negative anti-
TPO and anti-
TG antibodies 
N/A 
Limit levels for 
anti-TPO and 
anti-TG 
antibodies 
N/A 
Normal levels 
of thyroxine 
binding 
globulin 
X-ray 
abnormalities + + + N/A N/A 
 
Supplementary Table S1: Clinical phenotype of patients with a syndrome of thyroid hormone 
resistance due to mutations in the THRA gene. + present; - not present; N/A not available. All 
features that are present in four or more unrelated subjects of our cohort are highlighted in bold 
font. The full version of this table is available at http://jmg.bmj.com/content/52/5/312.long  
 
 
  THRS due to THRA mutations THRS due to THRB mutations 
fT4 Low or normal High 
fT3 Upper limit or high High 
T3:T4 ratio Altered High 
TSH Low or normal High 
Goiter Not present + 
Other 
Negative thyroperoxidase or 
thyroglobulin antibodies 
Negative thyroperoxidase or 
thyroglobulin antibodies 
 
Supplementary Table S2. Summary of clinical and laboratory findings relative to thyroid function 
in individuals with thyroid hormone resistance syndrome (THRS) due to mutations in THRA 
compared to those of individuals with THRS due to mutations in THRB.  
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 Patient 1 Patient 2 Patient 5 
Total mapped bases [hg19] 2,923,298,920    2,976,245,643.00                3,628,016,187  
Median target coverage 55.4 59.4 65.3 
Average target coverage 58.2 58 65.4 
 
Supplementary Table S3. Exome mapping statistics for patients on which exome sequencing was 
performed. The exomes from patient 1 and 2 were enriched with the SureSelect human exome v2 
kit and sequenced using a SOLiD4 platform, while the exome from patient 5 was based on v4 exome 
data and SOLiD 5500XL sequencing. 
 
  Patient 1 Patient 2 Patient 5 
All variants 32,904 35,635 48,207 
of which 
Coding and splice site 
variants 
13,894 14,685 17,150 
Private variants (i.e. not 
present in dbSNP132 nor in 
2094 in-house exomes) 
329 368 182 
Non-synonymous 252 274 125 
Variants found in genes 
overlapping in affected 
individuals 
2 - 
 
Supplementary Table S4. Variant filtering of exome data of patients 1, 2 and 5 (prioritization 
analysis, similar to Hoischen et al.8) 
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Supplementary Table S6. Sequences of the primers used to screen for mutations in THRA in our 
cohort. 
  
Primer name 5'-Sequence-3' 
THRA Exon 2 F CCCTTTTAAGCATTGTCAGC  
THRA Exon 2 R CTGGGCACATCCCACATTAC  
THRA Exon 3 F TTAGGGCAGAGATGGACAGG  
THRA Exon 3 R ATCACTTGAACCTGAAGGCG  
THRA Exon 4 F CCCTCACTGATCTTGCCTTC  
THRA Exon 4 R AGGACAGCAAGGACCAAGAC  
THRA Exon 5 F CCTCGGTTTCTCCAACCTG  
THRA Exon 5 R TGGACAGCAAAAGTGTGAAGAG  
THRA Exon 6 F CTTTGGGCCTGGGACTC  
THRA Exon 6 R TGCTGGGTGTATGTGTATGC  
THRA Exon 7 F CGTTCAGAGTCCATGGGG  
THRA Exon 7 R AGCCCAGAAGAAGATTCAGG  
THRA Exon 8 F TCCTGTCCACGTCTCTCAGG  
THRA Exon 8 R ATCCAAGGACGAGAGGAAGG  
THRA Exon 9 F GGGGCCAGAGGCTCATC 
THRA Exon 9 R CACCTCCTGCTCTTGGGG 
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First stages of division of mammalian embryos. a. Two cell stage; b. Four cell stage; c. Eight cell 
stage; d,e. Morula stage. z.p. zona pellucida; p.gl. polar bodies. 
Anatomy of the Human Body by Henry Gray & Henry Vandyke Carter (1918) 
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Abstract 
De novo mutations are recognized both as an important source of genetic 
variation and as a prominent cause of sporadic disease in humans. Mutations 
identified as de novo are generally assumed to have occurred during 
gametogenesis and, consequently, to be present as germline events in an 
individual. As Sanger sequencing does not provide the sensitivity to reliably 
distinguish somatic from germline mutations, the proportion of de novo 
mutations that occurs somatically rather than in the germline remains largely 
unknown. To determine the contribution of postzygotic events to de novo 
mutations, we analyzed a set of 107 de novo mutations in 50 parent-offspring 
trios. Using four different sequencing techniques, we found that 7 (6.5%) of these 
presumed germline de novo mutations were in fact present as mosaic mutations 
in the blood of the offspring and were therefore likely to have occurred 
postzygotically. Furthermore, genome-wide analysis of “de novo” variants in the 
proband led to the identification of 4 out of 4,081 variants which were also 
detectable in the blood of one of the parents, implying parental mosaicism as the 
origin of these variants. Thus, our results show that an important fraction of de 
novo mutations presumed to be germline in fact occurred either postzygotically 
in the offspring or were inherited as a consequence of low-level mosaicism in one 
of the parent 
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Introduction 
In humans, DNA replication is estimated to entail one error every 108 base 
pairs, giving rise to 30 to 100 genome-wide de novo mutations in each new 
generation.1–3 While neutral or benign de novo point mutations contribute to 
normal genetic variation, single detrimental de novo mutations have been 
established to cause a number of rare developmental disorders4–6 and are 
increasingly recognized as a major contributor to common sporadic disorders, 
such as intellectual disability (ID) and autism.7,8 De novo mutations are thought to 
occur predominantly in the egg or sperm cell, resulting in an embryo with a 
constitutive mutation. However, de novo mutations may also appear 
postzygotically, leading to mosaicism in the embryo, a state in which two or more 
genetically distinct cell populations in an individual develop from a single 
fertilized egg.  
Several reports have shown a high frequency of mosaicism for copy 
number variations from cleavage stage embryos9 to fully differentiated tissues.10–
12 Similarly, there is increasing evidence for a high prevalence of mosaicism for 
single nucleotide variants (SNVs) as a result of mutations appearing from early 
embryogenesis onwards13,14 and throughout adult life.15,16 Currently, postzygotic 
de novo mutations receive growing attention in developmental diseases.17–19 The 
timing of the event plays a key role in the clinical phenotype by determining not 
only the proportion of affected cells in the organism, but also the type of tissues 
involved.18 Despite its pervasiveness, however, the true extent of mosaicism for 
SNVs remains unclear. This is largely a consequence of the technological 
limitations to accurately detect these mutations; on one side, mutations with low 
levels of mosaicism are often below the threshold of sensitivity and specificity for 
automated and systematic detection of traditional sequencing methods,20 and on 
the other hand, mutations with a higher percentage of affected cells are easily 
detected by traditional sequencing methods but remain technically challenging 
to differentiate from germline de novo mutations. Indeed, to discriminate 
postzygotic from germline de novo mutations by sequencing DNA, it is crucial to 
distinguish biologically relevant allele imbalances from technical artifacts.  
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To gain insight into the frequency of postzygotic events among de novo 
mutations, we performed a systematic evaluation of de novo mutations identified 
by trio-based whole genome sequencing (WGS) of 50 individuals with severe ID 
and their parents. Previous analysis of WGS data from this cohort recently pointed 
to germline de novo mutations as the major cause of ID in the affected 
individuals.21 Additionally, these data indicated the presence of de novo 
mutations of somatic origin.21 By systematic assessment of allelic ratios using 
various sequencing techniques, we here show that a proportion of previously 
reported de novo mutations do not occur during gametogenesis but arise, in fact, 
as postzygotic events in the proband or are present as low-level somatic 
mutations in one of the parents. 
 
Results 
Determining the technical variation for WGS, ADS and Sanger sequencing 
To gain insight into the sensitivity of WGS, ADS and Sanger sequencing, 
we re-sequenced two different sets of inherited germline mutations, as proxy for 
true heterozygosity (Figure 1A and Supplementary Figure S2). We subsequently 
determined the distribution of the allelic ratios per technology (Supplementary 
Table S1 and Supplementary Figure S3). With an allele ratio of 48.2±4.4% (average 
±standard deviation), ADS showed to be the most precise technique for the 
identification of true heterozygosity. In comparison, WGS showed an allelic ratio 
of 50.5±8.9% and Sanger sequencing of 51.4±8.7% (Supplementary Table S2). 
Based on the obtained distributions for the allelic ratio, we determined that de 
novo mutations with an allelic ratio below 32.8% for WGS, 39.3% for ADS and 
33.9% for Sanger sequencing have a statistically significant deviation from the 
expected ratio for true heterozygous mutations and may, as such, reflect mosaic 
mutations. 
 
 
Figure 1. Workflow for the detection of mosaic mutations among a subset of apparently de 
novo mutations. (Part A) Assessment of technique-dependent variation in sequencing of two 
groups of heterozygous germline variants (in blue) to determine the distribution of allelic ratios for 
three different techniques (WGS, ADS and Sanger sequencing). (Part B) Previously identified de novo 
mutations were re-sequenced by ADS and Sanger sequencing to determine the variant ratio. Using 
the combined z-score, nine putative somatic variations were identified, which were validated by 
ADS with a second independent primer pair and smMIPs. Seven of nine mutations were confirmed 
to deviate in allelic ratio suggesting a non-germline event. (Part C) Identification of de novo 
mutations originating from parental mosaicism. Of 4,081 high confidence de novo mutations 
identified by WGS, thirteen variants were identified to have two or more variant reads in parental 
DNA. Using ADS data from the non-carrier parent to correct for the background sequencing error, 
four mutations appearing as de novo in the child were identified as low-level mosaicism in one of 
the parents.           
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Identification of postzygotic de novo mutations in probands 
Our next objective was to determine the proportion of postzygotic events 
among a subset of de novo mutations in our cohort. For this, we studied a pre-
defined set of 107 de novo mutations using WGS, ADS and Sanger sequencing 
(Figure 1B).21 Similar to the inherited variants, allelic ratios for each mutation were 
determined for each sequencing technique. After calculation of the mean allelic 
ratio across the three sequencing techniques, nine de novo mutations showed a 
statistically significant deviation from the expected ratio for true germline 
heterozygosity (Supplementary Figure S4 and Supplementary Figure S5). 
To exclude technical artifacts resulting from biased allele amplification 
during PCR which would thereby falsely suggest the presence of mosaicism, we 
generated a second independent amplicon with different PCR primers to re-
sequence all nine mutations by ADS (Table 1, Supplementary Table S1 and 
Supplementary Table S3). This analysis confirmed a statistically significant 
deviation in the allelic ratio for eight out of nine de novo mutations. Of note, three 
of these mutations had been previously reported as possible mosaic mutations.21 
To validate these findings with an independent test, we set out to 
sequence the eight candidate mosaic mutations using smMIPs for increased 
depth and accuracy. By sequencing germline mutations within the same assay, 
we first established for this technique the average and standard deviation of the 
allelic ratio for true heterozygosity, which was shown to be 47.1±3.3%. Unique 
smMIPs could be designed for all but one candidate mosaic event, located in an 
intron of SETBP1 (MIM 611060). The remaining seven mutations were tested and 
confirmed to be present as mosaic events with allelic ratios between 20.8 and 
29.7%. Translating these allelic ratios into percentages of cells carrying the 
mutation predicts that the mutations must be present in 41.6 to 59.4% of the cells 
in blood. Thus, our results indicate that at least seven of 107 (6.5%) de novo 
mutations detected in our cohort did not occur in the germline of the parent, but 
arose postzygotically in the offspring.  
 
Parental mosaicism as a source of seemingly de novo mutations 
Gonadal mosaicism in a healthy parent can lead to the transmission of 
disease-causing mutations and recurrence of disorders with seemingly de novo 
ocurrence.24 In some cases, mosaicism may not be restricted to the germ cells; it 
was recently shown that healthy individuals with gonadal mosaicism for disease-
causing CNVs, revealed by recurrence of the disease in the offspring, carried low 
levels of mosaicism for this CNV in blood.25 Following this idea, we aimed to  
determine whether any of the seemingly germline de novo events in our cohort 
of 50 probands had actually occurred as somatic mutations in one of the parents 
(Figure 1C). For this, we re-analyzed all 4,081 high confidence de novo mutations 
 
Postzygotic mutations contribute to novel genomic variation | 97 
 
 
G
en
e 
G
en
e 
G
en
e 
G
en
e 
n
am
e
n
am
e
n
am
e
n
am
e     
M
u
ta
ti
o
n
 a
t 
g
D
N
A
 le
ve
l 
M
u
ta
ti
o
n
 a
t 
g
D
N
A
 le
ve
l 
M
u
ta
ti
o
n
 a
t 
g
D
N
A
 le
ve
l 
M
u
ta
ti
o
n
 a
t 
g
D
N
A
 le
ve
l 
(h
g
19
)
(h
g
19
)
(h
g
19
)
(h
g
19
)     
Lo
ca
ti
o
n
Lo
ca
ti
o
n
Lo
ca
ti
o
n
Lo
ca
ti
o
n
    
P
re
d
ic
te
d
 m
u
ta
ti
o
n
 a
t 
cD
N
A
 
P
re
d
ic
te
d
 m
u
ta
ti
o
n
 a
t 
cD
N
A
 
P
re
d
ic
te
d
 m
u
ta
ti
o
n
 a
t 
cD
N
A
 
P
re
d
ic
te
d
 m
u
ta
ti
o
n
 a
t 
cD
N
A
 
le
ve
l
le
ve
l
le
ve
l
le
ve
l     
P
re
d
ic
te
d
 p
ro
te
in
 
P
re
d
ic
te
d
 p
ro
te
in
 
P
re
d
ic
te
d
 p
ro
te
in
 
P
re
d
ic
te
d
 p
ro
te
in
 
su
b
st
it
u
ti
o
n
su
b
st
it
u
ti
o
n
su
b
st
it
u
ti
o
n
su
b
st
it
u
ti
o
n
    
pp pp
-- -- v
al
u
e*
va
lu
e*
va
lu
e*
va
lu
e*
    
A
ve
ra
g
e 
A
ve
ra
g
e 
A
ve
ra
g
e 
A
ve
ra
g
e 
%% %%
    
KA
N
SL
2 
ch
r1
2:
49
07
29
11
C
>
A
 
Ex
o
n
 4
 
N
M
_0
17
82
2.
3:
 c
.4
53
G
>
T 
p
.G
15
1=
 
6.
94
E-
21
 
20
.8
 
C
RE
BL
2 
ch
r1
2:
12
78
88
68
G
>
C
 
Ex
o
n
 2
 
N
M
_0
01
31
0.
2:
 c
.1
73
G
>
C
 
p
.R
58
P 
6.
40
E-
19
 
21
.0
 
PI
A
S1
 
ch
r1
5:
68
46
80
14
T>
A
 
Ex
o
n
 1
0 
N
M
_0
16
16
6.
1:
 c
.1
20
9T
>
A
 
p
. D
40
3E
 
1.
84
E-
18
 
22
.9
 
PN
KP
 
ch
r1
9:
50
36
75
25
C
>
T 
In
tr
o
n
 5
 
N
M
_0
07
25
4.
3:
 c
.5
79
-3
2G
>
A
 
N
/A
 
7.
05
E-
17
 
22
.7
 
H
IV
EP
2 
ch
r6
:1
43
09
26
83
C
>
T 
Ex
o
n
 5
 
N
M
_0
06
73
4.
3:
 c
.3
19
3G
>
A
 
p
.A
10
65
T 
2.
20
E-
14
 
25
.2
 
D
PY
D
 
ch
r1
:9
75
88
23
6C
>
T 
In
tr
o
n
 
21
 
N
M
_0
00
11
0.
3:
c.
26
23
-
24
04
8G
>
A
 
N
/A
 
3.
17
E-
10
 
29
.7
 
N
EK
1 
ch
r4
:1
70
35
92
95
T>
G
 
Ex
o
n
 2
7 
N
M
_0
01
19
93
97
.1
:c
.2
70
3A
>
C
 
p
.K
90
1N
 
3.
67
E-
08
 
29
.4
 
    T
ab
le
 1
. 
Ta
b
le
 1
. 
Ta
b
le
 1
. 
Ta
b
le
 1
. 
D
e 
n
ov
o
D
e 
n
ov
o
D
e 
n
ov
o
D
e 
n
ov
o     
m
u
ta
ti
o
n
s 
o
cc
u
rr
in
g
 a
s 
p
o
st
m
u
ta
ti
o
n
s 
o
cc
u
rr
in
g
 a
s 
p
o
st
m
u
ta
ti
o
n
s 
o
cc
u
rr
in
g
 a
s 
p
o
st
m
u
ta
ti
o
n
s 
o
cc
u
rr
in
g
 a
s 
p
o
st
-- -- z
yg
o
ti
c 
ev
en
ts
 i
n
 t
h
e 
o
ff
sp
ri
n
g
. 
zy
g
o
ti
c 
ev
en
ts
 i
n
 t
h
e 
o
ff
sp
ri
n
g
. 
zy
g
o
ti
c 
ev
en
ts
 i
n
 t
h
e 
o
ff
sp
ri
n
g
. 
zy
g
o
ti
c 
ev
en
ts
 i
n
 t
h
e 
o
ff
sp
ri
n
g
. 
*p
-v
al
u
es
 w
er
e 
co
rr
ec
te
d
 b
y 
B
en
ja
m
in
i-H
o
ch
b
er
g
 f
o
r 
m
u
lt
ip
le
 t
es
ti
n
g
; T
h
e 
le
ve
l o
f 
th
e 
m
u
ta
ti
o
n
 w
as
 c
al
cu
la
te
d
 b
y 
av
er
ag
in
g
 t
h
e 
va
ri
an
t 
ra
ti
o
 f
o
r 
ea
ch
 m
u
ta
n
t 
fr
o
m
 a
ll 
se
q
u
en
ci
n
g
 m
et
h
o
d
s.
 N
/A
, 
N
o
t 
ap
p
lic
ab
le
. 
 
98 | Chapter 4 
 
previously detected by WGS in the probands and selected those de novo 
mutations in which two or more variant reads could be detected in the raw 
sequence data in one of the respective parents. Thirteen such mutations were 
identified but two could not be amplified by PCR and were excluded from further 
analysis. Sequencing by ADS was performed on the remaining 11 mutations to 
determine whether we could detect the variant in DNA from the carrier parent. 
After stringent correction for the background sequencing error, four of these 
mutations were confirmed to be present in blood of one of the parents. These 
low-level parental mosaic mutations show an average allelic ratio of 3.54% (range 
0.22 to 6.15%; Table 2 and Supplementary Table S4). Of note, these low-level 
parental mosaic mutations, of which three were transmitted by the father and one 
by the mother, were not detected in the parental DNA by Sanger sequencing 
(Supplementary Figure S6). 
 
Modeling the effect of sequence coverage on the detection of mosaic 
mutations 
Evidently, sufficient sequencing coverage is required to reliably identify 
mosaic mutations. To investigate the impact of coverage on the detection of 
mosaic mutations, we modeled the probability to detect both postzygotic 
mutations in a proband as well as low-level parental mosaicism given different 
sequencing coverage. 
The detection of postzygotic de novo mutations requires two essential 
steps: calling of the variant in the proband and identification of a significant 
deviation of the allelic distribution. Modeling under the assumption that ≥5 
variant reads are required for variant calling and that these constitute ≥5% of the 
total number of sequence reads indicates that at least 100-fold coverage is 
required to call 90% of mosaic variants with an allelic ratio equal to 10% or higher 
(Supplementary Figure S7). Increased sequencing coverage decreases the 
standard deviation in the allele ratio, which reduces technical variation 
(Supplementary Figure S8) and allows for better discrimination between true 
heterozygosity and mosaicism. Provided that a postzygotic mutation is called, we 
also modeled the deviation in the allelic ratio of a mosaic variant required to 
reliably distinguish it from a heterozygous variant (Supplementary Figure S9). Our 
model indicates that at least 100-fold coverage is required to distinguish mosaic 
mutations with allelic ratios <40% from germline mutations with 95% probability.  
The analysis for parental mosaicism for de novo mutations identified in a 
proband requires a different approach; the identification of parental mosaicism 
for a seemingly de novo mutation in the offspring is guided by the presence of 
the variant in the proband. As a consequence, the only requirement for the 
identification of parental mosaicism is to distinguish the variant reads in the 
parent from the background sequencing error at the respective genomic location. 
  
Postzygotic mutations contribute to novel genomic variation | 99 
 
Genomic 
location 
Gene 
Gene 
location 
Origin 
Total 
reads 
(ADS) 
Variant 
reads (%) 
p-
value* 
chr13:78303535 
A>T 
SLAIN1 Intron Father 31,470 6.15 <0.001 
chr18:25210178 
C>T 
- Intergenic Father 34,149 2.56 <0.001 
chr5:11327458 
C>T 
CTNND2 Intron Mother 12,754 5.25 <0.001 
chr5:147855052 
G>A 
HTR4 Intron Father 20,927 0.22 <0.05 
Table 2. De novo mutations in the offspring originating from parental mosaicism. *p-values 
were corrected for multiple testing by Bonferroni correction. 
 
 
Under the assumption that 2 variant reads in the parent are sufficient for this, we 
modeled the coverage required to identify low-level parental 
mosaicism (Supplementary Figure S10) which shows that at least 140-fold 
coverage is needed to detect low-level mosaicism of ≥5% with ≥95% probability. 
 
Discussion 
The aim of our study was to investigate the presence of non-germline 
events among de novo mutations. Our results show that 6.5% of a subset of de 
novo mutations (seven out of 107) were present as mosaic mutations in blood of 
the proband, strongly suggestive of a postzygotic origin. Extrapolating our results 
to published genome-wide de novo mutation rates3,21 suggests that each 
individual carries at least 2 to 7 de novo mutations of postzygotic origin. 
Additionally, from a group of 4,081 mutations presumed to be de novo in the 
offspring, we detected four mutations which were in fact inherited from one of 
the parents in whom the mutation was present as a low-level mosaic mutation. 
Although this represents only 0.1% of all high quality de novo mutations, parental 
mosaicism for a seemingly de novo mutation in the offspring was observed in four 
out of 50 trios. Based on the stringent criteria which were used to validate variants 
as mosaics and our modeling data, we anticipate that our results are likely an 
underestimation of the true number of mosaic mutations present in blood.   
Our initial selection of potential mosaic variants was based on results 
obtained with relatively high coverage WGS (80-fold). We show that, for trio-
based WGS, 80-fold sequencing coverage is sufficient to identify postzygotic 
events among de novo mutations. However, statistical modeling of the 
probability to detect mosaicism given various sequencing depths showed that, 
with this coverage, there is only an 80% probability of obtaining sufficient reads 
to identify mosaicism present in ≥10% of the alleles (corresponding to ≥20% of 
the cells studied, Supplementary Figure S7). Similarly, with this coverage we are 
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only able to reliably distinguish somatic events with allelic ratios below 39% from 
germline mutations (Supplementary Figure S9). This suggests that postzygotic 
variants in the proband with allelic ratios at either extreme may have gone 
unidentified in our study. On the other hand, the probability of obtaining at least 
2 sequence reads to identify a ≥5% parental mosaicism is only 78% with 80-fold 
sequencing coverage, suggesting that the identification of these mutations can 
also be optimized by providing higher sequencing coverage (Supplementary 
Figure S10). Indeed, the low-level parental mosaic variants identified in our study 
had a significantly higher sequencing depth in the carrier parent than the other 
de novo or postzygotic mutations studied (Supplementary Figure S11). Our 
results and statistical modeling highlight the importance of high sequencing 
coverage in the design of trio-based WGS studies. Currently, most WGS studies 
are performed at 30-fold coverage.13,26,27 If we assume that sequence quality is 
comparable to that of our study, this entails that less than 20% of mosaic variants 
with an allelic ratio between 10 and 33% can be identified with 30-fold 
sequencing coverage. Additionally, at this sequencing coverage, only mosaic 
mutations with an allele ratio below 35% can be reliably distinguished from true 
heterozygous variants. Furthermore, our modeling suggests that there is less than 
20% probability of identifying parental mosaicism with an allelic ratio of less than 
5% with WGS at 30-fold coverage. Given these results, our findings underline the 
need for increased sequencing coverage in WGS for the accurate identification of 
mosaicism. 
Despite the aforementioned limitations, we show that WGS is a powerful 
method for genome-wide discovery of mosaic events. In this study, we used three 
additional techniques to confirm mosaicism of SNVs. After identification of de 
novo mutations by WGS, their status as postzygotic events was first evaluated by 
ADS and Sanger sequencing. A limitation of both these techniques is that they 
may show an allelic imbalance due to biased amplification of one allele over the 
other.28 For the most part, significant deviations in the allele ratio secondary to 
technical artifacts observed in Sanger and ADS were method–specific, rather than 
reproducible PCR artifacts (Supplementary Figure S12). We have attempted to 
remedy this problem by the use of smMIPs, which provide targeted high 
sequence coverage and the ability to identify individual captured molecules,23 
thus preventing any deviations in the allele ratio due to PCR amplification bias.  
The presence of parental gonosomal mosaicism as the cause of a sporadic 
disorder in a family places the subsequent offspring at higher risk for recurrence 
of the disease than when the mutation is caused by a germline de novo 
mutation.29 Considering this, the presence of parental mosaicism in four out of 50 
individuals of our cohort stresses the importance of a thorough follow-up in 
families affected by a disorder due to a de novo mutation.30 Notably, the lower 
limit of detection by Sanger sequencing has been reported to be close to only 
10%,25 whereas the highest level of parental mosaicism here detected was only 
6.15% and could not be identified by Sanger sequencing (Supplementary Figure 
S6). Since Sanger sequencing is commonly used in diagnostics, parental 
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mosaicism below the threshold of detection of this method could account for 
recurrence of de novo disorders within families24,31 and explain unsolved 
pedigrees with an apparently recessive inheritance of disorders otherwise known 
to be dominant.32 Under these circumstances, high coverage NGS should be 
favored over Sanger sequencing for the detection of low-level parental 
mosaicism and may even be warranted as a standard follow-up test for each 
pathogenic de novo mutation. Related to this, the frequent detection of mosaic 
events may partially explain the occurrence of known dominant pathogenic 
mutations within large-scale variant databases of healthy individuals such as 
Exome Variant Server. This point needs to be taken into account when these 
databases are used for clinical interpretation of possible pathogenic mutations. 
Also, previous studies have shown that certain mutations found as true 
heterozygous events in one tissue may be detected at low levels or completely 
absent in another.33 Clearly, further studies of mosaic mutations and their impact 
on phenotypic variation requires an in-depth analysis of different tissues. 
 
In summary, our results show that a proportion of de novo mutations 
presumed to be germline actually either occurred postzygotically in the offspring 
or were inherited from low-level mosaicism in one of the parents. This indicates 
that de novo mutations do not arise solely during gametogenesis but also as 
postzygotic mutations, suggesting that our genomes may be much more 
dynamic than previously considered. As the contribution of de novo mutations to 
human disease becomes increasingly apparent, this conclusion may well have 
clinical implications. Pathogenic variants in mosaic state require particular 
attention as to their detection using sequencing methods. Furthermore, their 
influence on the risk of recurrence of a disease underlines the importance of the 
identification of mosaicism to offer accurate genetic counseling in sporadic 
disorders caused by de novo mutations.  
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Materials and methods 
Defining a set of de novo mutations from whole genome sequencing of 
parent-proband trios  
This study was performed in accordance with the ethical standards of the 
Medical Ethics Committee of the Radboud university medical center. All 
participants or their legal representatives gave informed consent. WGS of 50 
parent-proband trios and subsequent de novo mutation detection was 
performed as described previously.21 Briefly, trio-based WGS was performed by 
Complete Genomics (CG) at 80-fold coverage. Sequence reads were mapped to 
the reference genome (GRChr37) and variants were called using CG software 
v.2.4. De novo mutations were called using CG’s cgatools calldiff program, which 
detects the differences between the genotypes of two samples and assigns a 
somatic score based on sequencing quality and paired sample comparison. 
Mutations with scores for offspring versus both parents ≥5 were called as high 
confidence de novo mutations (for which a total of 4,081 was detected in the 50 
trios). The original report identified a set of 127 de novo mutations, affecting 
either genome-wide coding sequence or specifically the non-coding sequence of 
known ID genes.21 This set served as the starting point for the current study.  
 
Sequencing methods used to assess the postzygotic state of de novo 
mutations 
PCR amplicons for amplicon-based deep sequencing (ADS) and Sanger 
sequencing were generated using standard PCR protocols. ADS was performed 
on an Ion Torrent PGM sequencer (Life Technologies, Carlsbad, CA, USA) as 
described previously.21 In brief, raw sequencing reads were mapped to the 
reference genome using the BWA software package and the alignment files were 
then analyzed in the Integrative Genomics Viewer (IGV).22 For Sanger sequencing, 
PCR products were sequenced after enzymatic clean-up.  
Sequencing using single molecule molecular inversion probes (smMIPs) 
was done following previously published protocols.23 Briefly, smMIP probes 
targeting the selected de novo mutation and a total of 112 bp surrounding 
sequence were designed in-house and ordered from Integrated DNA 
Technologies (IDT, Leuven, Belgium). The smMIPs were pooled and 
phosphorylated, after which the genomic regions of interest were captured with 
the probes and amplified. Sequencing was performed on the NextSeq 500 
desktop sequencer (Illumina, San Diego, CA, USA) and the reads were aligned 
using our in-house bioinformatics pipeline for molecular inversion probe analysis. 
Through the use of molecular barcodes, we were able to remove PCR duplicates. 
Read counts for the positions of interest were extracted from the alignment files 
through IGV. 
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Assessment of the allelic ratio distribution of true heterozygous variants 
To define the parameters of technical variation in WGS, ADS and Sanger 
sequencing, we determined for each technology the allelic ratio of inherited 
SNVs, as proxy for true heterozygous mutations. The allelic ratio was defined as 
the proportion of variant reads from the total number of sequencing reads 
covering a given base pair and is expressed here as a percentage. The distribution 
of the allelic ratio for true heterozygous variants in WGS data was established by 
determining the allelic ratio of 115 inherited SNVs from WGS data of a single 
individual (coding, synonymous variants absent from dbSNP138 or present at a 
frequency below 1.5%). To minimize the risk of false-positive variant calls, a 
second independent set of 109 inherited SNVs was used to determine the 
distribution of the allelic ratio in ADS and Sanger sequencing. This set was 
randomly selected from a larger set of 442 rare, coding variants inherited from 
either parent in 10 probands and variants were selected to have a coverage ≥20-
fold in WGS, with a percentage of variant reads between 40 and 60%. Variants on 
the X chromosome and/or located in established disease genes were excluded. 
For ADS experiments, after mapping with BWA, variants were visualized using IGV 
and allelic ratios were determined by assessing the number of total reads and 
each respective base at this position. For Sanger sequencing, the chromatogram 
trace files were visualized using Vector NTI (Life Technologies, Carlsbad, CA, USA) 
and intensities per dye per variant base were used to calculate the allelic ratio. 
 
Identification of postzygotic events in probands 
A set of 127 de novo mutations identified by WGS was re-sequenced by 
ADS and Sanger sequencing. For 107 of these variants (84%), allelic ratios could 
be determined for all three sequencing techniques. Using the distribution of the 
allelic ratio in true heterozygosity as a reference, we calculated the individual z-
score per method for each mutation. Z-scores were calculated using the values 
from sequencing heterozygous variants with each sequencing method as a 
reference and are defined as the difference between the value of the allelic ratio 
and the mean allelic ratio for heterozygous variants on that sequencing 
technique, divided by the standard deviation. Subsequently, these scores were 
brought together into a single combined z-score for each de novo mutation by 
summing the individual z-scores and dividing this total by the square root of the 
number of scores. The critical value for statistical significance was established at 
0.05 after Benjamini-Hochberg correction for multiple testing. To exclude 
amplification bias as the cause of a deviation in the allele ratio, de novo SNVs with 
a statistically significant combined z-score were re-sequenced by ADS using a 
second independent primer pair. Finally, smMIPs were used as an independent 
technique to validate the presence of these variants as mosaic mutations, using a 
set of 7 heterozygous mutations as a reference. 
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Identification of parental mosaicism in whole genome sequencing data  
To detect low-level parental mosaicism for SNVs mimicking germline de 
novo mutations in the child, we re-analyzed the WGS data of the 50 parent-
offspring trios. To this end, we used all 4,081 high confidence candidate de novo 
mutations identified in the probands, as these have previously been shown to 
have a de novo validation rate of 78%.21 We then filtered for de novo variants for 
which at least two reads carrying the same mutation in the raw sequencing data 
were found in either one of the parents. Sequencing of the position of interest by 
ADS in the DNA of the transmitting parent was performed to validate parental 
mosaicism for the remaining 11 mutations. The position-specific sequencing error 
rate was established by sequencing the same position by ADS in the DNA of the 
non-transmitting parent in an independent sequencing run to avoid any 
contamination or barcode bleed-through. Then, the fraction of reads showing a 
non-reference allele at the corresponding base pair was calculated. The presence 
of the variant as a mosaic mutation in the transmitting parent was confirmed if 
the proportion of variant reads for the position and nucleotide of interest was 
significantly higher than the sequencing error for that base-pair position 
established from the non-transmitting parent. 
 
Computational modeling of sequencing coverage for the identification of 
mosaicism 
To assess the ability of identifying mosaic variants from sequencing data, 
we simulated the effect of sequencing coverage on variant identification for 
different levels of mosaicism. To distinguish low-level mosaicism from 
sequencing artifacts, we assumed that automated variant-calling algorithms 
require the variant to be present in ≥5 sequencing reads and constitute ≥5% of 
the total number of reads at the position of interest. A binomial distribution was 
used to calculate the probability of reaching both these requirements for different 
depths of coverage and various levels of mosaicism. Assuming that a mosaic 
variant has been identified, we also modeled the deviation of the allelic ratio from 
50% (representing true heterozygosity) which is necessary to distinguish a mosaic 
from a germline variant. Reads for heterozygous variants at different sequencing 
depths were simulated (n=10,000) based on a binomial distribution. The standard 
deviation of this distribution was calculated and we assessed the level of 
mosaicism which could be reliably distinguished from a heterozygous variant for 
different thresholds of significance. Lastly, we determined the sequence coverage 
which would be required to identify low-level parental mosaicism. In this case, the 
position of interest is readily identified due to the offspring presenting an 
apparently de novo mutation at this position. For this, we considered that at least 
2 variant reads are sufficient to distinguish the variant from background 
sequencing error. Finally, we applied a binomial model for different sequencing 
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depths and levels of mosaicism to calculate the probability of obtaining 2 variant 
reads in the sequencing data. 
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Web resources 
Integrated Genomics Viewer: http://www.broadinstitute.org/igv/  
Exome Variant Server:  http://evs.gs.washington.edu/EVS/  
Online Mendelian Inheritance in Man: http://www.omim.org/  
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Supplementary data 
Supplementary Figures 
 
 
 
 
Supplementary Figure S1. Germline de novo mutations are present in all cells and are therefore 
truly heterozygous, with an equal distribution of the wild-type and the mutated allele (50:50, see 
top panel “germline mutation”). Somatic de novo mutations are not present in all cells of an 
organism; some cells will carry the mutation while others will not, leading to an unbalanced 
distribution of the mutated allele (e.g. 80:20, see bottom panel “post-zygotic mutation”). This 
unbalanced distribution of the mutated allele proper to somatic mutations can be detected by 
sequencing as a deviation in the allele ratio (i.e. the signal corresponding to the mutant allele versus 
the signal corresponding to the reference allele). For next generation sequencing (NGS) techniques, 
this is observed as lower number of reads carrying the mutated allele versus reads carrying the 
reference allele. When using Sanger sequencing, this unbalance is detected as a difference in the 
intensity of the bases in the chromatogram. However, there may also be an unbalance in the 
distribution of the alleles as a result of technical variation during sequencing. To identify mutations 
present in mosaic state, it is necessary to be able to differentiate the deviation in the variant ratio 
that is a result of technical variation from the deviation in the variant ratio that is secondary to a 
biological allele unbalance. Cells and chromosomes carrying a mutation are shown in green in the 
figure. 
  
Supplementary data | 109 
 
 
 
 
 
 
 
Supplementary Figure S2. Frequency of nucleotide substitutions per group of studied mutations. 
The frequency for all nucleotide substitutions was determined for each of the studied groups (115 
inherited variants studied by WGS, 109 inherited variants studied by ADS and Sanger sequencing 
(SS) and 107 out of 109 evaluated de novo mutations). Two mutations from the group of de novo 
variants were excluded from this analysis, as they were deletions and could not be classified. By the 
means of statistical analysis, we determined that the nucleotide substitution frequency is not 
significantly different between the analyzed groups (Chi square test, df = 6, Χ2=6.113, p = 0.41). 
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A. Whole genome sequencing             
       
 
B. Amplicon-based deep sequencing  C. Sanger sequencing 
 
 
 
Supplementary Figure S3. Allele ratio of inherited heterozygous variants sequenced using 
different sequencing techniques. Results include whole genome sequencing (panel A), amplicon-
based deep sequencing (panel B) and Sanger sequencing (panel C). For the WGS data, results from 
115 variants used to determine the allelic distribution of heterozygous variants are shown in left 
side of panel A, while the 109 variants used to establish the distribution in ADS and Sanger 
sequencing are shown on the right side of panel A. The allele ratio was calculated as the percentage 
of variant reads from the total of reads for NGS technologies and as the intensity of the mutated 
base in the chromatogram versus the sum of the intensities of the reference and the mutated bases 
for Sanger sequencing. The mean allele ratio ±2 standard deviations of each technique are also 
shown (marked by a black line and dotted gray lines, respectively). Refer to Supplementary Table S1 
for the raw data. 
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Supplementary Figure S4. Distribution of de novo versus true heterozygous variants (i.e. inherited 
heterozygous variants) as a histogram of the number of cases per combined z-score obtained with 
multiple sequencing techniques (WGS, ADS and Sanger sequencing). On the far left, several outlying 
de novo mutations do not fit the expected distribution for heterozygous variants, suggesting a 
statistically significant unbalance between the wild-type and the mutant allele. These mutations are 
present in mosaic state and represent post-zygotic mutations. 
 
We looked further into the de novo mutations found on the extreme right of the 
histogram (with a z-score of 3.64 and 4.88). Both these mutations are small deletions which have a 
high combined z-score value due to extreme deviation of the allele ratio higher than the reference 
ratio only visible in ADS (i.e. more than 50% of the total reads in ADS correspond to variant reads). 
The 7 variants presented as somatic mutations in our study show consistently a low allele ratio in 
different sequencing techniques and when sequencing was performed using independent primer 
pairs for amplification. 
  
112 | Chapter 4 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S5. Distribution of the allele ratio per sequencing technique in 7 de novo 
mutations identified as post-zygotic events compared to 100 germline de novo mutations in the 
proband. We plot here the median and the 10th, 25th, 75th and 90th percentile for each group. The 
difference between the variant ratio of postzygotic versus germline mutations was statistically 
significant for all methods (Student’s T-test, *** p<0.001). 
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Supplementary Figure S6. Sanger sequencing traces of de novo mutation chr5:11327457 C>T in 
CTNDD2 in the non-carrier father (top), carrier mother (middle) and proband (bottom). This 
mutation was originally identified by trio-based WGS and later confirmed in DNA derived from 
maternal blood by ADS, with a variant ratio of 5.25%. Note that the mutated allele (A, in red) is 
present in the maternal DNA sample but is indistinguishable from the background traces.  
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Supplementary Figure S7. Modeling of the probability of identifying variants with different levels 
of mosaicism given different sequencing coverage. We assumed that automated variant calling 
algorithms require a variant to be present in at least 5 sequencing reads which constitute at least 
5% of the total number of reads at a position. A binomial distribution was used to calculate the 
probability (i.e. power) of reaching both these requirements for different depths of coverage and 
various levels of mosaicism. The X-axis indicates the percentage of mosaicism (i.e. the true allelic 
ratio). The Y-axis shows the probability of identifying this mosaicism. Each line represents the results 
for different sequencing coverage according to the legend. 
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Supplementary Figure S8. Allele ratio per sequencing coverage of 115 inherited heterozygous 
variants in WGS data. Evaluated variants were classified according to sequencing depth at the base 
pair position (in bins increasing by 25 sequence reads) and the allele ratio for the variant allele was 
determined. Each mutation is shown as a circle, with the horizontal bar representing the average 
allele ratio per category. The groups comprise 6 (<25 reads), 28 (25-49 reads), 56 (50-74 reads), 19 
(75 to 99 reads) and 5 variants (≥100 reads). The average allele ratio does not significantly change 
with increases in sequencing depth above 25-fold coverage (49.8% with 25-49 fold coverage versus 
51.7% with ≥100-fold coverage). However, higher sequencing coverage decreases the standard 
deviation (11.9 with 25-49-fold coverage versus 5.27 with coverage ≥100-fold). This indicates that 
higher sequencing coverage decreases the technical variation and offers higher sensitivity for the 
detection of biologically relevant deviations in the variant ratio.  
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Supplementary Figure S9. Simulation of the level of mosaicism which can be statistically 
distinguished from a heterozygous variant given different sequencing coverage and thresholds for 
significance. We simulated reads for heterozygous variants (n=10,000) at different sequencing 
coverage based on a binomial distribution. From this, we calculated the standard deviation of this 
distribution and, for different significance thresholds, we assessed the level of mosaicism for which 
the allelic ratio can reliably be distinguished from the allelic ratio of a heterozygous variant. The X-
axis indicates the sequencing coverage, while the Y-axis indicates the level of mosaicism which can 
be distinguished from a heterozygous variant (note that 10% of the allelic ratio means that 20% of 
the cells carry the variant). Each line represents the significance threshold as the distance from the 
average in standard deviations, according to the legend. 
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Supplementary Figure S10.  Modeling of the probability of identifying different levels of mosaicism 
in at least three reads for different sequencing depths. In this case the position of interest is already 
identified, as the offspring will have a de novo mutation at this base pair. We considered 3 reads 
showing the mutated allele to be sufficient to distinguish the variant from background sequencing 
error. We applied a binomial model for different sequencing depths and levels of mosaicism to 
calculate the probability of obtaining 3 sequencing reads with the variant. The X-axis indicates the 
percentage of mosaicism as the allelic ratio, while the Y-axis indicates the probability of identifying 
at least 3 reads. Each line shows the result for different depths of coverage, according to the legend. 
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Supplementary Figure S11. Sequencing coverage in WGS data per mutation category. Sequencing 
depth in WGS data for the evaluated mutations are presented per category. The mutations include 
115 randomly selected inherited heterozygous mutations (WGS from the proband), 100 de novo 
heterozygous mutations (WGS from the proband), 7 postzygotic de novo mutations representative 
of high-level mosaicism (WGS from the proband) and 4 parental somatic mutations present as low-
level mosaicism (WGS from the parent). Plotted here are the median and the 10th, 25th, 75th and 90th 
percentile for each group. The asterisks denote that the difference in sequencing coverage between 
inherited heterozygous, germline de novo variants and postzygotic mutations in the proband and 
parental mosaic mutations is statistically significant (*** p <0.001, Student’s t-test). This suggests 
that the sequencing coverage required for the detection of de novo mutations is lower than the 
sequencing depth necessary for the detection of low-level parental mosaicism. This finding 
supports that WGS which would allow for identification of de novo mutations may not detect low-
levels of parental mosaicism. As a consequence, it is likely that our results are an underestimation of 
the true extent of de novo mutations originating from parental mosaicism. 
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Supplementary Figure S12. Comparison of the allele ratio obtained for different sequencing 
techniques in truly heterozygous variants. A group of 109 inherited variants were amplified using 
the same primer pair and sequenced both by ADS and Sanger sequencing. Each circle in this graph 
represents one variant, while the gray rectangles highlight the 95% confidence interval for each 
sequencing method. While there are several variants falling out of the 95% confidence interval for 
each method, only one SNV shows a statistically significant deviation in the allele ratio both in ADS 
and Sanger sequencing. This deviation in both sequencing methods may be secondary to biased 
allele amplification, while deviations observed in a single technique but not reproducible in another 
may be caused by technical error specific to each sequencing method. 
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Supplementary Tables 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S1. Raw data for the three groups of variants used in this study. Available at 
http://www.sciencedirect.com/science/article/pii/S0002929715001949. 
 
 
 
Whole genome 
sequencing 
Amplicon-based 
deep sequencing 
Sanger 
sequencing 
 Allele ratio % Allele ratio % Allele ratio % 
Average 50.5 48.2 51.4 
Standard deviation 8.9 4.4 8.7 
95% interval 32.8-68.3 39.3-57.0 33.9-68.8 
Maximum observed 72.7 57.9 72 
Minimum observed 22.9 20.2 24 
 
Supplementary Table S2. Table showing the technical specifications for each sequencing 
technique, including average variant ratio (expressed as the percentage of variant reads from total 
reads), standard deviation, 95% range and maximum and minimum observed in the studied 
germline heterozygous variants. Inherited heterozygous variants were sequenced using Whole 
Genome Sequencing, amplicon-based deep sequencing and Sanger sequencing. 
 
Supplementary Table S4. Detailed results from WGS and deep sequencing of de novo mutations 
evaluated for parental low-level somatic mosaicism. Available at 
http://www.sciencedirect.com/science/article/pii/S0002929715001949. 
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Human bone marrow. Highly magnified. 
Anatomy of the Human Body by Henry Gray & Henry Vandyke Carter (1918) 
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Abstract 
Clonal hematopoiesis results from somatic mutations in hematopoietic 
stem cells, which give an advantage to mutant cells, driving their clonal expansion 
and potentially leading to leukemia. The acquisition of clonal hematopoiesis-
driver mutations (CHDMs) occurs with normal aging and these mutations have 
been detected in over 10% of individuals ≥65 years.  
We aimed to examine the prevalence and characteristics of CHDMs 
throughout adult life. We developed a targeted re-sequencing assay combining 
high-throughput with ultra-high sensitivity based on single-molecule molecular 
inversion probes (smMIPs). Using smMIPs, we screened over 100 loci for CHDMs 
in over 2,000 blood DNA samples from population controls between 20 and 69 
years of age. Loci screened included 40 regions known to drive clonal 
hematopoiesis when mutated and 64 novel candidate loci. We identified 224 
somatic mutations throughout our cohort, of which 216 were coding mutations 
in known driver genes (DNMT3A, JAK2, GNAS, TET2 and ASXL1), including 196 
point mutations and 20 indels. Our assay’s improved sensitivity allowed to detect 
mutations with variant allele frequencies as low as 0.001. CHDMs were identified 
in over 20% of individuals 60 to 69 years of age and in 3% of individuals 20 to 29 
years of age, approximately double the previously reported prevalence despite 
screening a limited set of loci. 
Our findings support the occurrence of clonal hematopoiesis-associated 
mutations as a widespread mechanism linked with aging, suggesting that 
mosaicism as a result of clonal evolution of cells harboring somatic mutations is a 
universal mechanism occurring at all ages in healthy humans. 
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Introduction 
Low level mosaicism resulting from somatic mutations is frequent in 
healthy tissues,1 particularly in those with high turnover rates such as blood2–6 and 
skin.7,8 Novel mutations may arise due to failure to repair DNA replication errors9 
or secondary to DNA damage caused by exposure to endogenous and exogenous 
mutagens.10 While most somatic mutations are phenotypically silent in the cell in 
which they arise, some of them can lead to changes in cell behavior. For example, 
mutations abolishing the function of a gene can be detrimental or even lethal for 
the cell in which they arise. In contrast, a subset of mutations have the ability to 
promote cell proliferation and/or survival, granting mutant cells a growth 
advantage compared to wild-type ones.11,12 This fitness advantage can allow a 
single mutant cell to grow into groups of identical daughter cells, which is known 
as “clonal expansion”.13,14 Mutations driving clonal expansion can arise in all cell 
types including somatic stem cells, which are characterized by their longevity and 
continuous division. These two characteristics would allow somatic stem cells to 
undergo recurring cycles of acquisition of mutations and subsequent clonal 
expansion, leading to the accumulation and propagation of mutations over time. 
A number of recurrent somatic mutations have been implicated in “clonal 
hematopoiesis”, a process in which a mutant hematopoietic stem cell (HSC) 
expands clonally and contributes to a significant and detectable fraction of 
circulating blood cells.2–5 Somatic mutations involved in clonal hematopoiesis are 
often detected in blood-derived DNA at a variant allelic frequency (VAF) ranging 
from 0.008 to 0.1, suggesting that between 1.6 and 20% of nucleated cells 
circulating in blood are derived from mutant HSCs.2–5 Clonal hematopoiesis driver 
mutations (CHDMs) most often disrupt genes such as DNMT3A, TET2 and ASXL1, 
which are associated with blood disorders like myelodysplasia and leukemia.2–4 
Because of this link, the acquisition of CHDMs has been suggested to represent 
the earliest phase in the development of hematologic malignancies.15 Indeed, 
clonal hematopoiesis of indeterminate potential, defined by the presence of 
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CHDMs with a VAF ≥0.02 in individuals without overt hematologic disease, is 
currently considered a pre-cancerous state carrying a risk of converting to 
leukemia of 0.5 to 1% per year.3,16  
Clonal hematopoiesis is thought to be rare in individuals younger than 50 
years and increases in frequency with age, affecting at least 10% of individuals 
older than 65 years2,4 and close to 20% of persons above 90 years.5 Some 
mutations involved in clonal hematopoiesis, such as JAK2 or DNMT3A mutations, 
have been detected in blood of healthy adults of all ages and are thought to be 
able to cause clonal expansion of mutant HSCs throughout life. On the other 
hand, a subset of recurrent mutations has only been observed in individuals over 
the age of 70 years, such as mutations in SRSF2 or SF3B1, suggesting that clonal 
expansion of HSCs harboring these mutations is age-dependent.5 This 
observation has led to the hypothesis that the aging cellular background may 
play a crucial role in the selection and expansion of mutant HSCs.5 Indeed, aging 
is accompanied by a decline in HSC function,17 a bias towards myeloid 
differentiation18 and changes in the bone marrow niche.19 It is therefore possible 
that certain mutations provide a cellular advantage in the aging bone marrow 
environment, allowing for clonal expansion of mutant HSCs exclusively in this 
context.5,20,21 However, it is also possible that CHDMs associated with aging arise 
in young individuals but remain undetected due to technical limitations; because 
of the low VAF at which CHDMs are often present, the detection method used 
heavily influences the ability to identify these mutations.22 For instance, studies 
favoring a targeted approach to provide deep sequencing coverage in known 
hotspot regions have led to the identification of a number of CHDMs with low VAF 
which would have otherwise been missed by exome or genome sequencing.5,6 
In the present study, we aim to characterize the genetic profile and 
features of clonal hematopoiesis in individuals below the age of 70 years. To 
identify CHDMs with a VAF ≥0.002 in a cohort of over 2,000 population controls 
between 20 and 69 years of age, we use single molecule molecular inversion 
probes (smMIPs).23–26 As a novel and highly flexible method for targeted 
enrichment of genomic regions of interest, we have made use of smMIPs to 
screen our cohort for somatic mutations in 40 established loci for CHDMs.  
Furthermore, and unexpectedly, reference population databases for 
genetic variation have been found to contain pathogenic variants established to 
cause developmental disorders when present in the germline. A possible 
explanation for this surprising observation is that these mutations represent 
somatic mutations with elevated VAFs in blood due to their role as CHDMs.27 
However, the extent of the genetic overlap between somatic mutations in clonal 
hematopoiesis and germline mutations in developmental disorders remains 
unclear. Therefore, we screened our cohort for somatic mutations in an additional 
set of 64 loci in which recurrent germline de novo mutations have been found to 
cause severe developmental disorders. Several of these loci have been previously 
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implicated in paternal age effect disorders28 with the causative mutations shown 
to cause clonal expansion in spermatogonial stem cells.29–32 We here aim to 
determine whether these loci may represent novel sites for CHDMs. 
 
Results 
Sensitive and specific detection of somatic mutations in blood by smMIPs  
We sequenced 104 loci in 2,007 blood samples of population controls 
between 20 and 69 years of age with a median unique coverage of 845-fold per 
sample (see Supplementary Figure S1 and S2). The median unique coverage 
corresponds to the number of unique DNA molecules sequenced per sample and 
per position after removal of PCR duplicates. Using an approach based on 
modeling sequencing error rates per targeted position, we identified 224 somatic 
SNVs and indels, of which 223 localize to the coding regions screened, with VAFs 
ranging between 0.0008 and 0.35 (average 0.015, median 0.0061). The median 
unique coverage of these mutation loci was 4103-fold. 
To validate our findings, we used restriction digestion to analyze five 
somatic mutations localizing to a hotspot of DNMT3A, in which mutations disrupt 
a restriction digestion site for TauI (see Figure 1A and 1B). For all five samples, a 
band of undigested DNA was observed at 577 bp proportional in size to the 
mutation VAF per sample (Figure 1C and 1D). We selected one sample and one 
independent control for sequencing after restriction digestion and identified an 
enrichment for reads corresponding to the DNMT3A mutation compared to the 
wild-type allele for the sample in which a mutation was detected (Figure 1E). 
These findings support that mutations identified with VAFs as low as 0.002 
represent true mutations in the original DNA sample rather than false-positives. 
Somatic mutations in known clonal hematopoiesis driver genes in blood of 
population controls 
In total, 216 somatic mutations were identified in coding regions of 
known clonal hematopoiesis driver genes in our cohort (see Figure 2A). Among 
these, 170 were mutations previously identified in clonal hematopoiesis.2–5 For 
instance, several known clonal hematopoiesis driver missense mutations in genes 
such as DNMT3A, JAK2, GNAS, NRAS, SRSF2 and SF3B1, were detected in our 
cohort (see Table 1). Additionally, nonsense mutations were identified in genes 
previously identified to harbor truncating mutations in clonal hematopoiesis such 
as ASXL1, DNMT3A, TET2 and TP53 and a total of 20 indels involving DNMT3A and 
TET2 were detected (see Table 2). The most frequently mutated gene in our 
cohort is DNMT3A, for which a wide variety of mutations were observed including 
hotspot and non-hotspot missense mutations, loss-of-function point mutations 
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and indels (see Table 1, Table 2 and Figure 2B). Hotspots in DNMT3A are here 
defined as residues in which 5 or more missense mutations were detected in our 
cohort, including DNMT3A R326, R729, Y735, R736, W860 and R882. 
Furthermore, somatic mutations were identified in known clonal 
hematopoiesis driver genes which had not been previously reported as CHDMs 
(see Table 3). These consist of 46 SNVs in coding regions of BRAF, BRCC3, CBL, 
DNMT3A, GNAS, KRAS, NRAS, PIK3CA, PTPN11, TET2 and TP53. Several of these 
novel mutations were found adjacent to residues previously identified to harbor 
CHDMs. For instance, three individuals in our cohort were found to have KRAS 
G13D mutations. This missense mutation occurs contiguous to G12, a recurrently 
mutated residue in which G12C, G12R and G12S mutations have been identified 
in clonal hematopoiesis.3,5 Additionally, we detected mutations within specific 
genes with a different mechanism than those usually observed to drive clonal 
hematopoiesis. For instance, while loss-of-function somatic TET2 mutations are 
frequent in clonal hematopoiesis and leukemia, we detected one missense TET2 
mutation in a 20-year-old. Comparing the VAF of the 170 known and the 46 novel 
mutations we identified in genes involved in clonal hematopoiesis reveals a 
statistically significant difference in the VAF of both groups of mutations (0.0069 
vs 0.0038 for known versus novel, p=0.0003, Wilcoxon rank sum test). This 
difference between both groups suggests that known mutations identified have 
a stronger clonal advantage than the novel mutations identified in our cohort, 
which may explain why they had not been detected previously. 
Clonal hematopoiesis can arise throughout all adult life 
The abovementioned 216 somatic mutations in clonal hematopoiesis-
driver genes were identified in 192 individuals between 20 and 69 years of age, 
representing an overall prevalence of 9.56% for CHDMs throughout our cohort. 
Individuals in our cohort with clonal hematopoiesis were significantly older than 
those without (median 57 versus 43 years of age, p<2.2x10-16, Wilcoxon rank sum 
test). The prevalence of CHDMs increased in an exponential manner with age and 
at least one CHDM was observed in 2.5% of the 20 to 29-year-old group, in 3.2% 
of the 30 to 39-year-old group, in 8.2% of the 40 to 49-year-old group, in 13.2% of 
the 50 to 59-year-old group and in 20.6% of the 60 to 69-year-old group (see 
Figure 3A). Two or more CHDMs were identified in 22 individuals in our cohort, 
who were significantly older than those in whom only one CHDM was identified 
(median of 65 versus 56 years of age, p <0.01, Wilcoxon rank sum test). Sixteen of 
these individuals with more than one CHDM were 60 or older, representing close 
to 4% of the group of individuals between 60 and 69 years of age (see Figure 3B). 
No difference in the mutational status or number of mutations was observed 
between sexes.  
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Figure 1. Validation of mutations by restriction digestion and re-sequencing. A) Mutations 
identified in DNMT3A R882 selected for validation. B) Scheme showing recognition site for 
restriction digestion enzyme TauI in the genomic sequence corresponding to DNMT3A R882. 
Mutations chr2:25457242C>T and chr2:25457243G>A leading to R882H and R882C respectively are 
marked below with red arrows. C) Size analysis of restriction digestion of DNMT3A PCR products. 
Lanes 1 to 5 represent samples with mutations with different VAFs. C1 is a control with false-positive 
signal for a G>A mutation at chr2:25457243, as determined statistically. C2 is a control with no 
DNMT3A mutation. D) Gel trace of size analysis of digestion, with sample 4 on the left and C2 on the 
right. The peak corresponding to the full size product is marked with a red triangle for both samples. 
Note that C2 present a small peak at 577 bp, corresponding to undigested PCR products due to 
digestion enzyme saturation. E) Sequencing results of digested PCR product for sample 5. We obtain 
a higher ratio of mutation to wild-type reads than in the original sample due to digestion of the 
wild-type product. 
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Figure 2. A) Prevalence and distribution of clonal hematopoiesis-driver mutations identified in 
healthy individuals aged between 20 and 69 years of age. B) Prevalence of mutations in DNMT3A 
per age group. Hotspot in DNTM3A are defined as residues in which 5 or more mutations were 
identified in our cohort and include R326, R729, Y735, R736, W860 and R882. All other missense, 
loss-of-function and indels are included in the non-hotspot mutations.  
 
 
Remarkably, while the prevalence and number of CHDMs in the 
population increased with age, we did not detect a correlation between the VAF 
of CHDMs and the age of the individual in which they were identified (R2=-0.03, 
Pearson’s correlation; see Figure 3C). We examined a set of previously published 
CHDMs5 in which we also observed a lack of correlation between the VAF of 
mutations identified in individuals below the age of 70 and the age of the 
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individual in which they were detected (R2=0.06, Pearson’s correlation). However, 
when analyzing the VAF of mutations in individuals 70 years of age or older, we 
observed a moderate correlation between these two parameters (R2 = 0.3, 
Pearson’s correlation). No statistically significant difference between the VAF of 
mutations identified in the abovementioned study in individuals below and 
above the age of 70 was observed (0.025 versus 0.027, p=0.87, Wilcoxon rank sum 
test). 
Age-specific patterns of mutation in clonal hematopoiesis driver genes 
Over 85% of all somatic SNVs in clonal hematopoiesis driver genes 
correspond to A>G/T>C, C>A/G>T or C>T/G>A mutations (170 out of 196 
mutations). The distribution of these types of mutations differs between the 
individuals below the age of 45 and those 45 or older in our cohort (p<0.05, 
Pearson's Chi-squared test, df=2). While the most frequent CHMDs are C>T/G>A 
transitions, their frequency does not change with age, as they represent 51% and 
52% of all SNVs in the younger and older age group. On the other hand, A>G/T>C 
mutations increase with age, corresponding to 20% of all SNVs in individuals 45 
years or older in contrast with only 8% in individuals below this age (see Figure 4). 
This increase in frequency occurs at the expense of C>A/G>T mutations, which 
represent close to 30% of all SNVs in young individuals, as opposed to 
approximately 14% in individuals above the age of 45. This difference in patterns 
of mutations could not be attributed to mutations in any single gene. 
Aging is associated with different patterns of clonal hematopoiesis and it 
has been proposed that DNMT3A and JAK2 mutations appear throughout life, 
while mutations in SRSF2 and SF3B1 arise only in individuals over the age of 70.5 
Indeed, mutations in DNMT3A and JAK2 were observed throughout all age 
groups; the youngest individual in which an established CHDM was identified in 
our cohort was a 22-year old woman with a JAK2 V617F mutation at a VAF of 
0.003. As with CHDMs in general, the frequency of DNMT3A mutations increased 
with age, reaching a prevalence of 13.7% in population controls between 60 and 
69 years of age. The comparison of DNMT3A hotspot versus non-hotspot 
mutations reveals that the VAF of clones carrying DNMT3A hotspot mutations is 
significantly larger than that of clones with non-hotspot mutations (median 0.025 
vs 0.009, Wilcoxon test, p<0.01). For most genes in which 5 or more CHDMs were 
identified in our cohort, including CBL, DNMT3A, GNAS, JAK2 and TET2, no 
statistically significant difference was detected between the age of the carriers of 
mutations in any of these genes and individuals with one or more CHDMs in other 
genes. Although individuals with CHDMs in TP53 were older than carriers of 
CHDMs in other genes (63.2 vs 53.9 years of age, Wilcoxon test, p <0.05), once we 
corrected for multiple testing this observation lost statistical significance at 
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Age Gene Mutation 
VAF 
(%) 
 Age Gene Mutation 
VAF  
(%) 
42 ASXL1 Q588* 2.23  54 DNMT3A Y735C 0.46 
55e ASXL1 R404* 0.76  54 DNMT3A Y735C 0.58 
60 ASXL1 R693* 0.29  55d DNMT3A L773R 0.92 
66m ASXL1 R693* 0.91  55d DNMT3A R771G 0.20 
       55e DNMT3A G332E 0.16 
24 CBL R420Q 15.01  55 DNMT3A R729G 0.18 
44 CBL F418L 0.27  55 DNMT3A R771* 0.28 
45c CBL C404Y 0.61  56 DNMT3A R736C 0.73 
61 CBL C404Y 1.29  56 DNMT3A W860R 9.78 
63 CBL G415V 1.15  56 DNMT3A R882H 0.16 
       56 DNMT3A R326H 0.43 
25 DNMT3A Y735S 0.64  57 DNMT3A R736H 0.44 
25 DNMT3A R326C 1.64  57 DNMT3A W860R 1.94 
30 DNMT3A C861* 0.50  57 DNMT3A c.2597+2T>C 0.31 
30 DNMT3A R882C 0.61  58 DNMT3A R882C 0.18 
31 DNMT3A R326C 0.61  59 DNMT3A R882H 0.97 
35 DNMT3A W860R 0.59  59 DNMT3A R326C 0.63 
36 DNMT3A S770L 1.62  59 DNMT3A R882C 0.40 
36 DNMT3A R736C 8.37  59 DNMT3A R729W 0.28 
40 DNMT3A Y735C 1.94  60 DNMT3A R736H 1.03 
40 DNMT3A Q886* 0.29  60 DNMT3A R771* 0.92 
41a DNMT3A R882H 0.25  60 DNMT3A R326G 0.61 
41a DNMT3A S770L 4.69  60 DNMT3A R326C 11.08 
42 DNMT3A R882H 0.86  60 DNMT3A F734L 0.36 
42 DNMT3A R887* 0.23  61 DNMT3A W860* 0.61 
42 DNMT3A M761V 0.38  61 DNMT3A R882H 6.85 
44 DNMT3A R771* 1.35  61 DNMT3A R882H 6.06 
44 DNMT3A R736C 2.09  61 DNMT3A I769L 0.12 
44 DNMT3A R882H 0.61  62 DNMT3A W860R 0.09 
45b DNMT3A R771* 0.26  62 DNMT3A R882C 2.05 
45 DNMT3A R729W 1.79  62 DNMT3A R882H 0.21 
45 DNMT3A R771* 0.19  62 DNMT3A W330* 0.38 
47 DNMT3A Q886* 0.52  62 DNMT3A S770L 2.79 
47 DNMT3A R326C 1.74  62 DNMT3A R326C 14.43 
47 DNMT3A c.2322+3A>C 0.38  63 DNMT3A R736C 0.75 
47 DNMT3A S770* 2.04  63 DNMT3A R736H 2.21 
49 DNMT3A W860R 4.29  63 DNMT3A R729Q 0.33 
49 DNMT3A Y735C 1.18  63 DNMT3A Y735C 0.78 
50 DNMT3A E774* 0.42  64 DNMT3A R326S 35.02 
51 DNMT3A R882H 1.25  64 DNMT3A I769M 0.12 
51 DNMT3A R736C 0.25  64 DNMT3A R736H 0.33 
51 DNMT3A Y735C 5.72  65j DNMT3A R771* 0.93 
51 DNMT3A F732L 0.81  65k DNMT3A R326H 1.02 
52 DNMT3A R736C 1.88  65 DNMT3A F772C 2.84 
53 DNMT3A L737F 0.29  65 DNMT3A R326H 1.25 
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Age Gene Mutation 
VAF 
(%) 
 Age Gene Mutation 
VAF  
(%) 
65 DNMT3A R729W 0.46  26 JAK2 V617F 0.93 
66m DNMT3A R771* 0.34  30 JAK2 V617F 4.65 
66 DNMT3A R320* 0.35  54 JAK2 V617F 9.73 
66 DNMT3A R326H 0.78  55 JAK2 V617F 5.71 
66 DNMT3A Q886* 2.58  64i JAK2 V617F 2.72 
66 DNMT3A Y735C 2.09  65j JAK2 V617F 0.64 
67 DNMT3A M880V 0.21      
68n DNMT3A R771Q 2.15  45b MYD88 L273P 0.20 
68p DNMT3A R729G 0.18  68o MYD88 L273P 0.91 
68q DNMT3A Y735C 0.66        
68 DNMT3A E774K 1.24  47 NRAS Q61K 0.33 
68 DNMT3A M761V 0.69  56 NRAS Q61L 0.10 
68 DNMT3A c.2597+1G>A 2.16        
69r DNMT3A I769S 0.12  39 PTPN11 E69A 0.19 
69r DNMT3A M880I 0.53        
69r DNMT3A R736H 0.46  60f SF3B1 K666N 0.67 
69 DNMT3A Y735C 1.91  68n SF3B1 K700E 1.01 
         
45c GNAS R844H 2.10  49 SRSF2 P95L 9.01 
50 GNAS R844C 0.37  66 SRSF2 P95H 1.30 
56 GNAS R844H 1.59        
56 GNAS R844H 0.32  38 TET2 R550* 0.64 
57 GNAS R844S 0.55  51 TET2 R550* 0.69 
58 GNAS R844C 0.65  54 TET2 R550* 0.37 
62 GNAS R844H 2.32  56 TET2 R550* 0.72 
63h GNAS R844H 0.52  60g TET2 Q764* 0.13 
       62 TET2 Q530* 0.81 
60 GNB1 K57E 0.76  64 TET2 R550* 0.51 
63h GNB1 K57E 0.41  67 TET2 Q548* 0.44 
65 GNB1 K57E 0.73  67 TET2 Q886* 1.58 
69 GNB1 K57E 2.17        
       53 TP53 R110L 0.17 
62 IDH2 R140Q 0.58  62 TP53 R213* 0.29 
62 IDH2 R140Q 1.16  63 TP53 L114* 0.34 
     67 TP53 Y220C 1.04 
22 JAK2 V617F 0.31  60f U2AF1 S34F 0.98 
Table 1. Known clonal hematopoiesis driver SNVs identified. Samples with more than one 
mutation are marked with a superscript letter for identification. 
  
134 | Chapter 5 
 
Age Mutation (hg19 gDNA) Gene mRNA change Protein change VAF (%) 
33 chr2:25458597del DNMT3A c.2576del L859Yfs 1.67 
42 chr2:25463300dup DNMT3A c.2193dup F732Lfs 4.05 
48 g.25458620_25458627dup DNMT3A c.2546_2553dup M852Lfs 4.76 
49 chr2:25463297dup DNMT3A c.2196dup E733* 2.56 
49 chr2:25463196_25463197del DNMT3A c.2297_2296del K766Efs 0.32 
57 chr2:25458596dup DNMT3A c.2577dup W860Mfs 0.45 
57 chr2:25458591delinsTT DNMT3A c.2582delinsAA C861* 0.70 
58b chr2:25463196_25463197del DNMT3A c.2297_2296del K766Efs 13.60 
60 chr2:25463308del DNMT3A c.2185del R729Gfs 5.86 
61 chr2:25463196_25463197del DNMT3A c.2297_2296del K766Efs 7.17 
63 chr2:25463312del DNMT3A c.2181del G728Afs 2.05 
64 chr2:25463196_25463197del DNMT3A c.2297_2296del K766Efs 0.33 
65k chr2:25463297dup DNMT3A c.2196dup E733* 0.63 
66s chr2:25463291del DNMT3A c.2202del Y735Tfs 0.90 
66s chr2:25458605_25458606del DNMT3A c.2568_2567del E856Gfs 0.30 
67 chr2:25458608del DNMT3A c.2565del E856Rfs 0.91 
68 chr2:25463196_25463197del DNMT3A c.2297_2296del K766Efs 0.76 
68t chr2:25463190del DNMT3A c.2303del D768Afs 0.16 
68 chr2:25458595del DNMT3A c.2578del W860Gfs 0.12 
64 chr4:106157389dup TET2 c.2290dup Q764Pfs 0.44 
Table 2. Indels identified in known clonal hematopoiesis driver genes. Samples with more than 
one mutation are marked with a superscript letter for identification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3. Novel somatic mutations identified in coding regions of clonal hematopoiesis 
driver genes. Samples with more than one mutation are marked with a superscript letter for 
identification.  
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Age Gene Mutation 
VAF 
(%) 
Mutation type PhyloP 
CADD 
PHRED 
67 BRAF F595L 0.09 Missense 2.26 24.7 
67 BRAF K601N 0.98 Missense 1.12 21.3 
54 BRCC3 D88G 2.94 Missense 8.54 17.8 
35 CBL P395H 0.17 Missense 7.45 19.7 
41 CBL C384Y 1.58 Missense 9.42 18.4 
52 CBL H398Q 0.81 Missense 0.95 14.8 
58 CBL C419S 0.32 Missense 9.48 21.4 
69 CBL S376P 0.97 Missense 7.66 18.2 
65v CBL H398Q 0.27 Missense 0.95 14.8 
65v CBL T377I 1.75 Missense 7.45 18.1 
68t CBL C396Y 0.15 Missense 9.42 18.9 
41a DNMT3A V328F 0.53 Missense 7.57 27.8 
48 DNMT3A D768E 0.33 Missense 5.68 24.7 
49 DNMT3A L888P 0.43 Missense 9.34 18.7 
49 DNMT3A M864R 0.21 Missense 9.23 24.9 
49 DNMT3A T862I 0.36 Missense 9.75 32 
51 DNMT3A D765G 0.90 Missense 8.04 24.9 
51 DNMT3A V763G 0.11 Missense 7.33 25.5 
52 DNMT3A A884T 0.28 Missense 6.09 28.7 
54 DNMT3A E774E 0.42 Synonymous 7.78 15.6 
54 DNMT3A R885S 0.28 Missense 1.59 18.1 
55 DNMT3A K766N 1.10 Missense 2.56 19.6 
57 DNMT3A A884V 1.27 Missense 9.86 28 
59 DNMT3A R866M 0.16 Missense 7.73 35 
61 DNMT3A T862I 0.52 Missense 9.75 32 
64 DNMT3A D857A 1.32 Missense 7.95 28.4 
68 DNMT3A D768E 0.38 Missense 5.68 24.7 
68 DNMT3A L889V 0.35 Missense 7.99 19.8 
64i DNMT3A E863G 0.26 Missense 7.95 32 
68q DNMT3A T862I 0.80 Missense 9.75 32 
46 GNAS C843R 0.46 Missense 7.55 21.2 
62 GNAS L846P 0.42 Missense 7.55 21.2 
22 KRAS G13D 1.07 Missense 7.74 27.8 
25 KRAS G13D 0.37 Missense 7.74 27.8 
28 KRAS G13D 0.39 Missense 7.74 27.8 
35 NRAS E62* 0.08 Nonsense 7.55 38 
37u NRAS E62* 0.12 Nonsense 7.55 38 
23 PIK3CA E39* 0.08 Nonsense 9.41 29 
37u PTPN11 L65L 0.16 Synonymous 0.62 9.4 
56 PTPN11 T73A 0.11 Missense 9.33 19.5 
20 TET2 Q548K 1.68 Missense 0.57 4.4 
60g TP53 F113V 0.08 Missense 7.39 24.6 
63 TP53 M237I 0.52 Missense 7.56 22.8 
69 TP53 V216M 0.39 Missense 7.78 28.9 
68o TP53 M237K 0.31 Missense 9.02 24 
68p TP53 V216M 0.90 Missense 7.78 28.9 
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Figure 3. A) Prevalence of clonal hematopoiesis per age group, defined as the frequency of 
individuals with one or more CHDMs per decade of age. . B) Proportion of the population per age 
group with CHDMs.. C) Variant allele fraction per mutation identified per age of the individual in 
which the mutation was identified. The y-axis is in logarithmic scale. No correlation is observed 
between the age of the individual and the VAF of the mutation identified. A large number of low 
VAF mutations are detected in older individuals.  
 
 
p<0.05. Some genes included in our screen were found to be mutated only in 
individuals over the age of 60, such as GNB1, IDH2, SF3B1 and U2AF1. Although 
mutations in components of the spliceosome have been proposed to drive clonal 
hematopoiesis only in older individuals, SRSF2 mutations were identified in two 
individuals of 49 and 66 years of age. Remarkably, the mutation observed in the 
49-year old man was a P95L missense mutation in SRSF2 with a relatively high VAF 
of 0.09. 
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Figure 4. Type of mutation change per age group 
 
 
Somatic mutations in candidate loci for clonal hematopoiesis driver 
mutations 
Unexpectedly, mutations known to cause developmental disorders when 
arising in the germline can be found at low frequencies in population databases 
of genetic variation such as ExAC.27 It has been suggested that some of these 
findings may be explained by mutations which, in addition to causing 
developmental disorders when present in the germline, would also be involved 
in clonal hematopoiesis when arising in HSCs.27 A revision of published literature 
led to the identification of 1,158 somatic mutations in 90 genes involved in clonal 
hematopoiesis.2–5 We compared this list of 90 genes with a subset of 464 genes 
involved in dominant and de novo developmental disorders from DDG2P33 to 
determine whether there was significant overlap between genes involved in 
clonal hematopoiesis when mutated somatically and genes involved in 
developmental disorders. In this way, we identified 29 genes in which germline 
mutations cause developmental disorders while somatic mutations are involved 
in clonal hematopoiesis. This represents a significant enrichment compared to the 
expectation (hypergeometric distribution with a universe of 22,285 protein-
coding genes, p = 9.2x10-28).  
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Age Gene Mutation VAF (%) 
Mutation 
type 
PhyloP 
CADD 
PHRED 
Grantham 
Score 
25 COL4A3BP S260* 0.12 Nonsense 9.84 40 NA 
41 ADNP Y719Y 0.25 Synonymous -1.96 0.02 NA 
43 KCNQ3 S228N 0.30 Missense 5.91 19.7 46 
48 RHEB Y35Y 1.73 Synonymous 0.10 8.8 NA 
58 CUX2 L592P 2.46 Missense 8.04 21.2 98 
59 HECTD1 S2223P 0.12 Missense 8.96 12.6 74 
60 SMAD4 C499C 0.17 Synonymous 1.86 4.9 NA 
Table 4. Somatic mutations identified in candidate clonal hematopoiesis driver genes.  
 
 
In addition to the 40 known loci for CHDMs in our assay, we screened for 
somatic mutations in blood in 64 novel candidate loci for CHDMs. These included 
seven loci with nine residues in which recurrent missense mutations are known 
to be causative for paternal age effect disorders, such as achondroplasia, when 
present in the germline.29–31,34,35 These mutations cause clonal expansion in 
spermatogonial stem cells when arising during spermatogenesis28 and we 
hypothesized that some may also undergo clonal expansion in other tissues. 
Therefore, we considered mutations in these loci as candidates for clonal 
expansion in HSCs during hematopoiesis. Furthermore, we selected 57 additional 
loci in which recurrent identical de novo mutations have been found in 
developmental disorders.36–38 Screening of these 64 candidate loci for CHDMs led 
to the identification of 7 somatic mutations, including 1 nonsense, 3 missense and 
3 synonymous mutations with VAFs ranging from 0.0012 to 0.024 (average 
0.0074, median 0.0025). Genes in which mutations were detected include ADNP, 
COL4A3BP, CUX2, HECTD1, KCQN3, RHEB and SMAD4 (see Table 4). No mutations 
were identified that were identical to mutations involved in spermatogonial stem 
cell selection or found to be recurrently mutated in developmental disorders. 
 
Discussion 
 Recurrent somatic mutations have been recently identified in blood-
derived DNA of population controls.2–4 In this study, we established a smMIPs 
assay targeting 104 known or candidate loci for CHDMs and sequenced blood-
derived DNA of 2,007 population controls between the age of 20 and 69. With a 
median unique sequencing coverage of 845-fold, corresponding to the number 
of unique DNA molecules captured per position per sample, we identified 223 
somatic SNVs and indels in the coding regions screened of which 216 affected 
known clonal hematopoiesis-driver genes. A high ratio for non-synonymous to 
synonymous somatic mutations was observed for loci screened within genes 
known to drive clonal hematopoiesis (214 non-synonymous versus 2 
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synonymous point mutations). This observation suggests overall positive 
selection among a large proportion of the mutations identified in the screened 
loci.39  
 Both the prevalence of clonal hematopoiesis as well as the number of 
mutations increased with age, reaching a frequency over 20% for CHDMs in 
individuals between 60 and 69 years of age. This number is close to double that 
of previous reports mentioning a prevalence for CHDMs in 5 to 10% in healthy 
individuals older than 60.2–4 It is likely that the higher prevalence of clonal 
hematopoiesis detected in our study results from the increased sensitivity of 
smMIPs, compared to other sequencing methods used in previous studies.22 The 
use of a deep coverage smMIP approach has the advantage of allowing a large 
number of loci to be screened for mutations with high sensitivity for the 
identification of mutations with low VAFs. In contrast, exome sequencing has the 
advantage of allowing the identification of mutations throughout the coding 
region, but it may miss mutations present at low allelic frequencies when 
performed at current day standard coverage. Indeed, an average sequence of 84 
reads sets the lower limit for detection of somatic mutations at an allele fraction 
of approximately 0.035.3 More than 90% of the CHDMs detected in our study (198 
out of 216) are below this VAF and would most likely have been missed by average 
coverage exome sequencing.  On the other hand, amplicon-based sequencing 
limits the detection of mutations to the targeted regions but provides deep 
coverage, which enables the identification of mutations with low VAF. For 
instance, one study detected mutations in 15 loci using a sequencing coverage 
above 1000-fold, which lowered the limit for mutation detection to an allele 
fraction of 0.008.5 One of the main limitations for the detection of somatic 
mutations is the sequencing error rate of NGS platforms, ranging around 0.1-1% 
for sequencing by synthesis approaches.40 Mutations introduced during the 
preparation of the sequencing library further limit the ability to distinguish true 
CHDMs present in blood from false-positive signal.41 Some of these limitations can 
be bypassed by using smMIPs, which include a random tag in each probe 
assigning a unique molecule identifier (UMI) to each individual DNA molecule 
captured.23 Through this, multiple sequencing reads descending from the same 
DNA molecule can be traced in order to generate a true molecular count without 
PCR duplicates. Additionally, this can be used to create a consensus sequence of 
this DNA fragment, thus increasing the specificity for the detection of true 
somatic events. To ensure specificity in our detection of CHDMs, we modeled the 
sequencing error to identify statistically significant mutation counts in two 
replicates from the same sample. Furthermore, at least two independent smMIPs 
were used to target each DNA strand within the screened loci. The mutations 
identified in our assay had a median VAF of 0.0061, ranging from 0.0008 to 0.35, 
and a subset of mutations were validated using restriction digestion, confirming 
that the deviations in number of mutation reads at specific positions detected 
through sequencing data reflected a true mutation present in the sample DNA.   
140 | Chapter 5 
 
 Although the prevalence of clonal hematopoiesis increased with age, 
CHDMs were observed throughout all ages in our cohort. The youngest individual 
in which an established CHDM was identified in our cohort was a 22-year-old 
woman in whom we detected a JAK2 V617F mutation with a VAF of 0.003. CHDMs 
were detected in 2.3% of population controls between 20 and 29 years of age, 
suggesting that clonal hematopoiesis is not a rare finding in early adult life. While 
age was a poor predictor for the presence and number of CHDMs at the individual 
level, when analyzing our findings by ten-year age groups, we observed that age 
explained 96% of the variation in the presence and number of CHDMs in the 
population. This suggests that while age is a major factor in the occurrence of 
CHDMs at the population level, stochasticity and inter-individual differences, such 
as genetic variation or environmental factors, may play a prominent role in the 
occurrence of CHDMs at the individual level. Notably, we observe that the 
increase in prevalence and number of CHDMs at the population level is not linear. 
This supports that factors associated with aging may accelerate the occurrence of 
CHDMs over time, either due to increased DNA damage or to decreased DNA 
repair. An increase with age was observed in the proportion of A>G:T>C 
mutations detected in our cohort. This type of mutation has been linked to 
deamination of adenine and has been shown to be associated with transcription-
coupled repair.42 The prevalence of CHDMs in population controls contrasts with 
the incidence of leukemia in the general population. Given this discrepancy, it is 
unclear whether all individuals with CHDMs have an increased risk for developing 
leukemia. The presence of CHDMs may place individuals at increased risk for 
development of hematologic malignancies, but does not seem sufficient in itself 
to develop leukemia. It is therefore likely that the evolution from clonal 
hematopoiesis to leukemia is the result of many cycles of selection of mutant 
HSCs in which the cellular, tissue and organism environment plays a role. 
 While some CHDMs, such as those in DNMT3A and JAK2, were found in 
individuals of all ages, some CHDMs were exclusively detected in individuals over 
the age of 60, including mutations in GNB1, IDH2, SF3B1 and U2AF1. Additionally, 
individuals with CHDMs in TP53 were older than those with CHDMs in other 
genes, although this result did not reach statistical significance. It has been 
suggested that some mutations may arise in HSCs in young individuals but can 
only expand clonally in the context of the aging bone marrow.5,13,20 Mutations in 
components of the spliceosome, such as SRSF2 and SF3B1, have been proposed 
to fall under this category.5 Interestingly, we identified a SRSF2 mutation with a 
VAF of 0.09 in a 49-year-old individual, suggesting that although rare, clonal 
expansion of spliceosome mutations can occur in younger individuals. Compared 
to HSCs in young individuals, aging HSCs show decline in replication capacity17,22 
and a bias towards myeloid differentiation.18 These changes may be specific to the 
aging cells or could result from alterations in the bone marrow niche17,19,43. Cell-
intrinsic alterations arising in aging HSCs include epigenetic alterations and 
upregulation of genes involved in myeloid differentiation, DNA repair, cell death 
and genes linked to leukemia.14,17,43 However, computational modeling and 
Clonal hematopoiesis-associated mutations arise throughout adult life | 141 
 
studies in mouse models support that the aging microenvironment exerts strong 
selective pressure on HSCs.11,22 Therefore, certain mutations involved in clonal 
hematopoiesis may confer aging HSCs a growth advantage over wild-type aging 
HSCs in which function is generally declining. In contrast, the same mutations in 
young HSCs may not result in increased cellular fitness compared to wild-type 
young HSCs and thus hamper expansion.44 
 The gene harboring most CHDMs in our study was DNMT3A, where we 
identified hotspot and non-hotspot missense mutations, as well as truncating 
mutations throughout all five loci screened. Our assay covered approximately 
8.5% of the coding sequence of DNMT3A and mutations in this gene have been 
identified throughout its coding sequence. Similarly, our assay only included 
close to 2.5% of the coding sequence of ASXL1 and TET2, which are disrupted by 
truncating mutations that may arise throughout the gene. Therefore, the 
detected prevalence of somatic mutations in DNMT3A, ASXL1 and TET2 in our 
study is likely an underestimation and more mutations may be found outside the 
regions screened. Nevertheless, our findings support DNMT3A as the most 
frequently mutated gene in clonal hematopoiesis.2–5 Close to 60% of DNMT3A 
mutations identified in hematologic malignancies disrupt codon R882,45,46 while 
mutations involving codon R326 represent only 0.1% of DNMT3A mutations in 
hematologic cancer.47 In clonal hematopoiesis, we find that 9.6% of DNMT3A 
mutations identified in controls disrupt codon R882, similar to those disrupting 
R326 which represent 8.9% (13/135 and 12/135 mutations for R882 and R326, 
respectively). We therefore estimate that the ratio of DNMT3A R882 to R326 
mutations is approximately 600:1 in malignancy and observe that this ratio is 1.1:1 
in clonal hematopoiesis. This supports the hypothesis that recurrent DNMT3A 
mutations grant an advantage to mutated cells, but the risk of progressing to 
malignancy is much higher in the presence of DNMT3A R882 mutations.45 This 
higher risk associated with these mutations may stem from the dominant 
negative effect of DNMT3A R882 mutants which severely affects DNMT3A 
function through homodimeric interactions with the wild-type protein.48. 
Mutations in DNMT3A affecting residues other than R882 are thought to have a 
smaller effect on the activity of the wild-type protein, which may not be sufficient 
to drive the development of cancer.48 Residues other than R882 can also be 
mutated in myeloid and lymphoid malignancies and the bi-allelic presence of this 
type of DNMT3A mutations has been identified in different forms of leukemia. In 
our cohort, we identified six individuals with more than one DNMT3A mutation 
but the VAF reflected the existence of clones of different sizes. It is unclear 
whether in these subjects the two mutations may be present in the same cell or 
whether they represent completely independent DNMT3A mutant clones. 
 No significant correlation was observed between the VAF of the CHDMs 
identified and the age of the individuals carrying the mutations (R2=-0.03, 
Pearson’s correlation). This may result from an increase in the occurrence of 
mutations over time, leading to a higher number of mutant clones of small size in 
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older individuals that would lower the average VAF in this group. However, the 
fact that examining only mutations with a VAF ≥ 0.02 also reveals a lack of 
correlation between age and VAF argues against this point. Another explanation 
lies in the possibility that the size of a mutant clone depends on the age of the 
clone, rather than the age of the individual in which it is present. Our study 
consisted of a single measurement and as such, we are not able to follow the 
evolution of mutant clones over time. One paper analyzing multiple samples from 
the same individual followed the evolution of mutant clones over time and 
determined that all mutant clones were still present between 4 and 8 years after 
initial detection, with the vast majority of mutant clones increasing or remaining 
stable over time.3 These fluctuations may reflect actual changes in the size of 
mutant HSCs clones, but could also be due to variation over time in the 
contribution of mutant clones of HSCs to blood. It is unclear at present whether 
the size of a mutant clone as reflected by the VAF of a mutation does in fact 
increase with the age of the clone. The presence of a CHDM in itself may not be 
sufficient to lead to clonal expansion over time, either because of a weak 
proliferative effect or because an additional factor may be required to allow for 
expansion. A higher correlation between VAF and age was observed for 
individuals over the age of 70 from a different study 5, which may suggest that 
aging HSCs and bone marrow environment may represent this additional factor 
that allows for clonal expansion of mutant HSCs. 
 A recent study highlighted the unexpected presence of mutations 
associated with developmental disorders at high frequency in 60,706 reference 
exomes in ExAC.27 For instance, 345 individuals were found to carry 56 different 
truncating ASXL1 mutations, an unexpected finding, considering that germline 
truncating ASXL1 mutations cause Bohring-Opitz syndrome, a severe 
developmental syndrome.27,49 This study shows that these mutations had lower 
VAFs than expected for germline events and were present mainly in older 
individuals and therefore likely represented CHDMs. This suggests that the 
presence in ExAC of other mutations causative for developmental disorders may 
also reflect somatic events involved in clonal hematopoiesis rather than germline 
mutations.27 We therefore screened our cohort for somatic mutations in 
candidate genes for clonal hematopoiesis which cause developmental disorders 
when mutated in the germline. Similar to this previously published study, we 
identified somatic mutations in blood overlapping with germline mutations 
known to cause developmental disorders when present in the germline. In 
addition to four truncating mutations in ASXL1, we identified 13 missense 
mutations in DNMT3A R882, which is known to be mutated in Tatton-Brown 
syndrome, a developmental disorder with overgrowth.50 Similarly, 3 somatic 
missense mutations in CBL overlapping with germline mutations leading to a 
Noonan-like phenotype were identified in our cohort.51,52 However, we failed to 
identify somatic mutations in blood in our candidate loci which overlapped with 
known developmental disease-causing mutations. This suggests that this genetic 
overlap between developmental disorders and clonal hematopoiesis may be 
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restricted to specific mutations in known candidate genes for clonal 
hematopoiesis. Thus, the presence of other developmental disease-causing 
variants in reference databases remains unexplained and may also be due to 
other factors such as sequencing errors. We did, however, identify a somatic 
mutation in CBL leading to CBL R420Q at a VAF of 0.15 in a 24-year-old man, 
entailing that 30% of circulating blood cells carry this mutation. The high VAF for 
this mutation is remarkable given the young age of the individual and the fact 
that this was the only somatic mutation identified in this individual. As such, it is 
unknown whether this mutation represents a somatic event arising in a HSC 
during postnatal life or a postzygotic de novo mutation arising in early 
embryogenesis. Interestingly, this mutation has been reported to cause Noonan-
like syndrome when present in the germline51 and leukemia when present 
somatically.47 We could not access clinical information or additional samples from 
this individual to verify the presence of mosaicism in other tissues. It may be that 
pathogenic mutations such as the one identified in this individual or those 
present in these reference databases reflect genetic variation in resilient 
individuals.53 
 In summary, we have screened a cohort of population controls between 
20 and 69 years of age to identify somatic mutations in blood implicated in clonal 
hematopoiesis. Our method provides high sensitivity which allowed for the 
identification of CHDMs at higher prevalence than previously reported despite 
studying a limited set of mutations. Somatic mutations were identified in 
individuals of all ages, with differences in the profile of genes mutated per age 
group and a strong increase in the number of mutations detected with age, with 
over 20% of individuals between 60 and 69 years carrying at least one CHDM, 
while up to 3% of individuals younger than 30 years of age had at least one CHDM. 
Our findings support the occurrence of clonal hematopoiesis associated with 
somatic mutations as a widespread mechanism linked to aging, suggesting that 
clonal evolution of cells harboring somatic mutations is a universal mechanism 
occurring at all ages in humans. 
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Methods and materials 
Samples 
This study was performed using data and biomaterial from the Nijmegen 
Biomedical Study (NBS). The NBS is a population-based study among 9,350 
individuals, based on an age- and sex stratified random sample from the register 
of the municipality of Nijmegen, a city in the east of the Netherlands. Extensive 
questionnaire data on health and lifestyle were collected. Blood samples were 
collected in EDTA tubes and DNA was extracted by salt precipitation method.54 
For this study, we obtained DNA samples and information on age and sex for 
2,014 NBS participants via the Radboud Biobank.54 Approximately four hundred 
samples equally distributed between men and women were obtained for each 
age group (400 for age group 20-29, 405 for age group 30-39, 404 for age group 
40-49, 403 for age group 50-59 and 402 for age group 60-69 years of age; see 
Supplementary Table S1). The quality of purified DNA was tested and each sample 
was normalized to 25 ng/μl by optical density measurement (Dropsense, Trinean). 
This study was approved by the Committee on Research involving Human 
Subjects (Commissie Mensgebonden Onderzoek) of the Radboudumc (CMO 
approval: 2015-2228). 
Targeted loci to screen for mutations 
We performed a literature review to identify mutations observed 
recurrently in age-related clonal hematopoiesis. By combining the results from 
several published studies,2–5 we collected 1,158 coding mutations in 513 amino 
acid residues which were ranked by total number of mutations identified per 
residue. We selected 35 loci with the largest number of coding mutations 
observed in clonal hematopoiesis, which corresponds to a total of 599 single 
nucleotide variants (SNVs) in 87 residues. Furthermore, five loci in which CHDMs 
have been previously identified and in which overlapping germline or 
postzygotic de novo mutations are known to cause developmental disorders 
were included.55–58 In addition, we selected seven loci with nine residues in which 
mutations are known to be causative for paternal age effect disorders and to lead 
to spermatogonial stem cell expansion.28 Finally, we included 57 additional loci in 
which recurrent identical de novo mutations have been found in developmental 
disorders.36–38 These loci are therefore candidates either for elevated mutation 
rates at that genomic site or for mutations leading to expansion of 
spermatogonial stem cells. This analysis resulted in total in 104 loci.  
smMIP design 
To screen for mutations in these 104 loci, MIPGEN software59 was used to 
design probes covering the regions of interest, followed by manual curation and 
selection. The smMIPs were 80 nucleotide-long DNA molecules consisting of an 
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extension and ligation arm with a combined length of 40 nucleotides, separated 
by a linker sequence of 30 nucleotides (see Supplementary Figure S1 for more 
details). All smMIPs contained a unique molecule identifier (UMI) or molecular tag 
consisting of 2×5 random nucleotides to identify each individual captured DNA 
molecule. These smMIPs were designed to target regions of 54 nucleotides. At 
least one smMIP on the sense and on the antisense DNA strand were designed 
per locus. Probes targeting genomic regions containing a SNP with a population 
frequency above 1% were designed to have complementary arms targeting both 
alleles. In total, 231 smMIPs were designed to capture the 104 regions of interest. 
The smMIP oligonucleotides were produced by Integrated DNA Technologies 
(IDT, Leuven, Belgium) at 25nmol scale and normalized to a concentration of 
100µM.  
smMIPs assay setup 
The smMIPs assay was set up with minor modifications to previously 
published protocols.23,60 Briefly, individual smMIPs were pooled equimolarly and 
phosphorylated using T4 polynucleotide kinase and 10x T4 DNA ligase buffer 
supplemented with 10mM ATP (New England Biolabs). The smMIP capture was 
performed on 8µl of input DNA (200 ng) supplied with 17µl of capture mix 
containing 0.28µl of a phosphorylated smMIP pool dilution at 3.12nM, resulting 
in a ratio of 8,000 smMIP molecules per DNA molecule. The capture reaction was 
incubated for 18-22 hours at 60°C, after which the mix was cooled and treated 
with exonuclease. Each exo-treated sample was split in two technical replicates of 
10µl, which were then amplified and barcoded separately by PCR. The PCR 
products were run on gel, pooled, purified using AMPureXP Beads (Agencourt) 
and run on a Tapestation (Agilent) to verify the integrity of the sequencing library. 
Sequencing was performed on an Illumina NextSeq500 platform with 2×79-bp 
paired-end reads (i.e. each DNA insert being sequenced in both directions). A pilot 
smMIP experiment was performed on control DNA for the optimization of the 
smMIP library. The performance of each individual probe was evaluated by 
examining the sequencing coverage per probe, in order to identify under-
performing and over-performing smMIPs. After excluding smMIPs with off-target 
capture, a new and rebalanced smMIP pool was prepared adjusting the volumes 
for each probe. The new pool was phosphorylated and an experiment was run on 
control DNA samples to verify pool rebalancing. The library was subsequently 
prepared and sequenced as described previously using blood DNA samples from 
the cohort. After sequencing, 18 smMIPs were shown to have an overall median 
coverage <20-fold and were excluded from further analysis. Seven samples for 
which both replicates had an average sequencing coverage below 100-fold were 
excluded due to poor quality or quantity of the input DNA.  
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Analysis 
FASTQ files were obtained from the bcl files and demultiplexed using the 
sample barcode. Sequenced reads were mapped with BWA MEM, using a 
modified version of an in-house bioinformatics pipeline which allows trimming of 
the MIP extension and ligation arms (MIPVAR, available at 
www.sourceforge.net/projects/mipvar/). To analyze unique DNA molecules, we 
detected and removed PCR duplicates of individual captured molecules per 
sample and per smMIP by identifying reads with the same UMI. From the regions 
selected for screening, 88 out of 104 loci had one or two mutated residues. For 
these loci, we analyzed the genomic region corresponding to the mutated 
residue(s) +/- 6 base pairs. Regions with more than two mutated residues (13 out 
of 104 loci) were analyzed so that we would examine the entire region 
encompassing all mutated residues within the locus +/- 6 bp. For TP53, we 
analyzed the entire region captured by the smMIPs (3 out of 104 loci). Pileups 
were generated for all samples for these positions using SAMtools with the 
following filter settings: sequence quality ≥25 and a mapping quality ≥15.5 The 
coverage, each nucleotide change and the presence of insertions and deletions 
were counted at each position for each sample replicate. Within each sample 
replicate, positions with a unique molecule sequencing coverage below 200-fold 
were excluded. The sequencing error was calculated for each position and 
nucleotide change (A, C, G, T, insertion and deletion) based on all samples from 
the cohort. Additionally, the run-specific sequencing error for each position and 
nucleotide change was determined using only samples within the same 
sequencing run. Subsequently, we used a Poisson distribution to calculate a p-
value reflecting the probability to obtain a number equal or higher to the 
observed number of mutation reads per position for all sample replicates based 
on the sequencing error. This calculation was performed in parallel using each 
determined sequencing error in two independent analyses. For each sample, we 
extracted the p-values for all nucleotide changes for all positions from only one 
of the replicates and performed Benjamini-Hochberg multiple test correction on 
these values. All nucleotide changes with an adjusted p-value <0.05 and with ≥2 
reads for SNVs and ≥5 reads for indels were included as “statistically significant 
nucleotide changes”. We then extracted from the second sample replicate the p-
values obtained for the statistically significant nucleotide changes in the first 
replicate and performed Benjamini-Hochberg multiple test correction. We used 
the same filtering criteria and obtained a list of potential mutations. Finally, the 
list of potential mutations obtained with the overall and the run-specific 
sequencing error were overlapped. We included only mutations in which both 
replicates have ≥2 reads for SNVs and ≥5 reads for indels, representing a 
statistically significantly higher number of mutations counts than expected based 
both on the overall and the run-specific sequencing error. For positions within a 
mutational hotspot in which more than 5 mutations were identified (such as JAK2 
V617F and all DNMT3A hotspots), a separate analysis examining only nucleotide 
changes at those hotspots was performed. To exclude germline events, somatic 
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mutations were defined as mutations with a VAF ≤0.35 and an allele frequency 
<0.001 in ExAC.  
Validations 
 Mutations found recurrently in our cohort were selected for validation. 
Recurrent mutations in DNMT3A leading to DNMT3A R882C and R882H were 
found to eliminate a recognition site for the restriction enzyme TauI 61. Mutations 
in this residue were identified in 13 samples at different variant allele frequencies. 
These mutations were validated by PCR amplification (forward primer 5’- 
GAACTAAGCAGGCGTCAGAGGA-3’, reverse primer 5’- 
AAAAAGGGAAGGGGGAGGAAGG-3’) of a region of 577 bp surrounding the region 
of interest in DNMT3A, followed by restriction digestion. Amplicons of the wild-
type sequence are digested by TauI in two fragments of 369 and 208 bp, while 
amplicons of either mutant allele fail to be recognized by the enzyme and remain 
undigested. Size analysis of the digested products was performed on a 
TapeStation. A subset of the digested products was selected for subsequent 
sequencing on an Ion Torrent platform.
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Supplementary data 
 
Supplementary methods 
Preparation of smMIP library 
Individual smMIPs were pooled equimolarly and phosphorylated using T4 
polynucleotide kinase and 10x T4 DNA ligase buffer supplemented with 10mM 
ATP (New England Biolabs). The smMIP capture was performed on 8µl of input 
DNA (200 ng) supplied with 17uL of capture mixture (0.01µl Ampligase DNA ligase 
(100U/µl, Illumina), 2.5µl 10x ampligase buffer (Illumina), 0.28µl phosphorylated 
smMIP pool dilution (corresponding to a DNA:smMIP ratio of 1:8000), 0.32µl 
Hemo Klentaq (10U/µl, New England Biolabs), 0.03µl dNTPs (0.25mM) and 13.86µl 
H2O). The capture mix was incubated for 18-22 hours at 60°C, after which the mix 
was cooled and treated with exonuclease (0.5µl Exonuclease I (New England 
Biolabs), 0.5µl Exonuclease III (New England Biolabs), 0.2µl 10x Ampligase buffer 
(Illumina) and 0.8µl H2O for 45 minutes at 37°C and 2 minutes at 95°C to inactivate 
the exonucleases). Each exo-treated sample was split in two technical replicates 
of 10µl, which were then amplified and barcoded by PCR independently (1.25µl 
of barcoded reverse primer (10µM), 12.5µl 2x iProof (BioRad Laboratories), 0.125µl 
forward primer (100µM) and 1.8µl H2O). The PCR products were run on gel, 
pooled and purified using AMPureXP Beads (Agencourt). 
 
 
 
 
 
 
 
 
  Figure S1. Overview of smMIP protocol used in this study. Each smMIP is a single stranded 80 
nucleotide-long DNA molecule consisting of the extension and the ligation arm (shown in burgundy 
and blue, respectively) which together are 40 nucleotides long and are designed to be 
complementary to the targeted region. The two arms are connected by a 30 nucleotide-long linker 
sequence (in black). Each smMIP contains a unique molecule identifier (UMI) composed by 2 
barcodes of random 5 nucleotide sequences (shown in green). The smMIPs are designed for double 
tiling of regions of interest containing mutations (shown as red star) on the plus and the minus 
strand (A). The smMIPs are ordered as long oligonucleotides (B), after which they are pooled and 
phosphorylated (C). DNA capture is performed by mixing the phosphorylated smMIP probes with 
the DNA, dNTPs, polymerase and ligase to form the reverse complement of the region of interest to 
which the probe binds and ligate the probe into a circular single strand of DNA (D). Afterwards, the 
mix is digested with exonuclease to remove all linear DNA molecules (E). We subsequently 
separated the captured and circularized molecules in two separate technical replicates and 
performed PCR amplification separately (F), using a sample and PCR-specific barcode (shown in 
yellow and cyan). The PCR products were purified using AmpureXP beads and sequences on an 
Illumina Nextseq platform using 2×79 bp reads. 
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Figure S2. Median unique sequencing coverage per sample, corresponding to the number of 
unique DNA molecules sequenced per sample and per position after removal of PCR duplicates. 
Each sample is represented here by two bars, corresponding to each technical replicate. The median 
unique sequencing coverage per age group is shown as a horizontal dotted line. The overall median 
unique sequencing coverage was 418-fold per replicate and 845-fold per sample. 
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Mean 
age 
Median 
age 
Total Included Male 
Male 
(%) 
Female 
Female 
(%) 
20-29 24.7 25 400 396 195 49.5 201 50.5 
30-39 34.6 35 405 402 202 50.2 200 49.8 
40-49 44.7 45 404 404 202 50.0 202 50.0 
50-59 54.3 55 403 402 202 50.2 200 49.8 
60-69 64.5 64 402 402 201 50 201 50.0 
Total 44.6 45 2014 2006 1002 50.0 1004 50.0 
 
Table S1. Age and sex of participants in our study. 
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Abstract 
Schinzel-Giedion syndrome (SGS) is a rare developmental disorder 
characterized by multiple malformations, severe neurological alterations and 
increased risk of malignancy. SGS is caused by de novo germline mutations 
clustering to a 12 bp hotspot in exon 4 of SETBP1. Mutations in this hotspot 
disrupt a degron, a signal for the regulation of protein degradation, and lead to 
the accumulation of SETBP1 protein. Overlapping SETBP1 hotspot mutations 
have been observed recurrently as somatic events in leukemia.  
We collected clinical information of 47 SGS patients (including 26 novel 
cases) with germline SETBP1 mutations and of four individuals with a milder 
phenotype caused by de novo germline mutations adjacent to the SETBP1 
hotspot. Different mutations within and around the SETBP1 hotspot have varying 
effects on SETBP1 stability and protein levels in vitro and in in silico modeling. 
Substitutions in SETBP1 residue I871 result in a weak increase in protein levels and 
mutations affecting this residue are significantly more frequent in SGS than in 
leukemia. On the other hand, substitutions in residue D868 lead to the largest 
increase in protein levels. Individuals with germline mutations affecting D868 
have enhanced cell proliferation in vitro and higher incidence of cancer compared 
to patients with other germline SETBP1 mutations.  
Our findings substantiate that, despite their overlap, somatic SETBP1 
mutations driving malignancy are more disruptive to the degron than germline 
SETBP1 mutations causing SGS. Additionally, this suggests that the functional 
threshold for the development of cancer driven by the disruption of the SETBP1 
degron is higher than for the alteration in prenatal development in SGS. Drawing 
on previous studies of somatic SETBP1 mutations in leukemia, our results reveal a 
genotype-phenotype correlation in germline SETBP1 mutations spanning a 
molecular, cellular and clinical phenotype. 
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Introduction 
Schinzel-Giedion syndrome (SGS; OMIM 269150) is a rare developmental 
disorder characterized by multiple malformations including midface hypoplasia, 
cardiac defects, hydronephrosis and skeletal abnormalities.1–3 This clinically 
recognizable syndrome was the first dominant disorder for which the underlying 
genetic cause was identified by whole exome sequencing.4 In 12 of 13 unrelated 
individuals with this disorder, we identified germline de novo mutations in 
SETBP1 clustering to a hotspot of 12 base pairs coding for residues 868 to 871 of 
the SETBP1 protein.4 Interestingly, shortly after the identification of germline de 
novo mutations in SETBP1 as the cause of SGS, overlapping somatic mutations in 
SETBP1 were reported in several types of myeloid malignancies.5–7 This dual role 
in cancer and development is not unique to SETBP1; a growing number of genes 
in which germline mutations cause developmental disorders, such as HRAS, 
ASXL1, EZH2 and FGFR2, are also known to harbor overlapping somatic mutations 
which drive the development of cancer.8 This genetic overlap is not entirely 
unexpected; higher rates of childhood cancer have been identified in individuals 
with birth defects and vice versa,9–11 a finding which is thought to be the 
consequence of abnormalities in molecular pathways shared between 
embryogenesis and cancer development.12,13 
The precise function of SETBP1, which encodes the SET-binding protein 1 
(OMIM 611060), is yet to be discovered and, as a result, the molecular 
consequences of SETBP1 mutations remain largely unknown. However, the 
clustering of all germline SETBP1 mutations identified in SGS to a single region 
and their overlap with the somatic events identified in myeloid malignancies 
support a gain-of-function effect on the SETBP1 protein. This recurrently mutated 
region of the protein is highly conserved and has been identified as a degron 
signal targeted by the SCF-βTrCP1 E3 ligase.5 A degron is a peptide sequence that 
is recognized and bound by a component of the ubiquitin-proteasome pathway, 
thereby initiating degradation of the protein by ubiquitination.14 As a result, 
mutations localizing to the degron in SETBP1 disrupt binding by the βTrCP1 E3 
ligase, increase protein stability by interfering with ubiquitination15 and 
ultimately lead to accumulation of SETBP1 protein in cells.5 While the molecular 
consequences of germline SETBP1 mutations are poorly understood, somatic 
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mutations disrupting the SETBP1 degron lead to increased proliferation in 
myeloid progenitors,7 possibly mediated by effects on its interaction partner SET, 
phosphorylation of PP2A and transcriptional activation of HOXA9 and 
HOXA10.5,16,17  
Additional clinical and functional investigation is warranted to gain more 
understanding about the molecular mechanisms of SGS. Here we present the 
clinical characterization of the largest cohort of individuals with genetically 
confirmed SGS and establish genotype-phenotype correlations for SGS. Given the 
occurrence of overlapping germline and somatic SETBP1 mutations, we compare 
the mutations in SGS and leukemia to identify genetic and functional differences 
between SETBP1 mutations in both conditions. 
 
Results 
Clinical features of SGS 
Classic SGS is caused by mutations within four residues of the SETBP1 
degron (D868, S869, G870 and I871, Figure 1A and 1B), constituting the critical 
consensus sequence of the degradation signal18 (from here on, referred to as the 
canonical degron). Since the initial description of 12 mutation-positive cases,4 we 
have gathered clinical details of 26 additional individuals with SGS genetically 
confirmed by the presence of de novo mutations in SETBP1 (see Table 1). In 
addition, we present three patients with a milder phenotype variably overlapping 
with SGS and secondary to novel mutations in SETBP1 affecting highly conserved 
residues in close proximity to the canonical degron (current cases no. 27-29, with 
mutations in residues E862, S867 and T873 shown in green in Figure 1B). We 
report on the clinical features observed in our cohort in addition to previously 
published mutation-positive cases to further delineate this disorder (n=51 
individuals). 
 
Dysmorphic facial features 
All individuals with SGS have characteristic facial features that are easily 
recognizable (Figure 1C and Supplementary Figure S1). Typically, SGS patients 
have large fontanelles (n=37/41), a prominent forehead (n=41/44), bitemporal 
narrowing (n=32/36), shallow orbits or prominent eyes (n=36/38), hypertelorism 
(n=36/42) a retracted and shortened midface (n=45/45) and full cheeks, leading 
to a facial frontal silhouette in the shape of a number eight.19 Additionally, most 
patients have a deep groove under the eyes (n=38/39), upslanting palpebral 
fissures (n=21/26) and a short nose with a bulbous nasal tip (n=43/44). Some 
individuals may present with less recognizable facial features in the first weeks 
after birth and after the age of 18 months. In those cases, additional diagnostic 
clues that may facilitate the diagnosis include the abnormal shape of the ears 
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(n=38/39). Classically, the ears of individuals with SGS are low-set and posteriorly 
rotated with anteriorly angulated lobules giving rise to a question mark shape 
(Figure 1D). In individuals who do not have the typical lobules, the majority does 
have folded helices and prominent anti-helices. About half of the patients show a 
large mouth (n=17/33) with an everted lower lip and a protruding tongue 
(n=18/38). In addition, they may present with micrognathia (n=29/30) and a 
philtrum groove. Hypertrichosis was identified in two thirds of the patients 
(n=26/37), facial hemangioma in eight of 33 cases and a short neck in 30 of 33 
cases. 
 
Skeletal features 
As molecular testing for SETBP1 mutations has become available, the 
extent of diagnostic radiologic evaluations has diminished and, therefore, has not 
been performed in all patients within this cohort (data were available for 31 
cases). Skeletal characteristics present in over 75% of these patients included a 
sclerotic base of the skull (n=19/23) with wide occipital synchondrosis (n=18/23), 
widening of ribs (n=27/31), short pubic rami, wide pubic symphysis (n=18/20) and 
hypoplastic distal phalanges in hands and feet (n=21/25). In case 22, the 
synchondrosis had closed completely in a later radiologic examination. Post-axial 
polydactyly was noted in only 11% of patients (n=4/38). Retrospective study of 
photographs of the hands of individuals with SGS shows that a typical posture 
with clenched fingers is common (Figure 1E and 1F).  
 
Neurologic features 
Microcephaly was observed in approximately two thirds of the individuals 
with SGS (n=29/39). The occipitofrontal circumference in the remaining 
individuals for whom data were available, was always below the 50th percentile 
and often near the 10th percentile. Severe developmental delay occurs in all 
individuals with SGS and 95% present with epilepsy (n=42/44). Almost all 
common types of epilepsy occur and seizures are characteristically extremely 
refractory to treatment with medication or ketogenic diet. Many patients have 
hearing (n=24/27) or vision impairment (n=20/26) thought to be of cerebral 
origin. Spasticity was noted in 17 out of 20 of cases. 
Structural brain abnormalities are variable in SGS. The most common 
anomaly is hypoplasia or aplasia of the corpus callosum (n=31/38). Additional  
abnormalities often encountered are cortical atrophy (n=18/33), ventricle 
anomalies (n=26/42), abnormal gyration and delayed myelination and choroid 
plexus cysts (n=13/31).  
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⊳ Figure 1. Genetic and clinical characteristics of individuals with germline SETBP1 mutations and 
Schinzel-Giedion syndrome. A. Schematic representation of the SETBP1 protein, indicating changes 
found in SGS and in hematologicAL malignancies. The residues of the canonical degron are highlighted 
with arrows. Protein domains of SETBP1 are shown in different colors with green corresponding to 
three AT hooks, purple to the SKI homologous region, blue to the SET binding domain and orange to 
a repeat domain (modified from Piazza et al.5).  B. Sequence alignment of the region containing the 
degron of SETBP1 (in bold) in human (Uniprot accession number Q9Y6X0), chimpanzee (H2QEG8), 
mouse (Q9Z180), chicken (E1BWZ2), african clawed frog (F6TBV9) and zebrafish (B0R147). The 
consensus motif for βTrCP1 substrates is shown on top, with φ representing a hydrophobic residue 
and X any amino acid. Residues in which pathogenic germline mutations have been identified in classic 
SGS are highlighted in blue, while residues in which novel mutations leading to an atypical form of SGS 
are shown in green. C. Distinctive facial features encountered in classic SGS (current case 9 at 1,5 years 
of age). D. Typical question mark-shaped ear from observed in current case 18. E. Characteristic hand 
posture with clenched fingers, observed from current case 16. F. Facial features of current case 27 
with a mutation in SETBP1 residue S867 at 4 years of age. Note the clenched fingers. G. Facial features 
of current case 28 with a mutation in SETBP1 residue E862 at 5 years of age. H. Facial features of 
current case 29 with a mutation in SETBP1 residue T873 at the age of 23 months. 
 
 
Additional congenital anomalies 
Individuals with SGS nearly always present hydronephrosis (n=45/47), a 
feature that can be detected during routine prenatal medical exams. Two patients 
in our cohort were noted to have hydronephrosis at 20 weeks of gestation. Other 
kidney anomalies include abnormal ureters, renal cysts and stones. Almost all 
patients have genital anomalies (n=41/45), which include hypospadias, 
underdeveloped genitalia and displaced anus. Half of the patients (n=20/43) have 
structural cardiac malformations, the majority of which present with defects of 
the atrial septum. Other anomalies include patent foramen ovale, patent ductus 
arteriosus and cardiac hypertrophy. Alterations in the internal organs may be 
identified in some individuals with SGS, including hypoplasia of the pancreatic tail 
or hepatosplenomegaly. Microscopic evaluation in one patient (current patient 
no. 6) showed dilated glands and mucus depositions in intra-acinar pancreatic 
ducts at a post-mortem examination at 4 days of age. The observed features were 
similar to the mucus obstruction seen in cystic fibrosis. However, CFTR analysis in 
this patient proved negative. Nineteen patients (n=19/27) were noted to have 
alacrima. Inguinal hernia (n=8/15) and talipe(s) equinovarus (n=11/17) were also 
frequently noted.  
 
Swallowing and breathing difficulties 
A major medical problem encountered in the care of individuals with SGS 
is the difficulty in swallowing and breathing. This is caused by a combination of 
factors such as structural abnormalities of the respiratory apparatus (e.g. choanal  
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Residue affected in 
SETBP1 
E862 S867 D868 S869 G870 I871 T873 
All degron 
affecting 
mutations 
(868-871) 
Male(M):female(F) 1F 2F 8F:7M 2F 5F:10M 6F:9M 1M 21F:26M 
Microcephaly 1/1 1/2 10/12 1/2 10/13 8/11 0/1 29/39 74.4% 
SGS facial gestalt 0/1 2/2 15/15 2/2 15/15 15/15 0/1 47/47 100% 
Hydronephrosis 0/1 0/2 15/15 2/2 14/15 14/15 0/1 45/47 95.7% 
Genital 
abnormalities 
1/1 0/2 14/15 1/2 14/15 12/13 0/1 41/45 91.1% 
Cardiac defects 0/1 1/2 10/15 1/2 4/13 5/13 0/1 20/43 46.5% 
Tracheo- or 
laryngomalacia 
0/1 0/1 3/4 0/2 3/8 2/2 0/1 8/16 50.0% 
Inguinal hernia 0/1 0/1 2/4 0/2 6/8 0/1 0/1 8/15 53.3% 
Alacrima 0/1 2/2 6/10 0/2 7/9 6/6 0/1 19/27 70.4% 
Developmental 
delay 
1/1 2/2 14/14 2/2 13/13 10/10 1/1 39/39 100% 
Seizures 0/1 2/2 15/15 2/2 13/14 12/13 0/1 42/44 95.5% 
Spasticity and/or 
hypertonia 
0/1 1/1 4/4 1/2 8/10 4/4 1/1 17/20 85.0% 
Vision impairment 1/1 1/1 7/10 1/2 7/8 5/6 0/1 20/26 76.9% 
Hearing impairment 0/1 0/1 9/9 0/1 7/8 8/9 0/1 24/27 88.9% 
Progressive failure to 
thrive 
0/1 0/1 10/11 1/2 13/13 8/9 0/1 32/35 91.4% 
Ventriculomegaly 0/1 NA 6/12 2/2 11/14 7/14 0/1 26/42 61.9% 
Underdeveloped 
corpus callosum 
0/1 NA 9/11 0/2 12/13 10/12 0/1 31/38 81.6% 
Cortical atrophy or 
dysplasia 
0/1 NA 8/10 0/2 7/10 3/11 1/1 18/33 54.5% 
Choroid plexus cysts 0/1 NA 2/9 0/2 8/10 3/10 0/1 13/31 41.9% 
Sclerotic base of 
skull or mastoid 
NA NA 9/10 0/1 5/5 5/7 NA 19/23 82.6% 
Hypoplastic distal 
phalanges 
0/1 NA 8/9 0/1 8/9 5/6 NA 21/25 84.0% 
Broad ribs 0/1 NA 10/13 2/2 6/7 9/9 NA 27/31 87.1% 
Hypoplastic pubic 
bones 
0/1 NA 6/7 2/2 4/5 6/6 NA 18/20 90.0% 
Tumors 0/1 0/2 5/11 0/2 1/11 1/9 0/1 7/33 21.2% 
Table 1. Major clinical findings in 51 individuals with germline mutations in SETBP1. NA stands 
for “Not Assessed”. 
 
 
stenosis, n=10/34), tracheobronchomalacia (n=8/16), lung hypoplasia, poor 
management of oral and respiratory secretions (e.g. resulting from micrognathia, 
gingiva hypertrophy or excessive mucus production) and a high susceptibility to 
airway infections. Although gingiva hypertrophy can result from the use of anti-
epileptic medication, this feature was already noted in a newborn with SGS at four 
days of age (patient no.6). In this case, dilated laryngeal and broncheal glands 
filled with mucus were observed in the microscope, consistent with a previous 
report of thickened alveolar mucosa and fibrous hyperplasia of the gingiva with 
mucoid depositions,20 suggesting that this is a feature of SGS.   
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Cause of death 
Most affected individuals do not survive past childhood, with pneumonia 
as a major cause of death in SGS (n=8/15). Other reported causes in early infancy 
include congenital cardiac defects, tumors, lung hypoplasia, intractable seizures 
and sudden cardiac arrest. Six individuals developed solid tumors, predominantly 
of neuroepithelial origin in the lumbosacral region. Additionally, one individual in 
this cohort developed juvenile myelomonocytic leukemia. Although the majority 
of individuals die during infancy, five out of twelve patients with a protein 
substitution in residue G870 lived to the age of 5 or older (5 to 15 years of age). 
The average age of death of deceased individuals with a substitution in D868, 
S869, G870 and I871 is 18 months (n=10), 32 months (n=2), 48 months (n=7) and 
25 months (n=8), respectively (see Supplementary Figure S3). Due to the small 
size of the cohort, it is not possible to draw conclusions on whether there are 
differences in survival depending on the mutated residue. 
 
Individuals with mutations outside of the degron 
Individuals with germline SETBP1 mutations occurring outside the 
degron (n=4) are reported in this separate section. Both patients with a mutation 
in residue S867 (one reported in reference 21 and current case no. 25 from our 
cohort, see Figure 1G and Figure S2A-D) had a characteristic facial appearance, 
genital anomalies and seizures but did not show hydronephrosis. Other features 
of these patients fit within the spectrum of SGS and are summarized in Table 1.  
One individual with a mutation in residue E862 did not have a 
characteristic facial appearance (Figure 1H and Figure S2E-H), seizures nor 
hydronephrosis. However, this patient had several other overlapping features 
with SGS, including dysphagia requiring a gastrostomy tube, vision loss due to 
retinal dystrophy, bilateral renal cysts and severe spasticity. She showed 
microcephaly, prognathism, small feet with short toes and a normal height. At five 
years of age, she had severe intellectual disability and could neither speak nor 
walk. 
  The individual with a mutation in residue T873 had the mildest 
phenotype, presenting with developmental delay, autistic features, spastic 
diplegia and milder dysmorphic features (Figure 1I and Figure S2I-L). This patient 
does not present any of the major congenital anomalies commonly found in SGS 
and, despite developmental delay, his initial developmental outcome seemed 
higher compared to individuals with SETBP1 mutations within the degron. He 
achieved several milestones: smiling at eight weeks, making vowel sounds at 14 
months, sitting unassisted at 22 months and, at 2 years of age, he was able to 
maintain crawling position, walk with help and feed himself. Thereafter, he 
entered a regression phase with loss of the aforementioned milestones and 
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started self-injurious behavior. An IQ test was not available but, at 4 years of age, 
his functional level was estimated to be that of an eight-month-old.  
 
Functional characterization of SETBP1 variants 
Mutations within the canonical degron of SETBP1 disrupt its interaction 
with βTrCP1, increasing protein stability and SETBP1 levels5,15 but the effect of 
SETBP1 mutations outside the canonical degron on protein stability is unknown. 
Clear differences in the severity of the phenotype resulting from germline SETBP1 
mutations within and outside the canonical degron suggest a difference in the 
effect of the mutations depending on their localization. Therefore, we performed 
the functional characterization of the most frequent SETBP1 mutations observed 
within the canonical degron and causative for classic SGS (D868N, S869N, G870S 
and I871T) as well as one mutation outside the canonical degron leading to 
atypical SGS (E862K). 
 
Effects of SETBP1 variants on protein levels and protein stability 
To investigate the effect of SETBP1 variants on protein stability, we 
quantified expression levels of YFP-fusion proteins in live HEK293 cells based on 
fluorescence intensity (Supplementary Figure S4). All three pathogenic SETBP1 
variants E862K, D868N and I871T showed increased protein levels compared to 
WT SETBP1 (Figure 2A; p<0.001, ANOVA). Interestingly, SETBP1 variants occurring 
within the canonical degron (D868N, I871T) showed higher protein levels 
compared to the variant adjacent to the degron sequence (E862K; p<0.001 versus 
other mutants, ANOVA). 
To verify that the increased protein levels seen in cells expressing 
pathogenic SETBP1 variants are due to resistance to degradation by the 
proteasome, we treated transfected HEK293 cells with MG132, a proteasome 
inhibitor (Figure 2B). WT SETBP1 protein levels were sensitive to inhibition of the  
proteasome, as evidenced by a significant increase in fluorescence intensity after 
MG132 treatment for 3 hours (132% vs 108% for treated versus untreated cells 
compared to baseline, p<0.05, Student’s T-test). The difference in expression 
levels after 3 hours of MG132 treatment was not significant for SETBP1 variants 
E862K, D868N and I871T (E862K: 126% vs 113%; D868N: 118% vs 115%; I871T: 
121% vs 121% for treated versus untreated cells compared to baseline). 
Prolonged treatment with MG132 resulted in a larger fold increase in fluorescence 
observed for treated versus untreated cells in cells transfected with WT versus 
mutant SETBP1 (1.58 for WT, 1.32 for E862K, 1.14 for D868N and 1.21 for I871T; 
p<0.01, ANOVA). Indeed, prolonged MG132 treatment results in a significant 
increase in expression levels of wild-type SETBP1 and the E862K mutant (SETBP1:  
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Figure 2. Functional analysis of SETBP1 mutations identified in SGS. A. Fluorescence 
measurements in live HEK293 cells expressing YFP-tagged SETBP1 variants. (*** p<0.001 versus 
wild-type and all mutants, ANOVA). All SETBP1 mutations studied displayed a statistically significant 
difference compared to wild-type and to all other mutations. This graph is representative of 3 
independent experiments performed, with 6 technical replicates per experiment. Bars represent the 
standard error. B. Relative expression of SETBP1 protein variants in live HEK293 cells treated with 
MG132 proteasome inhibitor or vehicle only. Bars represent the standard error. (*** p<0.001, * 
p<0.05, NS: not significant, Student’s T test and Mann-Whitney U test). C. ∆∆G values for degron-
βTrCP1 interaction for all germline mutations reported in SETBP1 per residue (** p<0.01 D868 versus 
other residues; ANOVA). D. Immunoblot of whole cell lysates of HEK293 cells expressing FLAG-
tagged SETBP1 variants probed with anti-FLAG antibody. E. Immunoblot of whole-cell lysates of 
fibroblasts probed with anti-SETBP1 antibody. Fibroblasts were derived from two cases of SGS, one 
carrying the I871T variant and the other carrying the D868N variant, as well as from two unrelated 
controls. In D and E, blots were stripped and re-probed with anti-β-actin antibody.  
 
 
261% vs 164%; E862K: 230% vs 173% for treated versus untreated cells compared 
to baseline, p<0.001, Student’s T test). Prolonged MG132 treatment did not 
significantly affect the expression levels of the D868N and I871T SETBP1 variants 
(211% vs 185% and 225% vs 186% for treated versus untreated cells compared to 
baseline, respectively). Cycloheximide chase of wild-type and mutant SETBP1 
suggests decreased degradation of mutant SETBP1 as compared to the wild-type 
protein (Supplementary Figure S5), further supporting that mutations in the 
SETBP1 degron confer increased stability to the protein. This suggests that 
pathogenic SETBP1 variant proteins have decreased sensitivity or resistance to 
proteasome inhibition with varying magnitude of effects. 
168 | Chapter 6 
Different magnitude of effect of SETBP1 variants within the canonical degron 
To explore the effect of disease-causing SETBP1 variants on the 
interaction of SETBP1 with βTrCP1, we performed in silico modeling of all known 
germline mutations that occur within the canonical degron (D868-I871) identified 
in patients with classic SGS. Although the protein structure of SETBP1 is not 
known, the sequence of the βTrCP1 binding site in the SETBP1 degron is similar 
to the sequence of a degron in β-catenin (Supplementary Table S1).18 We 
therefore used a protein model of the degron of β-catenin in complex with 
βTrCP1 as a template to analyze the effect of pathogenic germline SETBP1 
variants on molecule stability and on the degron/βTrCP1 interaction energy 
(molecule ∆∆G and βTrCP1 interaction ∆∆G, respectively; Figure 2C and 
Supplementary Table S2). Modeling of all pathogenic germline substitutions 
observed in the degron shows that the interaction with βTrCP1 was most affected 
for substitutions of the aspartate residue from the motif (p<0.001 versus other 
residues, ANOVA), which is in line with previous findings.18 This would entail that 
among the variants observed in SGS, mutations in residue D868 would have the 
largest effect on degron/βTrCP1 interaction, followed by mutations in G870. 
To verify the differences on protein stability observed at the 
computational level, we used immunoblotting to examine the protein levels of 
SETBP1 variants in transfected HEK293 cells. Pathogenic SETBP1 variants led to 
substantially higher protein levels than WT SETBP1 (Figure 2D and Supplementary 
Figure S6). Variants D868N and G870S resulted in dramatically increased protein 
levels, whereas E862K, S869N and I871T showed a more modest increase in 
protein levels (Figure 2D). To further explore these findings, we performed 
immunoblotting to examine endogenous SETBP1 protein levels in fibroblasts 
derived from individuals with SGS. Fibroblasts from an individual carrying the 
D868N variant showed increased SETBP1 protein levels compared to two 
unrelated age-matched controls, whereas fibroblasts from a patient carrying the 
I871T mutation did not show any differences in endogenous SETBP1 levels 
compared to the controls (Figure 2E). Analysis of mRNA levels showed decreased 
SETBP1 mRNA levels in cells of individuals with SGS as compared to controls, 
suggesting that the increase observed in endogenous SETBP1 protein does not 
result from increased SETBP1 transcription (Supplementary Figure S7). Together, 
these results suggest that SETBP1 degron mutations have variable effects on 
protein stability, with the D868N variant having a stronger effect than I871T.  
 
Overlapping SETBP1 mutations in SGS and in myeloid malignancies  
Overlapping mutations in SETBP1 have been identified as germline de 
novo events in SGS and as somatic mutations in myeloid malignancies (Figure 1A). 
Considering that canonical degron mutations vary in the magnitude of their 
effect, we compared germline and somatic SETBP1 mutations to detect 
differences between the mutations in both conditions. In total, 48 germline de 
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novo mutations within the SETBP1 degron have been reported in individuals with 
SGS, both from our cohort and from published literature.4,21–29 Similarly, we have 
retrieved from literature 245 individual somatic mutations in the SETBP1 degron, 
associated with different myeloproliferative disorders (see Supplementary table 
4).5–7,30–48 While the mutations overlap in both conditions, the distribution of the 
mutations within the canonical degron sequence is not the same; a significantly 
higher number of mutations affect residue I871 in SGS cases compared to myeloid 
malignancy cases (29% and 12%, respectively, p<0.01, Fisher’s test with 
Bonferroni correction; see Figure 3A). 
All SETBP1 degron mutations identified in leukemia were compared to 
mutations observed in SGS on their effect on the SETBP1-βTrCP1 interaction using 
in silico modeling (Figure 3B). Taking into account the frequency of each 
mutation, we then compared the difference in degron-βTrCP1 interaction energy 
for SETBP1 mutations observed in SGS versus those observed in myeloid 
malignancies (Figure 3C). Generally, mutations observed in myeloid malignancies 
showed higher ∆∆G values than mutations observed in SGS (p <0.05, Mann-
Whitney’s U test). However, the difference in ∆∆G between germline and somatic 
SETBP1 mutations after exclusion of mutations in codon I871 is no longer 
statistically significant. This suggests that the difference between ∆∆G values 
between germline and somatic SETBP1 mutations may be secondary mainly to 
the prevalence of mutations at codon I871 in each condition. 
 
Similarities in downstream consequences of germline and somatic SETBP1 
mutations 
The SETBP1-SET interaction regulates SET protein levels and can induce 
cleavage of SET.16 Higher levels of SET protein have been reported with 
overexpression of wild-type SETBP1 in HEK cells and of SETBP1 G870S in TF1 
cells.5,16 To establish whether pathogenic germline SETBP1 degron mutations 
D868N, S869N and I871T also lead to increased SET protein levels in SGS, we 
performed immunoblotting on protein lysates of lymphoblastoid cell lines (LCLs) 
derived from three unrelated patients with SGS. Compared to age-matched 
controls, we observed that cell lines derived from individuals with germline 
mutations in the SETBP1 degron show higher SET protein levels, with an increase 
in full length versus cleaved SET protein (Figure 4A and 4B).  
Somatic mutations in SETBP1 drive the development of myeloid 
malignancies by increasing proliferation in leukemic cells.15 We examined LCLs 
derived from individuals with germline SETBP1 mutations seen in SGS to 
determine whether they presented increased proliferation. In a time course 
experiment, we observed that LCLs derived from individuals with SGS proliferate  
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Figure 3.  On average, SETBP1 mutations seen in cancer are more severe than those observed 
in SGS. A. Distribution of mutations within the SETBP1 degron in SGS and in hematological 
malignancies. (** p<0.01, Fisher’s test and Bonferroni correction for multiple testing). B. ∆∆G values 
for protein stability (x-axis) and degron-βTrCP1 interaction (y-axis) for all mutations reported in 
SETBP1. The size of each circle is proportional to the frequency of the mutation in each condition. 
C. Difference in free energy of binding in the interaction between βTrCP1 and the degron of variants 
arising from germline or somatic SETBP1 mutations compared to that of the interaction between 
βTrCP1 and the wild-type degron (* p <0.05, Mann-Whitney’s U test). The median is highlighted by 
an arrow head. 
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Figure 4. Increased SET protein and proliferation in cell lines of patients with SGS. A. 
Immunoblot of whole cell lysates of lymphoblastoid cell lines (LCLs) derived from three SGS patients 
and two age-matched controls. The blot was probed with anti-SET,  before stripping and re-probing 
with β-actin to confirm equal loading. * denotes full-length SET protein (37kDa), arrowhead denotes 
cleaved SET protein (22kDa). B. SET protein levels as determined by densitometric analysis of 
Western blot data and normalized to actin (n=2 independent experiments). Bars represent the 
standard error. C. Proliferation assay of LCLs derived from SGS individuals and age-matched controls 
over 3 days (*** p< 0.001 versus controls, ANOVA). Bars represent the standard error. D. Mean 
doubling time for LCLs derived from individuals with germline SETBP1 mutations compared to 
controls over 3 days (* p<0.05 versus controls, ANOVA). The mean of two experiments is shown, bars 
represent the standard error. 
 
 
faster and have shorter doubling times than cells derived from age-matched 
controls in a genotype-dependent manner (p<0.001 versus controls by ANOVA, 
see Figure 4C and 4D). LCLs from unrelated individuals carrying D868N mutations 
had the shortest doubling times, followed by LCLs from unrelated patients 
carrying I871T mutations and by cells derived from age-matched controls (23.2, 
27 and 33.8 hours respectively, p<0.05, ANOVA). LCLs from an individual with a 
S869N mutation consistently showed lower proliferation and longer doubling 
time (41.7 hours; Figure 4D). RNA sequencing of LCLs of individuals with germline 
SETBP1 mutations revealed differential expression of 1,811 genes between 
controls and individuals with SGS (Supplementary Figure S8), of which 632 were 
upregulated and 1,179 were downregulated.49 Gene set enrichment analysis of 
differentially expressed genes between controls and individuals with germline 
SETBP1 mutations shows an enrichment for genes involved in mRNA transcription 
and translation, mitochondrial respiration and cell cycle (Supplementary Table 
S4).50  
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Increased tumorigenesis in individuals with mutations in residue D868 
To determine whether a correlation exists between the magnitude of 
effect of a germline SETBP1 mutation and tumorigenesis in individuals with SGS, 
we examined the clinical data of our cohort and previously published mutation-
positive cases. In total, 7 malignancies have been reported in mutation-positive 
individuals, of which 5 occurred in patients with mutations in residue D868 (four 
tumors of primitive neuroectodermal origin and one myeloid leukemia). The 
remaining tumors included one ependymal tumor with myxopapillary and 
ependymoblastic differentiation in an individual with mutation G870D and one 
primitive neuroectodermal tumor in an individual with mutation I871T. To 
compare the intensity of effect of mutations in the group of individuals who 
developed cancer versus those who did not, we calculated the median SETBP1-
βTrCP1 interaction ∆∆G value for each group based on results from in silico 
protein modeling (Figure 3B and Figure 5). The group of individuals who 
developed cancer carry SETBP1 mutations which are more disruptive to the 
interaction of SETBP1 with βTrCP1 than the group of patients who did not 
develop cancer (Figure 5; βTrCP1 interaction ∆∆G = 3.57 vs 0.65, p = 0.029, Mann-
Whitney U test). Finally, we analyzed the prevalence of malignancy per genotype 
in 33 mutation-positive individuals with SGS for whom we had data. While the 
incidence of tumorigenesis is 21.2% in this pooled group, individuals with 
mutation D868 have a statistically significantly higher risk of developing tumors 
than individuals with other germline mutations in SETBP1 (OR = 9.16, 95% CI = 1.4 
– 59.6, p = 0.02). Remarkably, mutations in residue D868 represent the most 
prevalent mutation observed somatically in cancer.  
 
 
Figure 5. Correlation between functional effects of germline SETBP1 mutations and risk of 
malignancy. Degron-βTrCP1 interaction ∆∆G for SETBP1 mutations in individuals with SGS who did 
not develop a malignancy versus those who did (*p<0.05, Mann-Whitney’s U test). The median for 
each group is marked by an arrowhead. The criteria to be considered negative for the development 
of a malignancy was either reaching the age of 60 months or dying without developing a malignant 
tumor or leukemia. 
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Discussion 
 
The aims of our study were: to present the phenotype of the largest cohort 
of individuals with SGS and germline SETBP1 mutations, establish genotype-
phenotype correlations for germline SETBP1 mutations and, by using these and 
previous findings from cancer research, provide insight into the molecular 
mechanism of SGS. 
We present the clinical features of 47 individuals with “classic” SGS caused 
by germline mutations in SETBP1 affecting the canonical degron (D868-I871). All 
mutations were found de novo in the affected proband, although two individuals 
in our cohort were siblings carrying the same disease-causing mutation in residue 
I871. This recurrence suggests parental mosaicism as the origin of the mutation 
but we were unable to detect the mutation in DNA from parental blood samples 
by deep sequencing. Interestingly, the first published report of SGS in 1978 
described two siblings with the phenotype, which initially led to believe that this 
disorder was inherited autosomal recessively.1  
SGS is a rare but clinically recognizable developmental disorder 
consisting of typical facial features, neurological alterations, various congenital 
anomalies and increased risk of malignancy. Neurological problems often 
encountered include severe intellectual disability, intractable epilepsy and 
cerebral blindness and deafness. Individuals with SGS frequently present with 
congenital anomalies in multiple organ systems including heart defects, kidney 
and/or genital malformations and bone abnormalities. Most affected individuals 
do not survive past childhood due to the severity of this disorder.  
Four additional individuals presented a developmental phenotype with 
clinical characteristics overlapping classic SGS caused by atypical SETBP1 
mutations in close proximity to the canonical degron. SGS is often recognized and 
diagnosed based on the reminiscent clinical features and, interestingly, the 
amount of clinical overlap with SGS seems to be related to the position of the 
mutation in relation to the canonical degron. Both individuals carrying a mutation 
affecting SETBP1 residue S867 had the characteristic facial features of SGS, genital 
anomalies and seizures but no hydronephrosis. The absence of hydronephrosis in 
these cases is remarkable, since it is considered one of the hallmark features of 
SGS.51 However, hydronephrosis was also absent in two individuals with 
mutations within the degron, suggesting that it should not be recognized as an 
obligatory feature for the diagnosis of SGS. Although both individuals with an 
atypical SETBP1 mutation in residues E862 and T873 share some features with 
SGS, they would not have been classified as typical SGS. In both these individuals, 
the mutations were detected by whole exome sequencing and lead to the 
diagnosis of atypical SGS a posteriori. Therefore, as Carvalho et al. recently 
suggested,44 previously proposed clinical diagnostic criteria for SGS may not be 
applicable for these cases. Due to the limited number of atypical cases, we cannot 
draw any conclusions on the survival and progress of the disease in these cases. 
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Somatic SETBP1 mutations observed in myeloid malignancies have been 
shown to have a gain-of-function effect on the SETBP1 protein, leading to 
decreased binding of the βTrCP1 and increased protein levels.5 This gain-of-
function mechanism seems to also pertain to germline SETBP1 mutations, as we 
observe that cells of individuals with germline SETBP1 mutations have increased 
levels of SETBP1 protein. Furthermore, recent reports of germline chromosomal 
deletions and truncating mutations in SETBP1 show that loss-of-function 
mutations in this gene cause a completely different phenotype from SGS.52 
Clinically, individuals with these genetic lesions present a phenotype 
characterized by a complete lack of expressive speech with intact receptive 
language abilities, decreased fine motor skills, subtle dysmorphisms and 
hyperactivity and autistic traits.53 
The distribution of germline SETBP1 mutations within the canonical 
degron differs from that of somatic events; mutations affecting residue I871 are 
significantly more frequent in the germline than somatically. Furthermore, 
germline SETBP1 mutations are on average less disruptive to the βTrCP1-SETBP1 
interaction than somatic mutations. Notably, the isoleucine at position 871 is a 
variable residue within the SETBP1 degron, which is defined as “DpSGφXpT” 
where φ (in this case, isoleucine) represents a hydrophobic amino acid and X 
stands for any residue.18 Previous studies of the structure of the conserved 
destruction motif in β-catenin show that the isoleucine residue in the degron has 
a small role in the interaction with βTrCP1, while the first three residues of the 
degron and the asparagine in particular are essential for protein-protein 
binding.20 Thus, the molecular differences observed between germline and 
somatic SETBP1 mutations are likely caused by variation in the prevalence of 
mutations in residue I871 in each condition. As a consequence of the weak role of 
residue I871 in the interaction of SETBP1 with βTrCP1, mutations in this residue, 
although disruptive when present in the germline, are functionally milder. 
The difference in molecular consequences between somatic and germline 
SETBP1 mutations is in line with findings from previous studies examining 
somatic and germline mutations in PTPN11, involved in juvenile myelomonocytic 
leukemia and in Noonan syndrome, respectively.54,55 In contrast with SETBP1 
mutations, germline PTPN11 mutations causative for Noonan syndrome rarely 
overlap with somatic mutations observed in leukemia. This mutual exclusivity 
between germline and somatic PTPN11 mutations has been proposed to result 
from the existence of distinct thresholds for gain-of-function mutations in 
developmental phenotypes and tumorigenesis.55 Despite their overlap, our 
analysis of germline and somatic SETBP1 mutations supports this model. 
Malignant cell behavior in cancer can only be driven by somatic mutations with 
an intense activation, while germline mutations with mild activation are sufficient 
to disrupt normal development. Consequently, gain-of-function mutations 
usually found somatically may lead to prenatal lethality or severe developmental 
alterations features when present in the germline, as a result of intense 
activation.56 Likewise, mild hypermorphic mutations associated with 
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developmental disorders may be less likely to drive malignancy and are 
encountered less frequently as somatic events in cancer. In line with this, 
functional analysis of D868N, the SETBP1 mutation most commonly found in 
cancer, shows that it leads to the highest increase in SETBP1 protein levels and 
cell proliferation, suggesting it has the strongest effect at the biochemical and 
cellular level. Remarkably, individuals with SGS caused by mutations in residue 
D868 have higher incidence of tumorigenesis with odds ratio above 9 when 
compared to individuals with SGS caused by other mutations. Our findings 
suggest that individuals with strongly activating germline mutations in SETBP1 
are at increased risk of malignancy. Due to the extremely low prevalence of SGS 
and the fact that malignancy is still a relatively infrequent complication of SGS, 
our study is limited by the small number of individuals with SGS who developed 
a malignancy. The correlation between strongly activating germline SETBP1 
mutations and risk of malignancy should be reproduced in a larger cohort, in 
order to provide accurate prognosis and personalized follow-up for individuals 
with germline SETBP1 mutations. 
Despite the increased risk for tumorigenesis, most individuals with SGS do 
not develop cancer. This observation that can be extended to individuals with 
developmental disorders resulting from germline mutations in genes involved in 
cancer when mutated somatically such as ASXL1, EZH2 or ARID1A.57–59 As 
mentioned previously, this observation may be in part due to the effect of 
germline mutations not reaching the threshold of functional activation required 
to drive cancer. Furthermore, early lethality could also explain why most 
individuals with developmental disorders caused by germline mutations in genes 
involved in cancer do not develop malignancies. For instance, somatic SETBP1 
mutations have been associated mainly with chronic myeloid leukemia, a disease 
occurring generally in individuals above the age of 60.5,31 Individuals with SGS 
have a short life span, which may not allow for the accumulation of additional 
somatic mutations required for tumorigenesis. Additionally, the cellular context 
is also important for the expression of a mutation: certain cancer-driving 
mutations can only do so in the context of “aged” hematopoietic stem cells.60–62 
This combination of factors may explain why myeloid malignancy is a rare 
malignancy in SGS, while embryonic cancers are observed more frequently. 
Finally, the presence of mutations in all cells of the organism instead of a subset 
may eliminate cellular advantage in a single cell which would allow for clonal 
expansion and, eventually, malignancy.  
Cell lines derived from individuals with SGS recapitulate some of the 
features identified in myeloid cells with SETBP1 mutations, including increased 
SETBP1 and SET protein levels and enhanced cell proliferation.5,7 Although we 
observed a SETBP1 mutation-specific effect on cell proliferation, we did not detect 
visible differences in SET protein levels between individuals with different SETBP1 
mutations. It is possible that different SETBP1 mutations have a subtle but distinct 
effect on SET protein levels that are not detectable by Western blot. However, we 
cannot rule out the absence of a mutation-specific effect of SETBP1 mutations on 
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SET protein levels with additional mutation-specific downstream alterations 
resulting from pathways that do not involve SET protein. In light of our findings, 
cell lines derived from patients with developmental disorders caused by germline 
mutations in genes implicated in tumorigenesis may be a valuable model for the 
study of downstream consequences of cancer mutations at the molecular level. 
Furthermore, the similarities observed in the molecular consequences of 
germline and somatic SETBP1 mutations support the rationale behind recent 
studies which have elegantly repurposed drugs used in cancer therapy for the 
treatment of developmental disorders in mouse models.63 An increase in SETBP1 
protein as a result of mutations or overexpression leads to an increase in SET 
protein which results in the inactivation of PP2A. Although currently there are no 
known SETBP1 antagonists, several compounds have been described to 
antagonize SET protein or to lead to PP2A activation.64 For example, OP449 is a 
synthetic peptide that binds to SET protein, activates PP2A and selectively inhibits 
cell growth in leukemia cell lines and primary patient cells.65 Other compounds 
that directly activate PP2A, such as FTY720, have also been described.66 While 
promising, it is yet unclear whether compounds targeting SET or PP2A may prove 
useful in the treatment of individuals with germline SETBP1 mutations. For one, 
the window of time between diagnosis and potential therapeutic interventions 
for early developmental phenotypes may be minimal. However, although this is 
still a speculative point, future therapeutic interventions may be useful to prevent 
progression of certain features of SGS, such as neurodegeneration.28 Finally, it is 
still possible that individuals with SGS present alterations in other proteins 
downstream of SETBP1. 
 
In summary, we describe the largest cohort of SETBP1 mutation-positive 
SGS patients to date. Our results support that typical SGS is caused by gain-of-
function mutations of SETBP1 affecting a degron involved in SETBP1 protein 
stability, while novel mutations outside the canonical degron cause an atypical 
form of SGS characterized by a milder phenotype. We observe variability in the 
magnitude of effect of germline mutations within the canonical degron of SETBP1 
with consequences at the biochemical level and influencing the cellular and 
clinical phenotype. Furthermore, our results highlight that, despite the 
identification of overlapping SETBP1 mutations in SGS and myeloid malignancies, 
the mutation spectrum is significantly different in both conditions with 
functionally weaker mutations appearing predominantly as germline mutations 
in SGS. The parallelisms between the functional consequences of germline and 
somatic SETBP1 mutations is relevant for the better understanding of SGS but 
could also deliver insight into the role of SETBP1 as a cancer driver. Finally, our 
findings highlight that the convergence of the fields of cancer and developmental 
disorders uncovers common molecular mechanisms of disease for overlapping 
germline and somatic pathogenic mutations and may support the development 
of drugs with a dual therapeutic role in developmental disorders and cancer. 
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Materials and methods 
DNA studies 
This study was approved by the institutional review board Commissie 
Mensgebonden Onderzoek Regio Arnhem-Nijmegen NL36191.091.11. Written 
informed consent was obtained from all individuals. All legal representatives of 
the patients included consented to participate in our study. Genomic DNA was 
extracted from saliva or blood using the QIAamp DNA Mini kit (QIAGEN). The 
hotspot region of SETBP1 was amplified by PCR and Sanger sequenced. Primer 
sequences are listed in Supplementary Table S3. 
Phenotyping of individuals with SGS 
Clinical features of participants were initially evaluated by clinicians from 
various countries. Photographs and medical information of all individuals were 
further assessed by a single clinical geneticist (BvB). Separate informed consent 
was obtained for publication of photographs. 
DNA constructs 
The full-length SETBP1 construct fused to a C-terminal Myc-FLAG tag was 
purchased from Origene (RC229443). SETBP1 variant constructs were generated 
using the Quikchange II Site-Directed Mutagenesis kit (Agilent). Primer sequences 
are listed in Supplementary table S3. SETBP1 cDNAs were subcloned using 
EcoRI/XhoI restriction sites into a modified pEGFP-C2 vector (Clontech) where the 
N-terminal EGFP tag was replaced with a YFP tag. All constructs were verified by 
Sanger sequencing. 
Cell culture and transfection 
Fibroblast cell lines were established from skin biopsies of SGS cases and 
controls. HEK293 cells and fibroblasts were cultured in DMEM supplemented with 
10% fetal bovine serum (all from Invitrogen). LCLs were established by Epstein-
Barr virus transformation of peripheral lymphocytes from blood samples of SGS 
patients and controls. LCLs were cultured in RPMI medium (Lonza) with 10% fetal 
bovine serum and 5% HEPES. Transfections were performed using the GeneJuice 
transfection reagent following the manufacturer’s instructions (Merck Millipore).  
Western blotting 
Whole-cell lysates were prepared as described previously 67. Total protein 
was quantified using the Pierce™ BCA protein assay kit (ThermoFisher Scientific). 
Proteins were resolved on 4-15% Tris-Glycine gels and transferred to PDVF 
membranes (Bio-Rad). After blotting, membranes were incubated overnight at 
4⁰C with the appropriate primary antibodies: rabbit anti-SETBP1 (Santa Cruz, sc-
85148, 1:100), rabbit anti-SET (Abcam, ab1183, 1:4000), mouse anti-β-actin 
(Sigma, AC-15, 1:10000) and mouse anti-FLAG (Sigma, F1804; 1:1000). Membranes 
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were then incubated with HRP-conjugated donkey anti-rabbit (Abcam) or goat 
anti-mouse (Bio-Rad) secondary antibodies. Proteins were visualized using the 
Novex ECL Chemiluminescent Substrate Reagent kit (Invitrogen) and the 
ChemiDoc XRS+ System (Bio-Rad).  
Protein stability assays 
Cells were transfected in clear-bottomed black 96-well plates in triplicate 
with YFP-SETBP1 expression plasmids together with a modified pmCherry-C1 
plasmid to normalize for transfection efficiency. Fourteen hours post-transfection, 
YFP and mCherry fluorescence intensities were measured for 24h in live cells in a 
TECAN M200PRO microplate reader at 37°C and 5% CO2. In the case of stability 
assays with proteasome inhibitor, MG132 (Sigma) was added to the culture 
medium (10uM final concentration) 48 hours post-transfection and fluorescence 
intensities were measured at 0, 3 and 12 hours.  
Fluorescence microscopy 
Cells were grown on poly-L-lysine (Sigma) coated coverslips and were 
fixed 48 hours post-transfection with 4% paraformaldehyde (Electron Microscopy 
Sciences) for 10 minutes at room temperature. YFP was visualized by direct 
fluorescence. Nuclei were visualized with DAPI (Vectorlabs). Fluorescence images 
were obtained using an Axio Imager Z1 fluorescence microscope (Zeiss).  
Proliferation assays 
Lymphoblastoid cell lines were synchronized by overnight serum 
starvation, after which they were seeded in 24-well plates at a concentration of 
160,000 cells/mL (three replicates per cell line). A measurement was performed 
every 24 hours, in which the cells were mixed with Trypan blue and counted. 
Modeling of protein in Yasara and FoldX 
The SETBP1 degron variants observed in SGS and in leukemia were 
manually curated from previously published reports) 4–7,23–27,30–48. Mutations were 
modeled using the YASARA structural simulation software 
(http://www.yasara.org/). The protein model for βTrCP1 and degron sequence 
from β-catenin was obtained from the RCSB protein bank (1p22) 18. The FoldX 
plugin for YASARA was used to calculate ∆∆G values 68. 
RNA-sequencing 
LCLs from individuals with SGS were derived from blood samples of 
individuals with germline SETBP1 mutations D868N or I871T (n=2 for each). LCLs 
from controls (n=8) were derived from blood samples of individuals with different 
forms of intellectual disability 69. RNA was purified from cell cultures using RNeasy 
mini kit from QIAGEN and RNAseq libraries were prepared using the TruSeq 
Stranded mRNA kit (Illumina) and sequenced on a Nextseq platform using  
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2x75 bp paired end sequencing. RNA-seq samples were mapped using Kallisto 
(version 0.42.4) to the human genome (hg19.75). At least 70% of the reads for 
each sample were mapped to the human genome entailing at least 39.6 million 
reads in the sample with the lowest sequencing depth. Differential gene 
expression was performed using DESeq2 49. Gene set enrichment analysis was 
performed using the GSEA software 50. 
Statistics 
Statistical analysis was performed using R Statistical Software 
(http://www.r-project.org/ version 3.1.2, R Foundation for Statistical Computing, 
Vienna, Austria). Student’s T test was used for comparison of two groups with 
normal distribution, otherwise Mann-Whitney’s U test was used. For comparison 
of multiple groups against each other, we used ANOVA and Tukey’s test. To 
determine whether the distribution of mutations within the degron was the same 
in germline and somatic mutations, we used Fisher’s test and performed 
Bonferroni multiple test correction. 
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Gene name 
Uniprot 
accession 
number 
Sequence of βTrCP 
binding site 
(DpSGφXpS/pT) 
Motif start 
position 
Motif stop 
position 
SETBP Q9Y6X0 DSGIGT 868 873 
CTNNB1 P35222 DSGIHS 32 37 
NFE2L2 Q16236 DSGISL 343 348 
ATF4 P18848 DSGICM 218 223 
EEF2K O00418 DSGYPS 440 445 
CLSPN Q9HAW4 DSGQGS 29 34 
REST Q13127 DEGIHS 1008 1013 
CDC25A P30304 DSGFCL 81 86 
PDCD4 Q53EL6 DSGRGD 70 75 
PER1 O15534 TSGCSS 121 126 
 Supplementary Table S1. Protein sequence alignment of degrons targeted by βTrCP. Based on 
Low TY, Peng M, Magliozzi R, Mohammed S, Guardavaccaro D, Heck AJR. A systems-wide screen 
identifies substrates of the SCF bTrCP ubiquitin ligase. 2014;7: 1–12.  
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Mutation 
Stability 
∆∆G 
(kcal/mol) 
ST 
DEV 
βTrCP1 
Interaction 
∆∆G (kcal/mol) 
ST 
DEV 
Interpretation Germline Somatic 
D868A 1.08 0.24 2.78 0.14 Destabilizing Y N 
D868G 0.99 0.21 2.72 0.21 Destabilizing N Y 
D868H 9.98 3.04 10.77 3.43 
Highly 
destabilizing N Y 
D868N 2.30 0.17 3.57 0.49 
Highly 
destabilizing Y Y 
D868Y 12.31 2.88 11.74 2.77 
Highly 
destabilizing Y Y 
S869G 0.10 0.11 0.06 0.11 Neutral N Y 
S869N -0.25 0.12 -0.47 0.21 Neutral Y Y 
S869R -0.97 0.16 -1.05 0.17 Neutral Y Y 
G870C 1.27 1.04 0.79 0.98 Destabilizing Y N 
G870D 4.94 1.46 4.78 1.48 
Highly 
destabilizing Y Y 
G870R 11.72 1.81 10.84 2.02 
Highly 
destabilizing N Y 
G870S 1.07 0.51 0.65 0.50 Destabilizing Y Y 
G870V 5.40 2.12 5.21 2.05 
Highly 
destabilizing N Y 
I871S 0.17 0.31 -0.38 0.34 Neutral Y Y 
I871T -0.22 0.42 -1.15 0.34 Neutral Y Y 
Supplementary Table S2. ∆∆G values for protein stability and degron-βTrCP1 interaction for 
SETBP1 variants reported in SGS cases and in myeloproliferative disorders. ST DEV: Standard 
deviation. 
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Name Sequence (5'-3') Purpose 
SETBP1 Exon4 F CTTCACCAGCAGCTATGCAC Sanger sequencing 
SETBP1 Exon4 R CGGTGGGAGATTCTGAACAC Sanger sequencing 
SETBP1 E862K F GAGTCCCACAGTAAGGAGACGATCCC Site-directed mutagenesis 
SETBP1 E862K R GGGGATCGTCTCCTTACTGTGGGACTC Site-directed mutagenesis 
SETBP1 D868N F GACGATCCCCAGCAACAGCGGCATTGG Site-directed mutagenesis 
SETBP1 D868N R CCAATGCCGCTGTTGCTGGGGATCGTC Site-directed mutagenesis 
SETBP1 S869N F GACGATCCCCAGCGACAACGGCATTGG Site-directed mutagenesis 
SETBP1 S869N R CCAATGCCGTTGTCGCTGGGGATCGTC Site-directed mutagenesis 
SETBP1 G870S F AGCGACAGCAGCATTGGGACAGAC Site-directed mutagenesis 
SETBP1 G870S R GTCTGTCCCAATGCTGCTGTCGCT Site-directed mutagenesis 
SETBP1 I871T F GACAGCGGCACTGGGACAGACAAC Site-directed mutagenesis 
SETBP1 I871T R GTTGTCTGTCCCAGTGCCGCTGTC Site-directed mutagenesis 
Supplementary Table S3. Sequences of primers used in this study. 
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Name Size ES NES 
FDR 
q-val 
FWER 
p-val 
Reactome peptide chain elongation 100 0.54 6.55 <0.00001 <0.001 
Reactome influenza viral RNA transcription and 
replication 
116 0.47 6.08 <0.00001 <0.001 
Reactome 3 UTR mediated translational regulation 121 0.46 5.82 <0.00001 <0.001 
Reactome nonsense mediated decay enhanced by 
the exon junction complex 
121 0.44 5.62 <0.00001 <0.001 
Reactome translation 163 0.35 5.44 <0.00001 <0.001 
Reactome SRP dependent cotranslational protein 
targeting to membrane 
124 0.42 5.32 <0.00001 <0.001 
Reactome influenza life cycle 150 0.35 4.95 <0.00001 <0.001 
Reactome metabolism of proteins 427 0.16 3.95 <0.00001 <0.001 
Reactome formation of the ternary complex and 
subsequently the 43s complex 
53 0.44 3.80 <0.00001 <0.001 
Reactome activation of the mRNA upon binding of 
the cap binding complex 
61 0.40 3.75 <0.00001 <0.001 
Reactome metabolism of mRNA 224 0.20 3.49 <0.00001 <0.001 
Reactome respiratory electron transport ATP 
synthesis by chemiosmotic coupling and heat 
production by uncoupling proteins  
80 0.33 3.42 <0.00001 <0.001 
Reactome TCA cycle and respiratory electron 
transport 
116 0.27 3.40 <0.00001 <0.001 
Reactome cholesterol biosynthesis 21 0.62 3.39 <0.00001 <0.001 
Reactome metabolism of RNA 269 0.17 3.30 <0.00001 <0.001 
Reactome respiratory electron transport 65 0.33 3.18 <0.00001 <0.001 
Reactome telomere maintenance 73 0.32 3.15 <0.00001 <0.001 
Reactome generic transcription pathway 323 0.14 2.94 1.28E-04 0.002 
Reactome cell cycle 396 0.13 2.90 1.22E-04 0.002 
Reactome glycolysis 25 0.48 2.89 1.15E-04 0.002 
Reactome chromosome maintenance 116 0.23 2.84 2.28E-04 0.004 
Reactome RNA Pol I promoter opening 59 0.30 2.75 3.28E-04 0.006 
Reactome gluconeogenesis 29 0.41 2.63 7.19E-04 0.014 
Reactome meiotic recombination 80 0.25 2.59 0.001 0.024 
Reactome packaging of telomere ends 46 0.32 2.53 0.001 0.039 
Supplementary Table S4. Gene set enrichment analysis for genes differentially expressed in 
LCLs from individuals with germline SETBP1 mutations D868N or I871T and LCLs from 
controls. Gene set enrichment analysis was performed as described in Subramanian et al. PNAS 
2005 using curated gene sets from the reactome pathway database. An enrichment is observed for 
genes involved in mRNA transcription and translation, mitochondrial respiration and in the cell 
cycle. While no enrichment was observed for specific pathways, a closer examination of the genes 
involved in cell cycle that we detected to be enriched in the samples of individuals with germline 
SETBP1 mutations revealed that the genes identified were associated with mitosis, sister chromatid 
cohesion, DNA replication and nucleosome assembly. 
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Supplementary figures 
 
 
 
Supplementary Figure S1. Facial features in typical Schinzel-Giedion syndrome. Panels A to I 
show the facial features of patients with germline SETBP1 mutations within the canonical degron 
leading to typical SGS (A: current case 1; B: current case 2; C: current case 3; D: current case 12; E: 
current case 8; F: current case 16; G: current case 18; H current case 20; I current case 23). Progression 
of facial features with age in current case 9 with germline SETBP1 mutation G870S at 1 week of age 
(J), at 1 ½ years of age (K), at 6 years of age (L) and at 7 years of age (M). 
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Supplementary Figure S2. Phenotype of individuals with germline SETBP1 mutations outside 
the canonical degron leading to atypical Schinzel-Giedion. Individual with germline SETBP1 
mutation S867R (current case 27) at 1 week of age (A), at nine months (B), at two years of age (C) 
and at four years of age (D). Patient with germline SETBP1 mutation E862K (current case 28) at 5 
years of age (E and F). Right hand and foot (G and H), note the small feet with short toes. Individual 
with germline SETBP1 mutation T873I (current case 29) at one month of age (I), at eleven months 
(J), at three years of age (K) and at four years of age (L). 
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Supplementary Figure S3. LogRank survival analysis performed for 44 individuals with SGS for 
which data was available from our own cohort and previous reports. Dots represent censored data, 
for age at which the individual was last known to be alive. The group of patients with mutations in 
residue G870 had a statistically significantly longer survival than individuals with mutations in 
residue D868 (median of 60 months versus 24 months respectively, p<0.01). 
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Supplementary Figure S4. Fluorescence imaging of HEK293 cells expressing YFP-tagged SETBP1 
variants (green). Nuclei were stained with DAPI (blue). Wild-type (WT) SETBP1 and disease-causing 
SETBP1 variants were expressed in HEK293 cells as YFP fusion proteins. Direct fluorescence imaging 
of SETBP1 variants showed that the WT protein localizes to the nucleus, with a speckle-like pattern 
typical of chromatin-interacting proteins. Pathogenic SETBP1 protein variants occurring within 
(D868N, I871) or in close proximity (E862K) to the canonical degron sequence had no effect on 
protein localization.  
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Supplementary Figure S5. Relative expression of SETBP1 protein variants in live HEK293 cells 
treated with 50ug/uL cycloheximide or vehicle only as controls. Bars represent the standard error. 
(* p<0.05, ** p<0.01, *** p<0.001 versus cells at same time point treated with vehicle; Student’s T 
test and Mann-Whitney U test for measurements with non-normal distribution). 
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Supplementary Figure S6. Densitometry for Western blot of overexpressed wild-type and mutant 
SETBP1-FLAG in HEK293 cells using actin for normalization. 
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Supplementary Figure S7. Levels of SETBP1 mRNA in fibroblasts and lymphoblastoid cell lines 
(LCLs) from individuals with SGS as compared to controls. SETBP1 mRNA levels were normalized to 
ACTB and GAPDH. The results shown represent the mRNA levels in fibroblasts cells lines from 2 
controls, fibroblast cell lines from 2 individuals with SGS, LCLs from 2 controls and LCLs from 3 
individuals with SGS. The bars represent the standard error. NS: not significant. ** p<0.01, Student’s 
T test.  
The decrease in SETBP1 mRNA levels observed in individuals with SGS compared to 
controls could be the result of a feedback mechanism in which increased SETBP1 protein levels may 
lead to a reduction in SETBP1 transcription thereby decreasing SETBP1 protein levels. A similar 
observation was reported for myeloid progenitor cells immortalized by mutant SETBP1 compared 
to cells immortalized by wild-type SETBP1 in Makishima H. et al. Nat Genetics 2013. We speculate 
that this mechanism would be able to lower SETBP1 protein to normal levels for SETBP1 harboring 
weaker mutations, such as I871T, but not for stronger mutations, such as D868N. 
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Supplementary Figure S8. Heatmap of RNAseq transcriptome analysis showing differential gene 
expression between LCLs from controls (n=8) and LCLs from individuals with germline SETBP1 
mutations D868N or I871T (n=2 for each). Only the top 250 most significant genes are shown in this 
figure. Yellow indicates high expression while red indicates low expression. Differential gene 
expression was performed using DESEq2, which showed differential expression of 1,811 genes 
(adjusted p-value <0.01), of which 632 are upregulated and 1,179 are downregulated
  
  
Human brain. The insula of the left side is exposed by removing the opercula. 
Anatomy of the Human Body by Henry Gray & Henry Vandyke Carter (1918) 
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Next generation sequencing, a revolution in human genetics 
Over the last decade, the field of human genetics has enthusiastically 
embraced Next Generation Sequencing (NGS) both in the clinic and in research. 
Whole exome sequencing (WES) was first used for clinical diagnosis of a patient 
in 2009,1 followed shortly after by a report in which the application of WES led for 
the first time to the identification of genes responsible for dominant and recessive 
monogenic diseases.2,3 Since then, the implementation of NGS and further 
technical developments have been instrumental to identify mutations linked to 
hundreds of human genetic diseases, including autosomal dominant, recessive 
and X-linked disorders.4,5 It is currently used routinely in medical centers around 
the world for the diagnosis of human genetic diseases, including pediatric 
disorders, neurodevelopmental and neurological diseases, sensory disorders and 
familial predisposition to cancer. NGS of cell-free DNA in blood can be used for 
non-invasive prenatal diagnosis,6 as a promising replacement for chorio- and 
amniocentesis, but also to screen for cancer by searching for tumor DNA in blood 
as part of a so-called liquid biopsy.7 Furthermore, sequencing of a tumor offers 
the possibility of analyzing its genetic characteristics to help guide treatment.8 
Finally, NGS is a powerful tool that, by studying the transcriptome,9 the 
epigenome10 and even chromatin interactions,11 can help understand the 
consequences of genetic mutations in human biology and disease. All in all, the 
application of NGS in medicine opens the door for personalized medical 
interventions while shedding light on the biology of human diseases.  
While the development of NGS has made it possible to sequence entire 
genomes with relative ease, we are only beginning to interpret the effect of 
genetic variation on phenotypes. The pathogenicity of a mutation is determined 
by different factors, such as the type of mutation, the genomic region in which it 
arises and the context in which it occurs, including the genetic background and 
the timing. In this thesis, I have made use of NGS to identify mutations leading to 
human disease, focusing on de novo mutations, the time at which they arise 
throughout life and the influence of timing in the consequences of mutations in 
human health and disease. 
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De novo mutations in human biology and human disease 
NGS uncovers the role of de novo mutations in disease 
NGS-based studies have revealed that de novo mutations arise in each 
generation and have established that pathogenic mutations with de novo 
occurrence represent a frequent cause of disease for both common and rare 
disorders with sporadic appearance. I discuss the different types of human 
disease that can be caused by de novo mutations in Chapter 2, including 
pediatric and adult-onset diseases. However, phenotypes associated with 
strongly reduced fitness and reproductive lethality, such as severe and early-
onset disorders, are the human diseases most prominently associated with de 
novo mutations. 
A large number of genes in which de novo mutations cause rare and 
sporadic developmental disorders have been identified through NGS, guided 
either by a genotype-first or a phenotype-first approach. The former relies on trio-
based WES and whole genome sequencing (WGS) of an individual and both of his 
or her parents which can be used to identify de novo germline mutations 
throughout the exome or genome.3 The latter is based on the use of WES and WGS 
to identify mutations shared by two or more unrelated individuals with the same 
phenotype or disorder. In Chapter 3, we followed a phenotype-first approach and 
performed WES in two unrelated individuals sharing the same clinical phenotype. 
We identified truncating mutations in the gene THRA in both individuals, which 
were later shown to be de novo by Sanger sequencing. These patients present 
with growth retardation, characteristic facial features, mild intellectual disability, 
constipation and skeletal alterations which together form a clinically well-defined 
thyroid hormone resistance syndrome. This study shows that a phenotype-first 
approach can be used for disease-gene identification but it requires great 
precision in the clinical phenotyping and selection of patients for WES or WGS. In 
our study, the two patients with the most severe phenotype were selected for 
WES, which resulted in the identification of truncating mutations in the same 
gene. However, three additional individuals presented the same clinical 
phenotype, among which two were found to have a missense mutation in THRA 
and one did not present mutations in THRA. Thus, from the point of view of 
disease, clinical homogeneity increases the likelihood of identifying rare 
mutations in the same gene in more than one individual. Furthermore, individuals 
with the same clinical phenotype can share mutations in two or more genes, thus 
requiring additional analysis to determine the most likely candidate for 
pathogenicity.  
Most of the issues pertaining to a phenotype-first approach can be 
circumvented by trio-based sequencing. For one, trio-based analysis allows the 
identification of candidate pathogenic mutations in single cases presenting a 
highly heterogeneous phenotype. If de novo mutations are expected to be the 
likely cause of a disease, trio-based sequencing significantly diminishes the 
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number of candidate variants from more than four million to less than one 
hundred mutations per genome and 1 to 2 per exome.12–16 However, as de novo 
mutations arise in all individuals and most of them do not result in disease, the 
identification of de novo mutations is not sufficient by itself to establish disease 
causality. Therefore, de novo mutations identified by trio-based sequencing need 
to be interpreted bioinformatically, functionally, clinically and statistically.17 For 
instance, de novo mutations can be evaluated by in silico prediction programs 
like SIFT, PolyPhen, MutationTaster and CADD.17–20 Additionally, bioinformatic 
approaches leveraging large scale databases of genetic variation can be used to 
assist in the interpretation of de novo mutations.21,22 Pathogenic de novo 
mutations involved in early-onset severe disorders are unlikely to be found in 
population databases, such as the Exome Aggregation Consortium (ExAC).23 
Furthermore, constraint scores established from the population frequency of 
mutations in each gene can be used to indirectly estimate the pathogenicity of a 
mutation in a gene.22 Functional validation to link a gene or a mutation to a 
phenotype can provide robust experimental evidence of the pathogenicity of a 
mutation, but it is often laborious and the necessary assays may differ per gene 
and per mutation. Many recent scientific developments can assist in the 
interpretation of de novo mutations in human disease. For instance, experimental 
studies can be performed on induced pluripotent stem cells from patient-derived 
samples which can be differentiated into cells and tissues relevant for the specific 
disease.24 Additionally, CRISPR/Cas9-based methods for in vitro and in vivo 
genetic manipulation offer great promise in the experimental validation of 
mutations.25,26 From the clinical point of view, the phenotype of patients in whom 
we identify candidate de novo mutations needs to be compared to that of other 
individuals with similar mutations in the same genomic region, either within the 
study cohort or among those previously reported in literature.27,28 This phenotypic 
comparison is vital to determine whether individuals with similar mutations have 
overlapping phenotypic features underlying the same disorder. Finally, statistical 
analysis should be performed to determine whether the number of de novo 
mutations identified within a gene in a study cohort exceeds the expected 
number of de novo mutations in the general population.29 The presence of a 
statistically significant number of mutations in a gene in individuals with 
overlapping phenotypic features is currently the golden standard to establish 
causality between mutations in a specific gene and a particular human disorder. 
 
Unsolved exomes 
Unfortunately, a clear-cut pathogenic de novo mutation cannot be 
identified in all individuals with a sporadic phenotype in whom we perform trio-
based WES. This can be due to technical issues including low sequencing quality 
or coverage in any of the trio samples or mis-mapping of reads to erroneous 
regions of the genome.30 A mutation may be sequenced correctly in a sample but 
may not be called by the variant calling software or may be filtered out during 
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analysis as a candidate pathogenic mutation for various reasons. For instance, 
disease-causing mutations can be mistakenly interpreted as benign due to 
misleading in silico predictions on evolutionary conservation or effect. 
Additionally, mutations may be filtered out if they are found in a gene known to 
be involved in a different phenotype. The inability to identify a genetic mutation 
that could explain a phenotype may also be due to the phenotype having a 
different form of inheritance than hypothesized, leading to erroneous 
prioritization of candidate mutations. Incomplete penetrance, variable 
expressivity of the phenotype or non-Mendelian forms of inheritance may also 
impede the correct prioritization of candidate mutations. Finally, we regularly 
detect mutations predicted to be damaging in genes that are biologically 
plausible for the underlying phenotype in the patient but that have not been 
previously linked to disease. It is unclear in these situations whether the mutation 
is truly causative or not for the phenotype of the patient and it is essential to find 
at least one additional patient with a similar genetic lesion and clinical phenotype 
to replicate the finding and establish causality. This is particularly troublesome for 
rare and ultra-rare phenotypes, but a novel way to find such individuals is 
emerging from genetic matchmaking platforms such as Matchmaker exchange31 
or GeneMatcher32 (www.matchmakerexchange.org and www.genematcher.org, 
respectively), which enable easy data sharing. 
As an example of how pathogenic mutations can be missed in WES data, 
I tried to identify the disease-causing gene for Neu-Laxova syndrome (NLS), a rare 
autosomal recessive disorder, by sequencing three individuals affected by this 
disorder and two obligate carriers of the disease allele. Despite meticulous 
analysis and sequencing multiple samples, I initially failed to identify any 
pathogenic mutations that could explain the phenotype. It was only after PHGDH 
was found to be involved in this disorder,33 that I identified pathogenic mutations 
in two other genes, PSAT1 and PSPH, within the same biological pathway.34 
Retrospectively, I observed that three of the disease-causing variants were 
present in the sequencing data but were not called by the variant calling software: 
one was found in direct proximity to a known SNP, one was a 5 nucleotide indel 
and one was a deletion of at least 4.5 kb. Additionally, NLS was genetically more 
heterogeneous that initially hypothesized and the families included in our study 
had mutations in three different genes PHGDH, PSAT1 and PSPH, which 
complicated the search of a mutation in the same gene in two individuals. Finally, 
homozygous mutations in all three genes had been previously identified in 
children with neurological alterations, a clinical phenotype distinct from NLS that 
leads to prenatal or perinatal lethality due to severe malformations affecting the 
central nervous system. 
Targeted enrichment methods, such as WES, may fail to target the region 
where a disease-causing mutation is located such as non-coding areas of the 
genome. Recent studies have shown that de novo mutations in non-coding 
regions of the genome can cause human disease.26 However, even if detected by 
WGS, these mutations often remain difficult to pinpoint as pathogenic amongst 
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the dozens of benign de novo variants that arise throughout the genome in each 
generation. As WGS becomes routine, variation in the non-coding regions of the 
genome of thousands of healthy individuals will be catalogued databases such as 
Kaviar35 (db.systemsbiology.net/kaviar) and the Genome Aggregation Database 
(gnomad.broadinstitute.org), which will undoubtedly help in detecting 
pathogenic non-coding mutations.  
 
Mosaicism and missing mutations 
Failure to detect genetic mutations underlying a phenotype may be due 
to postzygotic occurrence of pathogenic mutations. Mosaicism for a pathogenic 
mutation may go undetected due to low levels or even absence of the mutation 
in the sampled tissue undergoing genetic analysis.  
Some monogenic disorders, such as Cornelia de Lange syndrome (CdLS) 
have a relatively high prevalence of mosaicism for pathogenic mutations.36 There 
are several possible explanations for this observation, which may also apply to 
other disorders. First, a large proportion of pathogenic de novo mutations in CdLS 
may arise postzygotically rather than in the germline, for yet unknown reasons. 
Second, individuals with CdLS may present a high incidence of revertant 
mosaicism, in which a cell carrying a germline pathogenic mutation mutates back 
to a wild-type allele.37 Cells carrying a disease-causing mutation for CdLS may 
have a growth disadvantage compared to wild-type cells, which would result in 
the outgrowth of mutant cells reverting to a wild-type allele. This has been 
suggested to be a likely mechanism in CdLS, particularly for cells within the 
hematopoietic compartment.36 Finally, another explanation may lie, not in a 
higher incidence of mosaicism, but in a higher probability for survival in 
individuals with CdLS caused by postzygotic mutations compared to individuals 
with CdLS caused by germline mutations.  
Some disorders are caused exclusively by mosaic de novo mutations 
arising during early embryonic development, such as Proteus syndrome or 
Sturge-Weber syndrome.38,39 The disease-causing mutations underlying these 
phenotypes have never been observed as germline events, suggesting either that 
they are incompatible with gamete differentiation if they arise during 
gametogenesis or that they are lethal when present constitutively in the zygote.40 
Interestingly, the pathogenic mutations responsible for Proteus syndrome and 
Sturge-Weber syndrome have been observed as somatic events driving cancer, 
which supports the hypothesis that they may block cellular differentiation either 
in gametogenesis or in early embryonic development.  
Genetic mosaicism is difficult to detect using traditional methods for 
genetic analysis. For instance, Sanger sequencing lacks sensitivity to detect 
mutations present in less than 20% of cells within a sample. Prior to the 
development of NGS, clinical suspicion for mosaicism often guided the 
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identification of such mutations by meticulously analyzing chromatogram traces 
to identify varying levels of mutations among different samples from the same 
individual. As a result, our current knowledge and understanding of mosaicism is 
likely underestimating its contribution to human biology and disease. Mosaicism 
has been detected in disorders in which phenotypic changes are grossly 
observable or which affect tissues that can be obtained easily, such as the skin or 
blood. There is no reason, however, why other disorders lacking these 
characteristics would not be caused by mosaicism for genetic mutations.41 With 
further improvements in NGS leading to a higher detection rate for these 
mutations, it is likely that we will see an explosion in this field and become aware 
of the contribution of mosaicism to many human diseases.  
 
NGS to unveil mosaic mutations 
Mosaicism can be detected by identifying deviations in the variant allele 
fraction (VAF) suggestive of a genetically heterogeneous population of cells 
within a sample. The digital nature of NGS provides sequence information for 
individual DNA molecules, which expands the range of detection for mosaicism 
that can be achieved with traditional methods. As shown in Chapter 4, high level 
mosaicism with mutations present in more than 60% of cells is difficult to 
distinguish from true heterozygous germline mutations when sequenced by 
Sanger sequencing. Furthermore, NGS is indispensable to detect low level 
mosaicism with mutations present in less than 20% of cells, as Sanger sequencing 
most often fails to detect these mutations.42 
For NGS, the accuracy in the detection of mosaicism is dependent on the 
sequencing quality and sequencing coverage. Detection of high level mosaicism 
(present in more than 20% of cells) is based on the identification of mutations 
with a VAF deviating from the 50:50 ratio observed for heterozygous mutations. 
Higher sequencing coverage leads to a more precise representation of the allelic 
ratio in the biological sample, which is essential to detect whether a mutation 
presents a statistically significant deviation from the 50:50 ratio. Similarly, high 
sequencing coverage increases the sensitivity for detection of low-level 
mosaicism, which is based on the identification of mutations with low VAF that 
are statistically significantly higher than the background sequencing error. WGS 
and WES are usually performed at less than 100-fold coverage which translates 
into a probability of less than 40% to detect a mutation present in 10% of cells. 
Targeted approaches can provide sequencing coverage of over 1000-fold which 
lowers the detection threshold considerably. The additional use of molecular 
tagging or unique molecular identifiers (UMIs) can significantly increase the 
sensitivity of these methods. For instance, in Chapter 5, the UMI used in smMIPs 
allows one to trace multiple sequencing reads back to an individual DNA 
molecule captured and detect mutations present in 0.1% of cells. UMIs can be 
used to guide the generation of a consensus sequence from that individual 
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molecule, thereby circumventing both PCR amplification errors during library 
preparation, as well as, to a certain degree, sequencing errors.43 Detection of low 
level mosaicism can also be achieved with technologies that do not rely on 
increased sequencing coverage; for instance, digital droplet PCR can detect 
mutations with a VAF of 0.1%. Nevertheless, sequencing-based approaches for 
the detection of low-level mosaicism encounter the problem that below a certain 
threshold, very low level mosaicism can easily be mistaken for sequencing errors 
and vice versa. The detection of mosaicism may be furthered by developments in 
NGS, such as lowering the background sequencing error rate and improving 
algorithms for variant calling of mutations with low VAFs, in order to discriminate 
low-level mosaicism from background sequencing error. The implementation of 
long sequencing reads will enable phasing of mutations and detection of a third 
haplotype in the presence of somatic mutations. Finally, single-cell sequencing 
represents a promising technique for the study of extremely low-level mosaicism 
as it is based on sequencing individual cells within a mixed population.44 
Mosaicism can also be detected by comparing sequencing data from 
different tissues. Multiple samples per individual are occasionally collected in the 
clinical setting, particularly if mosaicism is suspected, but this is often avoided to 
prevent patient discomfort. Thus, implementing minimally invasive sampling of 
DNA from multiple tissues as a regular practice in clinical genetics would facilitate 
the routine detection of mosaicism. For instance, extracting cell-free DNA from 
plasma can represent a non-invasive form of sampling for which the original 
tissue serving as the source of DNA can be identified by methylation studies45 or 
by examining nucleosome positioning46. 
As the detection of mosaicism improves and its role in disease becomes 
more widely understood, an effort needs to take place to improve the 
interpretation of the pathogenicity of mosaicism for disease-causing mutations. 
While standards and guidelines for the interpretation of genetic variants present 
in the germline have been released by the American College of Medical Genetics 
and the Association for Molecular Pathology,47 non-germline variants pose 
additional challenges in their interpretation. The timing of a mutation, the tissues 
in which it is present and its frequency within those tissues can have an effect on 
the resulting phenotype. As such, these features should be investigated and 
included in databases such as Human Gene Mutation Database and Clinvar, which 
serve as catalogues for pathogenic human genetic variation. 
 
Postzygotic and somatic mutations in human biology and disease 
As a result of the previously mentioned improvements in NGS, attention 
has been drawn to the unexpectedly high prevalence of postzygotic and somatic 
mutations in health as well as in disease. Mutations arise continuously in all 
tissues, from the first few cell divisions and all throughout life. 
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Stage Description Time 
Early embryogenesis 
Mutation arising in any cell of an organism 
between fertilization and primordial germ cell 
specification (Carnegie stages 1 to 6) 
Day 1 to day 
17 
Somatic 
Prenatal 
mutation 
Late 
embryogenesis 
Mutation arising in any somatic cell of an 
organism after primordial germ cell 
specification until formation of all major organs 
(Carnegie stages 7 to 23) 
Day 18 to 
day 56 
Fetal 
development 
Mutation arising in any somatic cell of an 
organism during fetal development until birth 
Week 9 to 
birth 
Postnatal 
mutation 
Early postnatal 
Mutation arising in any somatic cell of an 
organism during infancy 
From 0 to 3 
years 
Late postnatal 
Mutation arising in any somatic cell of an 
organism during childhood 
From 3 years 
until puberty 
Adult 
Mutation arising in any somatic cell of an 
organism after puberty 
After puberty 
Gonadal 
Early gametogenic 
Mutation arising in any germ cell or germ cell 
precursor between specification of primordial 
germ cells and up until puberty 
Day 56 of 
development 
to puberty 
Late gametogenic 
Mutation arising in any germ cell from puberty 
onwards 
After puberty 
Table 1. Terminology to describe temporal characteristics of mutations. 1 Note that the division 
between embryogenesis and fetal development is arbitrarily defined. During fetal development, 
organogenesis is concluded but the organs continue to grow and differentiate. 
 
The terminology used to describe mutations in terms of location is 
standardized and divides mosaicism into somatic mosaicism affecting only 
somatic tissues, gonadal mosaicism affecting only gametes and gonosomal 
mosaicism in which both gonadal and somatic tissues are affected. This is in 
contrast with germline or constitutive mutations that are already present at the 
single cell stage and are therefore found in all cells of the organism. Constitutive 
mutations are present in the zygote before the first cell division, having occurred 
either before or after fertilization. As the terminology used to describe mutations 
in terms of time is less well specified, I propose the terms in Table 1 to be used to 
expand and complement the description of mutations to include timing 
characteristics. 
In Chapter 4, we studied mutations arising in the context of 
gametogenesis and in early embryogenesis to determine the proportion of de 
novo mutations occurring postzygotically. By analyzing the VAF of mutations 
identified by trio-based WGS, I found that 6.5% of seemingly germline de novo 
mutations did not arise during gametogenesis in the parent but actually originate 
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from mutations during early embryogenesis in the offspring. This result is 
supported by recent observations based on comparative genetic studies of 
monozygotic twins by WGS,48 genetic studies from multiple tissues from the same 
individual by WGS49 and additional studies analyzing WGS data from parent-
offspring trios.50,51 Depending on when and where they arise, mutations can be 
transmitted to the offspring; mutations occurring prior to the specification of 
primordial germ cells will be present both in somatic cells and in the gametes, 
which entails that they can be passed on to the next generation.49 In this same 
study, we came to the very conservative estimate that 0.1% of seemingly germline 
de novo mutations in the offspring in fact occurred during early embryogenesis 
in one of the parents, leading to the presence of the mutations both in germ cells 
as well as in blood. This finding was obtained by analyzing sequencing data from 
WGS to detect sequencing reads denoting low level mosaicism in one of the 
parents for all de novo mutations identified in the offspring. This analysis was 
based on a biased data set of de novo mutations, as only high quality mutations 
were included. By definition, this excludes mutations for which reads are 
identified in the parents which is likely to filter out most low-level mosaic 
mutations in parents. Because of this, we expected that the number 0.1% would 
be an underestimation of the true frequency of low-level parental mosaicism as 
the origin of de novo mutations. A recent study has examined this phenomenon 
in more detail and placed this number at 3.8%.51 The combination of these results 
suggests that over 10% of de novo mutations do not arise during gametogenesis 
but during early embryonic development in the parents or in the offspring.  
Although a substantial proportion of mutations arise early in life,52 
somatic mutations accumulate over time and mosaicism increases with aging. 
Different tissues present differences in the mutation rates as well as some degree 
of variation in the mutational profile, as a result of exposure to different 
mutational processes.53–55 In Chapter 5, I study somatic mutations arising in blood 
throughout adulthood based on ultra-deep sequencing of DNA extracted from 
blood of 2,014 healthy individuals between 20 and 69 years of age. I detected an 
increase in the burden of somatic mutations with age, even though mutations in 
blood could be detected in individuals as young as 21 years old. The contribution 
of somatic mutations to physiology has not been studied in detail, but mosaicism 
leads to variability among cells within a tissue, which may well contribute to 
health and tissue adaptability.40 Nevertheless, mutations occasionally have an 
effect on cells, leading to changes in cell behavior and ultimately to disease40. 
 
Role of timing of de novo mutations in human disease 
Recurrence risk 
As shown in Chapter 4 and mentioned previously, although most de 
novo mutations arise during gametogenesis and are transmitted to the offspring 
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as germline events, more than 10% of de novo mutations occur as mosaic events. 
Approximately 4% of de novo mutations occur during early embryogenesis in the 
parent and are transmitted as a constitutive event to the offspring51, while close 
to 7% occur during early embryogenesis in the offspring. Mutations arising during 
early embryogenesis can lead to gonosomal mosaicism entailing that a significant 
proportion of gametes may carry the mutation, which translates into a higher risk 
for transmitting this mutation to multiple offspring. This is exemplified by 
previous reports of families with clinically unaffected parents having two or more 
children affected by a disorder caused by a de novo mutation56–59.  
Genetic counseling received by parents of an individual with a disease 
caused by a pathogenic de novo mutation includes an estimation of the risk of 
recurrence of the phenotype in subsequent offspring close to 1%.60 However, 
gonosomal mosaicism in the parent, evidenced by the presence of the mutation 
in blood and transmission of the mutation to the offspring, entails a higher risk of 
recurrence.60 In contrast, the risk of recurrence of a mutation that occurred during 
early embryogenesis in the offspring is equal to the population risk for this 
mutation, which is often many orders of magnitude lower than 1%. Put together, 
this implies that over 10% of couples with a child affected by a disorder caused by 
a de novo mutation are receiving inaccurate genetic counseling on their 
recurrence risk, which has significant implications for subsequent reproductive 
decisions.  
The high prevalence of early embryonic events as the origin of de novo 
mutations supports routine assessment for the presence of mosaicism both in the 
offspring as well as in the parents as part of the diagnosis of disorders caused by 
pathogenic de novo mutations. The identification of mosaicism either in blood 
one of the parents or in the affected offspring or the detection of the pathogenic 
mutation in paternal sperm would allow a more accurate estimation and a 
stratification of the risk of recurrence, which would provide personalized genetic 
counseling and informed reproductive decisions60. 
 
Mutation timing shapes the resulting phenotype 
The timing of a de novo mutation not only influences the risk of 
recurrence for disease, but also has a direct effect on the percentage of affected 
cells within tissues and within the organism. In the context of pathogenic 
mutations, the proportion of mutated cells within a tissue or organism shapes the 
resulting disease phenotype.61 The important role of timing in determining the 
effect of genetic mutations is supported by the existence of healthy individuals 
with mosaicism for pathogenic de novo mutations. This situation poses an 
interesting question: when does the occurrence of a pathogenic mutation no 
longer cause disease?62 Parents of individuals with developmental disorders, 
presenting parental gonosomal mosaicism for the pathogenic mutation are for 
the most part clinically unaffected. However, there are reports of mosaic parents 
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presenting clinical features related to their offspring’s disorder due to mosaicism 
for the pathogenic mutation in relevant tissues. For instance, a study recently 
reported on the father of an individual with Costello syndrome, in whom 
gonosomal mosaicism for his son’s disease-causing mutation was identified.63 The 
HRAS mutation, resulting in a G12S substitution, had a VAF close to 50% in the 
proband and of 8% in a buccal swab of the father. While the proband presented 
with a severe clinical picture characteristic of Costello syndrome, his mosaic father 
had relatively mild clinical features with patchy skin and hair abnormalities and 
mild developmental delay. Collectively, these findings suggest, first, that a 
pathogenic de novo mutation may or may not cause disease in an individual, 
depending on its timing. Second, that a pathogenic de novo mutation may cause 
different phenotypes depending on the timing at which it occurs. There are 
several genes in which mutations can lead to different disorders depending on 
the time in which they arise (see Figure 1 for an example of multiple phenotypes 
caused by HRAS G12S mutations). Notably, over 90 of these, which I refer to as 
onco-developmental genes (see Supplementary Tables S1 and S2), have been 
found to cause developmental disorders when mutated in the germline and have 
been implicated in cancer when mutated somatically.  
Temporal pleiotropy of a gene may stem from it being expressed and 
having a role at different moments of human life. If one considers a temporal 
window as an interval of time during which a gene is expressed and plays a role 
in a cell, tissue or organism, a gene’s temporal windows are the moments in which 
gene dysfunction can lead to a phenotype at the cell, tissue or organism level. 
Genes with a transitory role during development have a temporal window of 
pathogenicity after which their dysfunction no longer disrupts development. In 
healthy individuals with gonosomal mosaicism for pathogenic mutations in such 
genes, either the mutation occurred late enough so as to not affect relevant 
tissues or it arose after the closure of the window for gene function and, therefore, 
for gene pathogenicity. However, if a gene has several temporal windows 
encompassing distinct time periods throughout life, the dysfunction of a gene 
can still be disruptive at different intervals and thereby lead to different 
phenotypes (see Figure 2). For instance, germline mutations in genes of the 
RAS/MAPK pathway leading to Noonan syndrome are present in those individuals 
throughout life. These genes are functionally active during embryonic 
development and therefore, genetic dysfunction during this temporal window is 
accompanied by congenital malformations. However, mutations in these genes 
during postnatal life can result in development of leukemia, suggesting a role for 
these genes in hematopoiesis within a posterior temporal window. Therefore, one 
might expect mutations in genes of the RAS/MAPK pathway in individuals with 
Noonan syndrome to also have consequences in this postnatal window. Indeed, 
individuals with Noonan syndrome have subclinical hematological alterations, 
including mild activation of RAS/MAPK signaling and decreased apoptosis of 
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circulating hematopoietic progenitors,64 as well as spontaneous growth of 
colonies from peripheral blood cells.65 Furthermore, Noonan syndrome associates 
with a mild and transitory myeloproliferative disorder and leukemia during 
childhood.66 Mutations in onco-developmental genes can lead both to 
developmental abnormalities and oncogenesis, indicating that these genes have 
several temporal windows for pathogenicity. This, in turn, suggests that onco-
developmental genes are likely to have several temporal windows for gene 
expression and function. While a mutation in an onco-developmental gene may 
cause a clinical phenotype in the first temporal window it disrupts, the very same 
mutation may disrupt gene function in a posterior temporal window and lead to 
disease within a different temporal window for pathogenicity (Figure 2A and 2B). 
 
SETBP1 as a model gene to study the timing of de novo mutations 
During my PhD, I have used germline and somatic mutations in a gene 
called SETBP1 as a model to study the temporal pleiotropy of 
  
 
Figure 1. Pleiotropy of HRAS G12S mutations. The timing of HRAS mutations leading to HRAS 
G12S influences the resulting phenotype. Mutations present in the germline lead to Costello 
syndrome, a developmental disorder characterized by intellectual disability, characteristic facial 
features, heart abnormalities, skin laxity and joint flexibility. Mutations arising in embryogenesis 
have been identified in epidermal nevus and woolly hair syndrome. Remarkably, HRAS G12S 
mutations arising in embryogenesis have also been involved in recurrent urothelial cancer. Somatic 
HRAS G12S mutations have been observed in head and neck cancer, as well as urothelial and skin 
cancer. Finally, somatic mutations HRAS G12S arising in spermatogonial stem cells during 
spermatogenesis have been shown to lead to clonal expansion of spermatogonial stem cells. As a 
result of this clonal expansion of mutant spermatogonial stem cells, Costello syndrome is a paternal 
age effect disorder with elevated prevalence in the (aged) human population.  
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onco-developmental genes. Germline de novo mutations in a 12 bp coding 
region of SETBP1 cause Schinzel-Giedion Syndrome (SGS), a rare and severe 
developmental disorder.3 SGS is characterized by typical facial features, multiple 
congenital malformations, severe neurodevelopmental alterations and an 
increased incidence of malignancies, particularly neuroectodermal tumors. 
Remarkably, identical mutations arising during adulthood in hematopoietic stem 
cells have been implicated in myeloid malignancies.67 
 
Parental origin and timing of de novo SETBP1 mutations in SGS 
A recent report included the case of a woman who gave birth to a child 
with SGS and was found to have gonosomal mosaicism for the SETBP1 mutation 
causative for the disease in her child.68 The mother did not present with SGS but 
had a clinical history of neonatal malignant sacrococcygeal teratoma, one of the 
most frequent tumors in this disease. The mutation likely occurred in the mother 
at a time when she no longer presented the developmental phenotype resulting 
in congenital malformations characteristic for SGS, but could still develop a 
teratoma. This observation indicates that mosaicism for a mutation in an onco-
developmental gene may cause disease other than the expected developmental 
phenotype. 
In unpublished work, I examined the parental origin and timing of de 
novo mutations in SETBP1 found in individuals with SGS to trace back the origin 
of these disease-causing mutations and potentially identify early embryonic 
SETBP1 mutations. We used smMIPS to perform trio-based ultra-deep sequencing 
of the SETBP1 hotspot in 21 trios with SGS to detect mosaicism either in the 
affected proband or in the parents. All SETBP1 mutations were present as 
constitutive events in the proband and we could not identify the pathogenic 
mutation in any of the parental blood samples. Due to the small size of our cohort, 
the absence of postzygotic events among the 21 SETBP1 mutations studied is not 
statistically significant and it is therefore difficult to interpret whether this result 
has biological meaning. However, one possibility could be that pathogenic 
SETBP1 mutations arising in early embryogenesis do not cause SGS but a different 
phenotype, such as isolated teratoma, and are therefore absent from our cohort. 
Using a long-read sequencing platform, we then sequenced a region of 10 kb 
surrounding the SETBP1 hotspot in 22 individuals with SGS in order to phase the 
pathogenic de novo mutation and genotype the mutant allele. We subsequently 
performed trio-based genotyping of this region to determine whether the de 
novo mutation occurred in the maternal or paternal allele. We were able to 
identify the parental allele in which the mutation occurred for 17 individuals, of 
which 8 originated on the maternal allele and 9 on the paternal allele. This  
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⊳ Figure 2. Temporal windows for gene functions. A functional genetic window is considered 
here as an interval within time and space in which a gene is expressed, translated into a protein and 
has a role in a specific cell, tissue or organism. Some genes may have several windows 
encompassing distinct tissues and time periods throughout life. In panel A, different functional 
genetic windows are shown in pink for HRAS, which is likely to play a role in different tissues and 
from early embryonic development to adulthood. In B, germline HRAS G12S mutations are 
accompanied by congenital malformations. However, the HRAS mutation is present in all cells of 
the organism throughout life in individuals with Costello syndrome (shown in yellow). Therefore, 
germline HRAS mutations may also have consequences in this posterior functional genetic window, 
such as high risk of developing cancer. It is not known whether spermatogonial stem cell (SSCs) 
expansion occurs in men with germline HRAS mutations, but the mutation should not confer 
increased fitness to SSCs, as all cells in the organism carry the mutation. In C, an HRAS mutation 
arising during early embryogenesis does not give rise to Costello syndrome but to mosaic skin 
manifestations, such as epidermal nevi, and has been associated with increased risk of bladder 
cancer. In D, an HRAS mutation arises in spermatogenesis, granting an advantage to mutant cells. 
Production of mutant sperm cells and transmission of the mutation to the offspring causes Costello 
syndrome (in B, shown by the dotted line). 
 
 
suggests that 53% of mutations in our cohort occurred during paternal 
gametogenesis and 47% originated during maternal gametogenesis. Since 
approximately 80% of de novo mutations arising during gametogenesis are of 
paternal origin, this distribution with similar frequency of paternal versus 
maternal origin of mutations is unexpected. This finding could reflect increased 
mutagenesis or selection for SETBP1 mutant oocytes during maternal 
gametogenesis, although the reason behind this observation may once more lie 
in the small size of our cohort.  
 
Functional thresholds for germline and somatic mutations  
In Chapter 6, I present a genetic and functional comparison of 
overlapping germline and somatic de novo mutations arising in SETBP1. The 
downstream consequences observed in cell lines derived from individuals with 
pathogenic germline SETBP1 mutations were comparable to those reported 
previously in hematopoietic stem cells expressing mutant SETBP1.69 These 
observations include similar biochemical and cellular alterations resulting from 
SETBP1 mutations arising in different temporal windows such as increased levels 
of SET protein and enhanced cell proliferation. However, further downstream, the 
biochemical and cellular consequences of germline and somatic SETBP1 
mutations may diverge as these mutations disrupt the function of the gene within 
different temporal windows. A gene may be involved in different processes 
throughout different time points of human life. This may be intrinsic to the gene 
itself, due to moonlighting activity, in which the same protein product from a 
gene has two distinct functions, or because of changes in levels of gene 
expression or expressed isoforms. Furthermore, each temporal window is 
characterized by a distinct cellular, tissue and organism context. Thus, the 
expression of the same mutation at different time points may lead to different 
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phenotypes due to distinct roles of the protein and a biological context which 
may differ considerably between one time point and the other. 
Additionally, in Chapter 6, I describe differences between germline and 
somatic SETBP1 mutations observed despite their overlap. As a group, somatic 
mutations in SETBP1 identified in cancer are on average more disruptive to 
SETBP1 function than those identified as germline events in SGS. This finding 
suggests that embryonic cells in a developing organism are more sensitive to 
SETBP1 disruption than somatic cells. Obviating differences in mutational 
mechanisms in the germline compared to somatic cells, this finding exposes 
differences in pathogenicity between germline and somatic mutations. 
Organisms are likely more resilient to biological disruption arising somatically 
than to germline disruptions. For one, constitutive mutations are present in all 
cells of an organism while somatic mutations only affect a subset of cells within 
that organism. Furthermore, embryonic cells in a developing organism are more 
plastic than somatic cells in a fully developed organism, entailing that a weaker 
stimulus can already disturb the homeostasis of the former while a stronger 
stimulus is required to disturb the latter. Thus, mutations have to be functionally 
more disruptive to drive diseases such as cancer in somatic cells. This hypothesis 
is supported by the observation that in our SGS cohort, individuals with SGS who 
developed cancer had on average more disruptive SETBP1 mutations than those 
who did not. The existence of different functional thresholds for germline and 
somatic mutations has been proposed for other genes66. For instance, somatic 
mutations in PTPN11 observed in leukemia are rarely identified as germline 
events in Noonan syndrome and vice versa.70 Somatic PTPN11 mutations are 
functionally stronger than germline mutations and have been hypothesized to be 
lethal when present in the germline.71 Although most PTPN11 mutations 
observed in Noonan syndrome occur exclusively as germline events, individuals 
with germline PTPN11 mutations which have been identified as somatic events in 
cancer have been suggested to be at an increased risk of developing cancer70. The 
observation that the type of de novo mutation influences the expression of a 
phenotype depending on the time implies the existence of timing-related 
differences in cell, tissue and organism resilience to genetic mutations underlying 
distinct germline and somatic functional thresholds. 
 
Somatic consequences of germline SETBP1 mutations 
Germline SETBP1 mutations are associated with an increased risk of 
malignancy, mainly with a high incidence of neuroectodermal tumors. 
Remarkably, despite the fact that somatic mutations in SETBP1 plays a role in the 
development of myeloid malignancies, leukemia does not occur frequently in 
individuals with SGS. Many possible explanations can be offered to explain this 
observation. As shown in Chapter 5, the presence of one cancer-driving mutation 
is not sufficient for the development of cancer. Mutations are acquired in a 
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stepwise fashion and it is known from studies in other tissues that stochastic loss 
of mutant clones can occur. Therefore, the development of cancer requires time 
for mutations to accumulate and become fixed in tissues. Individuals with SGS 
have reduced life expectancy, which results in less time to accumulate mutations, 
but also in a biological context that is inadequate for these mutations to drive the 
development of myeloid leukemia. Myeloid leukemia is a disorder typically 
diagnosed in individuals over the age of 60 and it is likely that age-related 
changes in hematopoietic stem cells and in the bone marrow niche play a role in 
its development. For instance, as shown in Chapter 5, mutations involved in 
leukemia are accumulated throughout life and some mutations, such as those 
observed in genes within the spliceosome, only expand in the context of an aged 
cellular background. Furthermore, the somatic acquisition of a cancer-driving 
mutation confers the mutated cell an advantage over other cells. In an individual 
with a germline mutation, all cells are mutated and therefore the presence of the 
mutation in a cell does not grant it an advantage over other cells in the organism. 
This would suggest that the presence of mosaicism for a pathogenic mutation as 
a result of a mutation during embryonic development would result in genetically 
distinct cell populations and allow such competition to take place in a mosaic 
individual. Additionally, the existence of functional thresholds for mutations 
implies that mutations involved in cancer are on average stronger than those 
observed in developmental disorders. Thus, at least some individuals with 
developmental disorders could have a pathogenic mutation able to disrupt 
embryonic development but not strong enough to drive the development of 
cancer.  
 
Future perspectives 
Identifying individuals at increased risk for cancer 
Identical mutations in onco-developmental genes leading to 
developmental disorders as well as cancer highlight a genetic overlap between 
both conditions. Additionally, multiple studies have described a clinical 
correlation between developmental disorders and cancer showing that 
individuals with congenital abnormalities have a higher incidence of pediatric 
cancer compared to the general pediatric population.72–75 Conversely, individuals 
with pediatric cancer also show high prevalence of morphological abnormalities 
compared to controls.76 This clinical association hints at common pathological 
processes underlying developmental disorders and cancer, which can at least be 
partially explained by an overlap at the genetic level. One study found that close 
to 4% of individuals with pediatric cancer had a well-defined genetic disorder 
such as trisomy 21, a RASopathy or an overgrowth syndrome.77 Considering the 
high prevalence of mosaicism arising during early embryogenesis, a significant 
proportion of pediatric cancer could be associated with mosaicism for a 
pathogenic mutation in an onco-developmental gene without an overt 
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developmental phenotype. For instance, mosaicism for pathogenic NRAS 
mutations has been identified in children with juvenile myelomonocytic leukemia 
without a developmental syndrome.78 This suggests first, that onco-
developmental genes may have different windows of pathogenicity during 
prenatal development and postnatal life; and second, that mutations arising after 
the closure of the window for pathogenicity during embryonic development and 
leading to subclinical mosaicism could contribute to the development of cancer.  
Gonosomal mosaicism in parents of individuals with developmental 
disorders caused by mutations in a onco-developmental gene may place them at 
risk for developing cancer. This is exemplified by the clinical case of a woman with 
gonosomal mosaicism for a pathogenic SETBP1 mutation who developed a 
teratoma.68 Epidemiological studies have examined cancer risk in parents of 
children with congenital malformations, with mixed results. One study found no 
overall increased risk for cancer in parents of individuals with congenital 
malformations.73 Another study confirmed this negative finding for parents of 
children with malformations in general, but identified an increased risk for 
parents of children born with oral clefts.79 Gonosomal mosaicism is expected to 
be present in 4% of parents of individuals with a developmental disorder caused 
by a de novo mutation in a onco-developmental gene. Thus, individuals with 
gonosomal mosaicism for a mutation in onco-developmental gene could 
represent a yet-undetected subgroup of the population at increased risk for 
developing cancer.  
The accumulation of mutations throughout life drives the development 
of cancer, which entails that mutations arising during embryogenesis could be a 
frequent mechanism contributing to cancer in the general population.80 A recent 
study of pediatric cancer found that 0.3% of their cohort presented mosaic 
mutations in tumor suppressors TP53 or RB1.81 Furthermore, at least 7% of 
germline mutations in TP53 in individuals with Li-Fraumeni syndrome occurred 
de novo,82 suggesting that a fraction of these could be caused by postzygotic 
mutations. If this is the case, screening for cancer could be based on identifying 
this type of mutations by sequencing germline and cell-free DNA in plasma rather 
than searching for alterations in metabolic markers, histology or gross 
macroscopic changes. 
 
Pharmacological treatment of developmental disorders 
 The genetic and biological overlap between developmental disorders 
and cancer could represent a window of opportunity for intervention and 
therapy. Several cancer drugs exist on the market that target specific molecular 
alterations resulting from mutations in onco-developmental genes. These drugs 
could therefore be repurposed for the treatment of developmental disorders. For 
instance, postnatal treatment of a mouse model of Kabuki syndrome with a 
histone deacetylase inhibitor, originally intended for the treatment of cancer, 
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rescued neurological deficits in this mouse.83 Additionally, segmental overgrowth 
disorders caused by mutations in PIK3CA could be treated with drugs such as 
rapamycin, used in cancer treatment for the inhibition of downstream 
pathways.84 Rapamycin has also been shown to improve vascular malformations 
caused by TIE2 mutations both in mouse models and in humans.85 These hopeful 
findings may put an end to the dogma that developmental disorders cannot be 
treated.  
 
High throughput interpretation of disease-causing mutations 
As NGS becomes integrated in routine medical testing, millions of genetic 
variants will be identified in the human genome and will need to be assessed for 
pathogenicity.4 However, the interpretation of the functional consequences of 
genetic mutations has failed to follow a development comparable to that of NGS 
and most novel or rare mutations fall by default in the category of variants of 
unknown significance (VUS). For example, up to 10% of women undergoing 
genetic testing for BRCA1/2 mutations receive a VUS result and then face the 
decision of whether or not to pursue irreversible surgical treatment without 
knowing the clinical significance of their variant.86 Currently available in silico 
methods to predict the effect of mutations are often incorrect87 and, as a result, 
novel approaches for high-throughput and accurate evaluation of mutations are 
essential to deal with the immense number of genetic variants identified by large 
scale NGS studies. Saturation Genome Editing (SGE) is a new high-throughput 
genome editing technique in which hundreds of mutations are generated in vitro 
and are studied in parallel in a single assay.88 After mutagenesis, a mixed 
population of cells, each of them harboring one of the studied mutations, is 
subjected to a functional assay selected based on the gene of interest. A single 
experiment can be performed to assess the effect of mutations on mRNA levels 
and splicing, protein function, protein-protein interaction or more complex 
cellular phenotypes such as cell signaling or proliferation. Finally, sequencing on 
a NGS platform is used as a read out. SGE is a flexible and highly versatile method 
that allows for the analysis of the effect of hundreds of mutations in parallel. This 
has potential applications in the area of diagnostics, as SGE can be used to create 
a catalogue of mutations with a functional interpretation prior to their 
identification in a patient sample. Furthermore, SGE can be performed in different 
cell lines, which allows one to study the effects of different genetic mutations in a 
cell-specific context. During my PhD, I performed a pilot SGE experiment coupled 
to a cellular assay to observe the effect of 253 mutations in HRAS and 459 
mutations in SETBP1 on proliferation of K562 cells (see Figure 3). While gene 
editing by CRISPR-induced homology-directed repair was observed robustly, I 
was unable to see statistically significant differences in the effect of the 
introduced mutations on cell proliferation. The choice and setup of the functional 
assay used for cell selection after mutagenesis clearly represents a challenge and 
requires further optimization. 
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 Figure 3. Effect of mutations introduced by Saturation Genome Editing in the SETBP1 degron on 
proliferation of K562 cells, compared to wild-type cells. The mutated residue is indicated on the top 
of the figure, ranging from S854 to D880. Note that residues S854 to S867 and G872 to D880 
underwent single nucleotide mutagenesis, while residues within the canonical degron of SETBP1 
(D868 to I871) underwent trinucleotide mutagenesis to all possible codons. The amino acid to which 
the residue was mutated is indicated on the left side of the figure. Red indicates less cell counts 
while blue indicated more cell counts than cells in which the wild-type allele was introduced. Gray 
indicates no available data for the mutation at that position.   
General discussion | 221 
 
Conclusion 
 
Over the last ten years, the field of human genetics has undergone a 
transformation fueled by the application of NGS in research and in the clinic. Trio-
based sequencing, in particular, has enabled research on the biology and 
consequences of de novo mutations. Novel mutations arise between one 
generation and the next and continue to occur throughout life, giving rise to 
extraordinary genetic diversity among the population but also within a single 
individual. This proves the concept that “all the cells in our organism share the 
same genome” wrong. This genetic diversity is likely to play a role in human 
physiology and it contributes to sporadic human disease, both rare and common. 
While we are becoming aware of the role of de novo mutations in sporadic human 
disease, the significance of mosaicism in human disease is only starting to 
emerge. Mutations arise throughout prenatal development and postnatal life, 
illustrating that mosaicism is much more widespread than previously considered. 
As such, mosaicism may represent an important biological mechanism with 
implications on prenatal development, human physiology and evolution. 
Furthermore, mosaicism may explain certain aspects of human disease that 
continue to elude us, such as the link between developmental disease and cancer. 
As NGS technology continues to develop, we will gain further insight into the role 
of mosaicism in human biology and human disease, which will grant us a better 
understanding of the mechanism by which mutations arise and the effect of the 
expression of a mutation in the dynamic context of a cell, a tissue and a whole 
organism. 
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Web resources 
Cancer Gene census: http://cancer.sanger.ac.uk/census (accessed on 16/12/2016) 
Catalogue of Somatic Mutations in Cancer: http://cancer.sanger.ac.uk/cosmic  
Developmental Disorder Genotype-Phenotype Database (DDG2P):  
https://decipher.sanger.ac.uk/about#downloads/data  (accessed on 16/12/2016) 
Human Gene Mutation Database: www.hgmd.cf.ac.uk  
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Supplementary data 
 
Gene Developmental phenotype 
AFF4 Cornelia De Lange-Like Syndrome 
AKT1 Proteus Syndrome 
AMER1 Osteopathia Striata With Cranial Sclerosis 
AR Spinal And Bulbar Muscular Atrophy 
AR Androgen Insensitivity Syndrome 
ARID1A Coffin-Siris Syndrome 
ARID1B Coffin Siris Syndrome 
ARID1B Intellectual disability, Autosomal Dominant 12 
ASXL1 Bohring-Opitz Syndrome 
ATRX Alpha-Thalassemia Mental Retardation Syndrome X-Linked Non-Deletion Type 
ATRX Mental Retardation Syndromic X-Linked With Hypotonic Facies Syndrome  
BCL11A Intellectual Disability 
BCOR Microphthalmia Syndromic Type 2 
BRAF Cardiofaciocutaneous Syndrome 
BRAF Leopard Syndrome Type 3 
BRAF Noonan Syndrome Type 7 
CBL Noonan Syndrome-Like Disorder With Or Without Juvenile Meylomonocytic 
Leukemia 
CCND2 Megalencephaly-Polymicrogyria-Polydactyly-Hydrocephalus Syndrome 
CHD4 CHD4 Syndrome 
CHD4 Syndromic Intellectual Disability With Or Without Congenital Heart Disease 
CNOT3 CNOT3 Syndrome 
COL1A1 COL1A1/2-Related Osteogenesis Imperfecta 
COL1A1 Ehlers-Danlos Syndrome Type VIIA 
COL1A1 Ehlers-Danlos Syndrome, Classic Type, COL1A1-Related 
COL1A1 Osteogenesis Imperfecta Type I 
COL1A1 Osteogenesis Imperfecta Type IIA 
COL1A1 Osteogenesis Imperfecta Type III 
COL1A1 Caffey Disease 
COL2A1 Spondyloepimetaphyseal Dysplasia Strudwick Type 
COL2A1 Achondrogenesis Type 2 
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COL2A1 Kniest Dysplasia 
COL2A1 Platyspondylic Lethal Skeletal Dysplasia Torrance Type 
COL2A1 Rhegmatogenous Retinal Detachment Autosomal Dominant 
COL2A1 Spondyloperipheral Dysplasia 
COL2A1 Stickler Syndrome Type 1 Non-Syndromic Ocular 
COL2A1 Spondyloepiphyseal Dysplasia Congenita 
CREBBP Rubinstein-Taybi Syndrome Type 1 
CTCF Intellectual Disability 
CTNNB1 Mental Retardation, Autosomal Dominant 19 
DDX3X Intellectual Disability 
DNMT3A Overgrowth Syndrome With Intellectual Disability 
ELN ELN-Related Cutis Laxa 
ELN Supravalvar Aortic Stenosis 
EP300 Rubinstein-Taybi Syndrome Type 2 
EZH2 Weaver Syndrome 2 
FGFR1 Encephalocraniocutaneous Lipomatosis 
FGFR1 Osteoglophonic Dysplasia 
FGFR1 Pfeiffer Syndrome 
FGFR1 Idiopathic Hypogonadotropic Hypogonadism 
FGFR1 Kallmann Syndrome Type 2 
FGFR2 Acrocephalosyndactyly Type V 
FGFR2 Apert Syndrome 
FGFR2 Beare-Stevenson Cutis Gyrata Syndrome 
FGFR2 Crouzon Syndrome 
FGFR2 Jackson-Weiss Syndrome 
FGFR2 Antley-Bixler Syndrome 
FGFR2 Familial Scaphocephaly Syndrome 
FGFR2 Lacrimo-Auriculo-Dento-Digital Syndrome 
FGFR3 Achondroplasia 
FGFR3 Crouzon Syndrome With Acanthosis Nigricans 
FGFR3 Hypochondroplasia 
FGFR3 Muenke Syndrome 
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FGFR3 Thanatophoric Dysplasia Type 1 
FGFR3 Thanatophoric Dysplasia Type 2 
FGFR3 Camptodactyly Tall Stature And Hearing Loss Syndrome 
FGFR3 Lacrimo-Auriculo-Dento-Digital Syndrome 
FLT4 Milroy Disease 
FOXP1 Mental Retardation With Language Impairment And Autistic Features 
GATA2 Emberger Syndrome 
GNAS ACTH-Independent Macronodular Adrenal Hyperplasia 
GNAS GNAS Hyperfunction 
GNAS Albright Hereditary Osteodystrophy 
GRIN2A Epilepsy With Neurodevelopmental Defects 
GRIN2A Landau-Kleffner Syndrome 
HOXA13 Hand-Foot-Genital Syndrome 
HOXD13 Brachydactyly Type D 
HOXD13 Brachydactyly Type E 
HOXD13 Brachydactyly-Syndactyly Syndrome 
HOXD13 Syndactyly Type 5 
HOXD13 Synpolydactyly 1 
HOXD13 VACTERL Association 
HRAS Congenital Myopathy With Excess Of Muscle Spindles 
HRAS Costello Syndrome 
KAT6A Mental Retardation, Autosomal Dominant 32 
KAT6B Genitopatellar Syndrome 
KAT6B Blepharophimosis/Intellectual Disability Phenotype Which Is Noonan-Like 
KDM5C Mental Retardation Syndromic X-Linked JARID1C-Related 
KDM6A Kabuki Syndrome 2 
KIT Human Piebaldism 
KMT2A Wiedemann-Steiner Syndrome 
KMT2D Kabuki Syndrome 
KRAS Cardiofaciocutaneous Syndrome 
KRAS Noonan Syndrome Type 3 
LMNA Hutchinson-Gilford Progeria Syndrome 
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LMNA Lethal Tight Skin Contracture Syndrome 
LMNA Emery-Dreifuss Muscular Dystrophy Type 2 
LMNA Cardiomyopathy Dilated Type 1A 
LMNA Cardiomyopathy Dilated With Hypergonadotropic Hypogonadism 
LMNA Familial Partial Lipodystrophy Type 2 
LMNA Heart-Hand Syndrome Slovenian Type 
LMNA Limb-Girdle Muscular Dystrophy Type 1B 
LMNA Mandibuloacral Dysplasia With Type A Lipodystrophy 
LMNA Muscular Dystrophy Congenital LMNA-Related 
MAF Cataract, Deafness, ID, Seizures, And Down Syndrome-Like Facies 
MAF Cataract Congenital Cerulean Type 4 
MAF Cataract Pulverulent Juvenile-Onset Maf-Related 
MAFB Multicentric Carpotarsal Osteolysis Syndrome 
MAP2K1 Cardiofaciocutaneous Syndrome 
MAP2K2 Cardiofaciocutaneous Syndrome 
MAP3K1 46XY Sex Reversal 6 
MED12 Lujan-Fryns Syndrome 
MED12 Opitz-Kaveggia Syndrome 
MITF Waardenburg Syndrome Type 2 With Ocular Albinism 
MITF Waardenburg Syndrome Type 2A 
MITF Tietz Syndrome 
MNX1 Currarino Syndrome 
MYCN Feingold Syndrome Type 1 
MYH9 Macrothrombocytopenia With Progressive Sensorineural Deafness 
MYH9 May-Hegglin Anomaly 
MYH9 Sebastian Syndrome 
MYH9 Deafness Autosomal Dominant Type 17 
MYH9 Epstein Syndrome 
MYH9 Fechtner Syndrome 
NF1 Familial Spinal Neurofibromatosis 
NF1 Neurofibromatosis Type 1 
NF1 Neurofibromatosis-Noonan Syndrome 
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NF1 Watson Syndrome 
NKX2-1 Benign Hereditary Chorea 
NKX2-1 Choreoathetosis, Hypothyroidism, And Neonatal Respiratory Distress 
NOTCH2 Hajdu-Cheney Syndrome 
NRAS Noonan Syndrome Type 6 
NSD1 Sotos Syndrome 
NSD1 Weaver Syndrome 
NSD1 Beckwith-Wiedemann Syndrome 
PAX3 Craniofacial-Deafness-Hand Syndrome 
PAX3 Waardenburg Syndrome, Type 1 
PAX8 Congenital Hypothyroidism Non-Goitrous Type 2 
PDGFRB Familial Infantile Myofibromatosis 
PDGFRB Premature Aging Syndrome, Penttinen Type 
PHF6 Boerjeson-Forssman-Lehmann Syndrome 
PHOX2B Central Hypoventilation Syndrome, Congenital, With or Without Hirschsprung 
Disease 
PHOX2B Neuroblastoma With Hirschsprung Disease 
PIK3CA CLOVES; Congenital Lipomatous Overgrowth, Vascular Malformations, And 
Epidermal Nevi 
PIK3CA Hemimegalencephaly PIK3CA 
PIK3CA Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome, Somatic 3 
PIK3R1 Short Syndrome 
PPM1D PPM1D Syndrome 
PPP2R1A Intellectual Disability 
PRKAR1A Acrodysostosis 
PTCH1 Basal Cell Nevus Syndrome 
PTCH1 Holoprosencephaly-7 
PTEN Bannayan-Zonana Syndrome 
PTEN Cowden Disease 
PTEN Lhermitte-Duclos Disease 
PTEN Proteus Syndrome 
PTEN Macrocephaly/Autism Syndrome 
PTEN VACTERL Association With Hydrocephalus 
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PTPN11 Noonan Syndrome 1 
PTPN11 Leopard Syndrome Type 1 
RAD21 Cohesinopathy 
RAF1 Noonan Syndrome 5 
RET Multiple Endocrine Neoplasia IIB 
SET SET syndrome 
SETBP1 Schinzel-Giedion syndrome 
SETBP1 Developmental and Expressive Language Delay 
SMAD3 SMAD3-Related Loeys-Dietz Syndrome 
SMAD4 Myhre Syndrome 
SMAD4 Juvenile Polyposis Syndrome 
SMAD4 Juvenile Polyposis/Hereditary Hemorrhagic Telangiectasia Syndrome 
SMARCA4 Coffin Siris syndrome 
SMARCA4 Rhabdoid Tumor Predisposition Syndrome 2 
SMARCB1 Rhabdoid Predisposition Syndrome 1 
SMO Curry-Jones Syndrome 
SOX2 AEG Syndrome 
SOX2 Microphthalmia Syndromic Type 3 
TBX3 Ulnar-Mammary Syndrome 
TCF12 Coronal Craniosynostosis 
TGFBR2 Loeys-Dietz Syndrome 
TGFBR2 TGFBR2-Related Loeys-Dietz Syndrome 
TP63 Ectrodactyly-Ectodermal Dysplasia-Cleft Lip/Palate Syndrome Type 3 
TP63 Acro-Dermato-Ungual-Lacrimal-Tooth Syndrome 
TP63 Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate 
TP63 Ectodermal Dysplasia Rapp-Hodgkin Type 
TP63 Limb-Mammary Syndrome 
TP63 Non-Syndromic Orofacial Cleft Type 8 
TP63 Split-Hand/Foot Malformation Type 4 
TSC1 Tuberous Sclerosis Type 1 
TSC2 Lymphangioleiomyomatosis 
TSC2 Tuberous Sclerosis Type 2 
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TSHR Hyperthyroidism, Familial Gestational 
WT1 
 
Denys-Drash Syndrome 
WT1 Frasier Syndrome Frasier Syndrome Frasier Syndrome 
 
Supplementary Table S1. Developmental disorders resulting from germline or postzygotic de 
novo mutations in onco-developmental genes. This list was obtained by overlapping the list of 
genes involved in developmental phenotypes in the Developmental Disorder Genotype-Phenotype 
Database (DDG2P) from the Deciphering Developmental Disorders study and a list of genes 
mutated somatically in cancer, obtained from the Cancer Gene census from the Catalogue of 
Somatic Mutations in Cancer database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table S2. Genes with overlapping germline and somatic mutations in onco-
developmental genes observed in developmental disorders and in cancer, respectively. Germline 
and postzygotic pathogenic mutations leading to developmental disorders were extracted from the 
Human Gene Mutation Database. Recurrent somatic missense and truncating mutations in cancer 
were obtained from the Catalogue of Somatic Mutations in Cancer database by filtering for protein 
residues with 10 or more missense mutations and genes with 10 or more stop mutations throughout 
the coding sequence of the gene. Both sets of mutations were overlapped to identify missense and 
loss-of-function mutations leading to developmental disorders when arising in the germline or 
postzygotically and involved in cancer when arising somatically. XLR: X-linked recessive; XLD: X-
linked dominant; Act: activating; LoF: loss-of-function; DN: dominant negative; Mis: missense; ?: 
uncertain; T: translocation; M: missense; N: nonsense; D: deletion; F: frameshift, S: Splice site; A: 
amplification; O: Other.  
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Gene Developmental phenotype 
Type of 
inheritance 
Germline 
mut. Somatic mut. 
AFF4 Cornelia De Lange-Like Syndrome Dominant Act T 
AKT1 Proteus Syndrome Mosaic Act M 
AMER1 Osteopathia Striata With Cranial 
Sclerosis 
Dominant LoF F, D, N, M 
AR Spinal And Bulbar Muscular Atrophy XLR DN M 
AR Androgen Insensitivity Syndrome XLR LoF M 
ARID1A Coffin-Siris Syndrome Dominant LoF M, N, F, S, D, T 
ARID1B Coffin Siris Syndrome Dominant LoF M, F, N, O 
ARID1B Intellectual disability, Autosomal 
Dominant 12 
Dominant LoF M, F, N, O 
ASXL1 Bohring-Opitz Syndrome Dominant LoF F, N, M 
ATRX Alpha-Thalassemia Mental 
Retardation Syndrome 
XLR LoF M, F, N 
ATRX Mental Retardation Syndromic X-
Linked With Hypotonic Facies 
XLR LoF M, F, N 
BCL11A Intellectual Disability Dominant Mis T 
BCOR Microphthalmia Syndromic Type 2 XLD LoF F, N, S, T 
BRAF Cardiofaciocutaneous Syndrome Dominant Act M, T, O 
BRAF Leopard Syndrome Type 3 Dominant Act M, T, O 
BRAF Noonan Syndrome Type 7 Dominant Act M, T, O 
CBL 
Noonan Syndrome-Like Disorder With 
Or Without Juvenile Meylomonocytic 
Leukemia 
Dominant Act T, M, S, O 
CCND2 Megalencephaly-Polymicrogyria-
Polydactyly-Hydrocephalus Syndrome 
Dominant Act T 
CHD4 CHD4 Syndrome Dominant LoF M, F, N 
CHD4 Syndromic Intellectual Disability With 
Or Without Congenital Heart Disease 
Dominant LoF M, F, N 
CNOT3 CNOT3 Syndrome Dominant LoF M, N, F 
COL1A1 COL1A1/2-Related Osteogenesis 
Imperfecta 
Dominant DN T 
COL1A1 Ehlers-Danlos Syndrome Type VIIA Dominant DN T 
COL1A1 Ehlers-Danlos Syndrome, Classic Type, 
COL1A1-Related 
Dominant DN T 
COL1A1 Osteogenesis Imperfecta Type I Dominant DN T 
COL1A1 Osteogenesis Imperfecta Type IIA Dominant DN T 
COL1A1 Osteogenesis Imperfecta Type III Dominant DN T 
COL1A1 Caffey Disease Dominant ? T 
COL2A1 Spondyloepimetaphyseal Dysplasia 
Strudwick Type 
Dominant Mis F, M, N, T 
COL2A1 Achondrogenesis Type 2 Dominant DN F, M, N, T 
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Gene Developmental phenotype 
Type of 
inheritance 
Germline 
mut. Somatic mut. 
COL2A1 Kniest Dysplasia Dominant DN F, M, N, T 
COL2A1 Platyspondylic Lethal Skeletal 
Dysplasia Torrance Type 
Dominant LoF F, M, N, T 
COL2A1 Rhegmatogenous Retinal Detachment 
Autosomal Dominant 
Dominant LoF F, M, N, T 
COL2A1 Spondyloperipheral Dysplasia Dominant LoF F, M, N, T 
COL2A1 Stickler Syndrome Type 1 Non-
Syndromic Ocular 
Dominant LoF F, M, N, T 
COL2A1 Spondyloepiphyseal Dysplasia 
Congenita 
Dominant ? F, M, N, T 
CREBBP Rubinstein-Taybi Syndrome Type 1 Dominant LoF T, N, F, M, O 
CTCF Intellectual Disability Dominant LoF M, N 
CTNNB1 Mental Retardation, Autosomal 
Dominant 19 
Dominant LoF M, O, T 
DDX3X Intellectual Disability XLR Mis M, N, F 
DDX3X Intellectual Disability XLD LoF M, N, F 
DNMT3A Overgrowth Syndrome With 
Intellectual Disability 
Dominant LoF M, F, N, S 
ELN ELN-Related Cutis Laxa Dominant LoF T 
ELN Supravalvar Aortic Stenosis Dominant LoF T 
EP300 Rubinstein-Taybi Syndrome Type 2 Dominant LoF T,  N, F, M, O 
EZH2 Weaver Syndrome 2 Dominant Mis M 
FGFR1 Encephalocraniocutaneous 
Lipomatosis 
Mosaic Act T 
FGFR1 Osteoglophonic Dysplasia Dominant Act T 
FGFR1 Pfeiffer Syndrome Dominant Act T 
FGFR1 Idiopathic Hypogonadotropic 
Hypogonadism 
Dominant LoF T 
FGFR1 Kallmann Syndrome Type 2 Dominant LoF T 
FGFR2 Acrocephalosyndactyly Type V Dominant Act M 
FGFR2 Apert Syndrome Dominant Act M 
FGFR2 Beare-Stevenson Cutis Gyrata 
Syndrome 
Dominant Act M 
FGFR2 Crouzon Syndrome Dominant Act M 
FGFR2 Jackson-Weiss Syndrome Dominant Act M 
FGFR2 Antley-Bixler Syndrome Dominant ? M 
FGFR2 Familial Scaphocephaly Syndrome Dominant ? M 
FGFR2 Lacrimo-Auriculo-Dento-Digital 
Syndrome 
Dominant ? M 
FGFR3 Achondroplasia Dominant Act M, T 
FGFR3 Crouzon Syndrome With Acanthosis 
Nigricans 
Dominant Act M, T 
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Gene Developmental phenotype 
Type of 
inheritance 
Germline 
mut. Somatic mut. 
FGFR3 Hypochondroplasia Dominant Act M, T 
FGFR3 Muenke Syndrome Dominant Act M, T 
FGFR3 Thanatophoric Dysplasia Type 1 Dominant Act M, T 
FGFR3 Thanatophoric Dysplasia Type 2 Dominant Act M, T 
FGFR3 Camptodactyly Tall Stature And 
Hearing Loss Syndrome 
Dominant ? M, T 
FGFR3 Lacrimo-Auriculo-Dento-Digital Syndrome Dominant ? M, T 
FLT4 Milroy Disease Dominant Mis 0 
FOXP1 Mental Retardation With Language 
Impairment And Autistic Features 
Dominant LoF T 
GATA2 Emberger Syndrome Dominant LoF M 
GNAS ACTH-Independent Macronodular 
Adrenal Hyperplasia 
Mosaic Act M 
GNAS Gnas Hyperfunction Dominant Act M 
GNAS Albright Hereditary Osteodystrophy Dominant LoF M 
GRIN2A Epilepsy With Neurodevelopmental Defects Dominant LoF M, N, F, O 
GRIN2A Landau-Kleffner Syndrome Dominant LoF M, N, F, O 
HOXA13 Hand-Foot-Genital Syndrome Dominant LoF T 
HOXD13 Brachydactyly Type D Dominant ? T 
HOXD13 Brachydactyly Type E Dominant ? T 
HOXD13 Brachydactyly-Syndactyly Syndrome Dominant ? T 
HOXD13 Syndactyly Type 5 Dominant ? T 
HOXD13 Synpolydactyly 1 Dominant ? T 
HOXD13 VACTERL Association Dominant ? T 
HRAS Congenital Myopathy With Excess Of 
Muscle Spindles 
Dominant Act M 
HRAS Costello Syndrome Dominant Act M 
KAT6A Mental Retardation, Autosomal 
Dominant 32 
Dominant LoF T 
KAT6B Genitopatellar Syndrome Dominant DN T 
KAT6B Blepharophimosis/Intellectual 
Disability Phenotype (Noonan-Like) 
Dominant LoF T 
KDM5C Mental Retardation Syndromic X-
Linked JARID1C-Related 
XLR LoF N, F, S, M 
KDM6A Kabuki Syndrome 2 XLD LoF D, N, F, S 
KIT Human Piebaldism Dominant LoF M, O 
KMT2A Wiedemann-Steiner Syndrome Dominant LoF T, O 
KMT2D Kabuki Syndrome Dominant LoF N, F, M 
KRAS Cardiofaciocutaneous Syndrome Dominant Act M 
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Gene Developmental phenotype 
Type of 
inheritance 
Germline 
mut. Somatic mut. 
KRAS Noonan Syndrome Type 3 Dominant Act M 
LMNA Hutchinson-Gilford Progeria Syndrome Dominant Act T 
LMNA Lethal Tight Skin Contracture 
Syndrome 
Dominant Act T 
LMNA Emery-Dreifuss Muscular Dystrophy Type 2 Dominant LoF T 
LMNA Cardiomyopathy Dilated Type 1A Dominant ? T 
LMNA Cardiomyopathy Dilated With 
Hypergonadotropic Hypogonadism 
Dominant ? T 
LMNA Familial Partial Lipodystrophy Type 2 Dominant ? T 
LMNA Heart-Hand Syndrome Slovenian Type Dominant ? T 
LMNA Limb-Girdle Muscular Dystrophy Type 1B Dominant ? T 
LMNA Mandibuloacral Dysplasia With Type A 
Lipodystrophy 
Dominant ? T 
LMNA Muscular Dystrophy Congenital LMNA-Related Dominant ? T 
MAF Cataract, Deafness, Intellectual Disability, Seizures, And A Down Syndrome-Like Facies Dominant Mis T 
MAF Cataract Congenital Cerulean Type 4 Dominant ? T 
MAF Cataract Pulverulent Juvenile-Onset MAF-Related Dominant ? T 
MAFB Multicentric Carpotarsal Osteolysis Syndrome Dominant Act T 
MAP2K1 Cardiofaciocutaneous Syndrome Dominant Act M 
MAP2K2 Cardiofaciocutaneous Syndrome Dominant Act M 
MAP3K1 46XY Sex Reversal 6 Dominant LoF N, F, M, O, S 
MED12 Lujan-Fryns Syndrome XLR ? M, S, O 
MED12 Opitz-Kaveggia Syndrome XLR ? M, S, O 
MITF Waardenburg Syndrome Type 2 With 
Ocular Albinism 
Dominant LoF A 
MITF Waardenburg Syndrome Type 2A Dominant LoF A 
MITF Tietz Syndrome Dominant ? A 
MNX1 Currarino Syndrome Dominant LoF T 
MYCN Feingold Syndrome Type 1 Dominant LoF A 
MYH9 Macrothrombocytopenia With 
Progressive Sensorineural Deafness 
Dominant LoF T 
MYH9 May-Hegglin Anomaly Dominant LoF T 
MYH9 Sebastian Syndrome Dominant LoF T 
MYH9 Deafness Autosomal Dominant Type 17 Dominant ? T 
MYH9 Epstein Syndrome Dominant ? T 
MYH9 Fechtner Syndrome Dominant ? T 
NF1 Familial Spinal Neurofibromatosis Dominant LoF D, M, N, F, S, O 
NF1 Neurofibromatosis Type 1 Dominant LoF D, M, N, F, S, O 
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Gene Developmental phenotype 
Type of 
inheritance 
Germline 
mut. Somatic mut. 
NF1 Neurofibromatosis-Noonan Syndrome Dominant LoF D, M, N, F, S, O 
NF1 Watson Syndrome Dominant LoF D, M, N, F, S, O 
NKX2-1 Benign Hereditary Chorea Dominant LoF A 
NKX2-1 Choreoathetosis, Hypothyroidism, 
And Neonatal Respiratory Distress 
Dominant LoF A 
NOTCH2 Hajdu-Cheney Syndrome Dominant Act N, F, M 
NRAS Noonan Syndrome Type 6 Dominant Act M 
NSD1 Sotos Syndrome Dominant LoF T 
NSD1 Weaver Syndrome Dominant LoF T 
NSD1 Beckwith-Wiedemann Syndrome Dominant ? T 
PAX3 Craniofacial-Deafness-Hand 
Syndrome 
Dominant LoF T 
PAX3 Waardenburg Syndrome, Type 1 Dominant LoF T 
PAX8 Congenital Hypothyroidism Non-Goitrous Type 2 Dominant LoF T 
PDGFRB Familial Infantile Myofibromatosis Dominant Act T 
PDGFRB Premature Aging Syndrome, Penttinen Type Dominant Act T 
PHF6 Boerjeson-Forssman-Lehmann Syndrome XLR LoF F, N, S, M 
PHOX2B 
Central Hypoventilation Syndrome, 
Congenital, With Or Without 
Hirschsprung Disease 
Dominant ? M, F 
PHOX2B Neuroblastoma With Hirschsprung Disease Dominant ? M, F 
PIK3CA 
Cloves: Congenital Lipomatous 
Overgrowth, Vascular Malformations, 
And Epidermal Nevi 
Mosaic Act M 
PIK3CA Hemimegalencephaly PIK3CA Mosaic Act M 
PIK3CA 
Megalencephaly-Capillary 
Malformation-Polymicrogyria 
Syndrome, Somatic 3 
Mosaic Act M 
PIK3R1 Short Syndrome Dominant Mis M, F, O 
PPM1D PPM1D Syndrome Dominant LoF A, M, N, F 
PPP2R1A Intellectual Disability Dominant DN M 
PRKAR1A Acrodysostosis Dominant Act T, M, N, F, S 
PTCH1 Basal Cell Nevus Syndrome Dominant LoF M, N, F, S 
PTCH1 Holoprosencephaly-7 Dominant ? M, N, F, S 
PTEN Bannayan-Zonana Syndrome Dominant LoF D, M, N, F, S 
PTEN Cowden Disease Dominant LoF D, M, N, F, S 
PTEN Proteus Syndrome Mosaic LoF D, M, N, F, S 
PTEN Macrocephaly/Autism Syndrome Dominant ? D, M, N, F, S 
PTEN VACTERL Association With Hydrocephalus Dominant ? D, M, N, F, S 
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Gene Developmental phenotype 
Type of 
inheritance 
Germline 
mut. Somatic mut. 
PTPN11 Noonan Syndrome 1 Dominant Act M 
PTPN11 Leopard Syndrome Type 1 Dominant Mis M 
RAD21 Cohesinopathy Dominant LoF M, N, F 
RAF1 Noonan Syndrome 5 Dominant Act T 
RET Multiple Endocrine Neoplasia IIB Dominant Act T, M, N, F 
SET Set Syndrome Dominant LoF T 
SETBP1 Schinzel-Giedion Midface Retraction Syndrome Dominant Act M, T 
SETBP1 Developmental And Expressive Language Delay Dominant LoF M, T 
SMAD3 SMAD3-Related Loeys-Dietz 
Syndrome 
Dominant LoF M 
SMAD4 Myhre Syndrome Dominant Act D, M, N, F 
SMAD4 Juvenile Polyposis Syndrome Dominant LoF D, M, N, F 
SMAD4 Juvenile Polyposis/Hereditary Hemorrhagic Telangiectasia Syndrome Dominant LoF D, M, N, F 
SMARCA4 Coffin Siris Dominant LoF F, N, M, S 
SMARCA4 Rhabdoid Tumor Predisposition Syndrome 2 Dominant LoF F, N, M, S 
SMARCB1 Rhabdoid Predisposition Syndrome 1 Dominant LoF D, N, F, S 
SMO Curry-Jones Syndrome Mosaic Act M 
SOX2 AEG Syndrome Dominant LoF A 
SOX2 Microphthalmia Syndromic Type 3 Dominant LoF A 
TBX3 Ulnar-Mammary Syndrome Dominant LoF M, N, F, O 
TCF12 Coronal Craniosynostosis Dominant LoF T 
TGFBR2 Loeys-Dietz Syndrome Dominant LoF M, F, N 
TGFBR2 TGFBR2-Related Loeys-Dietz Syndrome Dominant LoF M, F, N 
TP63 Ectrodactyly-Ectodermal Dysplasia-
Cleft Lip/Palate Syndrome Type 3 
Dominant LoF M, N, T 
TP63 Acro-Dermato-Ungual-Lacrimal-Tooth Syndrome Dominant ? M, N, T 
TP63 Ankyloblepharon-Ectodermal Defects-
Cleft Lip/Palate 
Dominant ? M, N, T 
TP63 Ectodermal Dysplasia Rapp-Hodgkin Type Dominant ? M, N, T 
TP63 Limb-Mammary Syndrome Dominant ? M, N, T 
TP63 Non-Syndromic Orofacial Cleft Type 8 Dominant ? M, N, T 
TP63 Split-Hand/Foot Malformation Type 4 Dominant ? M, N, T 
TSC1 Tuberous Sclerosis Type 1 Dominant LoF D, M, N, F, S 
TSC2 Lymphangioleiomyomatosis Dominant LoF D, M, N, F, S 
TSC2 Tuberous Sclerosis Type 2 Dominant LoF D, M, N, F, S 
TSHR Hyperthyroidism, Familial Gestational Dominant Act M 
WT1 Denys-Drash Syndrome Dominant DN D, M, N, F, S, T 
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Summary of this thesis 
 
All the information needed for the development, growth, life and 
reproduction of a human being is encoded in the human genome and is 
transmitted from parents to their offspring. Differences in DNA sequence among 
individuals are called genetic variants and most genetic variants in the genome 
of any individual were inherited from his or her parents. However, a fraction of 
these variants only occurred for the first time in that individual and are therefore 
considered to be new or de novo mutations. Like genetic mutations in general, 
de novo mutations can be benign, neutral or damaging and they play an 
important role in evolution, diversity and disease in humans. In this thesis, I study 
the time at which novel mutations arise throughout human life and examine the 
effect of timing on the consequences of novel mutations.  
 
The mechanisms underlying the occurrence and genomic distribution of 
new mutations are reviewed in detail in Chapter 2. Novel mutations arise when 
DNA damage fails to be repaired, which can happen at any time and in any cell in 
the organism. As a result, novel mutations arise throughout human life, from 
mutations occurring in the sperm or egg cell during gametogenesis, giving rise to 
de novo mutations in the germline of the offspring, to mutations in somatic 
tissues during adult life. 
 
Novel mutations are an important cause of human disease, particularly 
sporadic human phenotypes and severe disorders affecting fitness or fertility, 
such as severe pediatric disease. Chapter 3 presents the identification of germline 
de novo mutations in THRA as the cause of a novel thyroid hormone resistance 
syndrome accompanied by developmental defects and alterations in growth. The 
results from this study illustrate the role that de novo mutations play in sporadic 
and severe pediatric disorders. Furthermore, the identification of the disease-
causing mutations in this sporadic phenotype was enabled by exome sequencing 
and comparative genetic analysis of two unrelated individuals. This study 
highlights the importance of the development of NGS to our understanding of 
the role of de novo mutations in human disease, particularly sporadic 
developmental disorders. 
 
De novo mutations most often arise during gametogenesis or prior to the 
first cell division of the zygote, but they can occur postzygotically and lead to 
mosaicism. Indeed, a number of human developmental disorders are caused by 
de novo mutations arising postzygotically and leading to genetic mosaicism. In 
Chapter 4, we use different NGS techniques to examine a set of seemingly 
germline de novo mutations and determine the contribution of postzygotic 
events to de novo mutations. In this study, we identified that 7% of de novo 
mutations which seemed to be present as constitutive events in the offspring 
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were in fact present as mosaic mutations suggesting that they had occurred 
postzygotically. Furthermore, several de novo mutations identified in individuals 
in our cohort were found back in blood in one of the parents as low level mosaic 
mutations, supporting that these mutations were not de novo in the offspring but 
had occurred during embryonic development in one of the parents. Together, 
these results indicate that the occurrence of de novo mutations is not limited to 
gametogenesis but that an important proportion of de novo mutations arise 
postzygotically. Genetic mosaicism resulting from mutations occurring during 
embryogenesis is common and, depending on their timing, postzygotic 
mutations can be transmitted to the next generation. This suggests that our 
genomes may be much more dynamic than previously considered. 
The occurrence of new mutations in humans is not limited to the early 
stages of life and mutations continue to arise postnatally and during adult life. In 
Chapter 5, we investigate the timing of novel mutations in somatic tissues 
throughout life by examining somatic mutations during human hematopoiesis. 
In this study, we focus on mutations leading to positive selection of 
hematopoietic stem cells and driving clonal expansion. These mutations are 
known as clonal hematopoiesis driver mutations and are often present as low-
level mosaic mutations in blood. In order to detect these somatic mutations, we 
developed an assay combining high-throughput and ultra-sensitive sequencing 
to screen the blood of individuals between 20 and 69 years of age. Clonal 
hematopoiesis driver mutations were detected in blood of 3% of individuals 
between 20 and 30 years of age. Furthermore, we observed an exponential 
increase in the frequency in clonal hematopoiesis driver mutations in blood with 
age, surpassing 20% of individuals between 60 and 69 years of age. The findings 
from this study support that the occurrence of somatic mutations in stem cells 
followed by the positive selection and clonal evolution of mutant stems cells is a 
universal mechanism occurring throughout human life. 
 
The timing of a new mutation influences the consequences of this 
mutation. For instance, the same mutation can lead to completely different 
phenotypes, depending on the time at which it arises, as shown in Chapter 6. This 
chapter explores the functional consequences of overlapping germline and 
somatic mutations in SETBP1, leading to Schinzel-Giedion syndrome and to 
myeloid leukemia, respectively. In this study, we identified parallelisms between 
the downstream effects of overlapping germline and somatic mutations in 
SETBP1, including biochemical and cellular consequences. Furthermore, despite 
the overlap between germline and somatic SETBP1 mutations in Schinzel-Giedion 
syndrome and myeloid leukemia, the mutation spectrum is different in both 
conditions. This stems from the fact that although SETBP1 mutations with weak 
functional consequences are observed frequently as germline events in Schinzel-
Giedion syndrome, they are rarely identified as somatic events in myeloid 
leukemia. This suggests that different functional thresholds exist for germline and 
somatic mutations with malignancy being driven strictly by strongly disruptive 
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mutations in SETBP1, while prenatal development is disrupted in Schinzel-
Giedion syndrome by strong or mild mutations in this gene. 
 
Finally, Chapter 7 offers an in-depth discussion on the findings of this 
thesis, including the use of NGS to detect and study both de novo germline and 
somatic mutations and the role of the timing of novel mutations in shaping their 
consequences.  
 
The work presented in this thesis shows that mutations arise constantly, 
between one generation and the next but also throughout life. This continuous 
occurrence of mutations leads to extraordinary genetic diversity between 
individuals but is also at the origin of the existence of genetically different 
populations of cells within a single human being. While the occurrence of novel 
mutations represents an important biological phenomenon in humans with a role 
on prenatal development, physiology and evolution, novel mutations also 
contribute to different forms of human disease ranging from rare and severe 
developmental disorders to adult-onset diseases such as cancer. In the last few 
years, NGS has played a central role in the identification and study of novel 
mutations, driving research in human genetics and quickly translating results into 
clinical practice. The work in this thesis supports that in addition to the detection 
of mutations, NGS can be used as a tool to identify the timing of mutations in 
order to include the dimension of time in the interpretation of mutations and 
their possible consequences. For instance, de novo mutations have different 
recurrence risks depending on the exact timing at which they occurred, which can 
be determined by meticulous analysis with NGS methods. Furthermore, the 
timing of a mutation can also shape the resulting phenotype, as the same 
mutation can be involved in different disorders depending on its timing. Future 
work focusing on the role of timing of somatic and germline mutations will 
provide us with a better understanding of the effect of the expression of a 
mutation in the dynamic context of a cell, a tissue and a whole organism. 
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Nederlandse samenvatting 
 
Alle informatie die nodig is voor de ontwikkeling, groei, het leven en de 
voortplanting van een mens is vastgelegd in het menselijk genoom en wordt 
doorgegeven door ouders aan hun nageslacht. Verschillen in het DNA tussen 
individuen worden genetische varianten genoemd. Alhoewel de meeste 
genetische varianten in het genoom van een individu overerft zijn van zijn of haar 
ouders, ontstaat een klein aantal varianten voor de eerste keer in het individu, en 
deze worden daarom beschouwd als nieuwe varianten, ook wel de novo mutaties 
genoemd. Net als genetisch varianten kunnen de novo varianten goedaardig, 
neutraal of schadelijk zijn, en spelen ze een rol in evolutie, diversiteit en ziekte in 
de mens. In dit proefschrift bestudeer ik wanneer deze de novo mutaties ontstaan 
gedurende de menselijk levensloop en onderzoek ik het effect van het 
ontstaansmoment op de consequenties van deze nieuwe mutaties. 
De mechanismen die ten grondslag liggen aan het ontstaan en de 
genomisch spreiding van nieuwe mutaties worden in detail beschouwd in 
hoofdstuk 2. Nieuwe mutaties kunnen ontstaan wanneer beschadigd DNA niet 
goed gerepareerd wordt, iets wat op ieder moment kan voorkomen, in iedere cel 
van het organisme. Het gevolg hiervan is dat nieuwe mutaties gedurende het 
gehele menselijke leven kunnen ontstaan, beginnend bij de ontwikkeling van de 
sperma of eicel, maar ook in somatische weefsels gedurende het volwassen leven. 
Nieuw ontstane mutaties zijn een belangrijke oorzaak van menselijke 
ziektes, met name sporadische humane fenotypes en ernstige aandoeningen met 
een effect op “fitness” of vruchtbaarheid zoals ernstige aangeboren 
aandoeningen. Hoofdstuk 3 toont dat kiembaan de novo mutaties in het gen 
THRA de oorzaak zijn van een nieuw schildklier-hormoon-resistentie syndroom 
dat gepaard gaat met ontwikkelingsdefecten en groeiveranderingen. De 
resultaten van deze studie illustreren de bijdrage van de novo mutaties aan 
sporadische en ernstige kindergeneeskundige aandoeningen. Bovendien werden 
deze bevindingen gedaan middels “exome sequencing” en het vergelijken van de 
genetische profielen van twee niet-gerelateerde individuen. Deze studie 
onderstreept het belang van NGS voor de ontwikkeling van ons begrip van de rol 
van de novo mutaties in menselijke ziektes in het algemeen, en voor sporadische 
ontwikkelingsstoornissen in het bijzonder. 
De novo mutaties ontstaan meestal gedurende de gametogenese of voor 
de eerste celdeling van de zygoot, maar kunnen ook post-zygotisch ontstaan en 
leiden tot mozaïcisme. Inderdaad wordt een aantal humane ontwikkelingsziekten 
veroorzaakt door de novo mutaties die post-zygotisch ontstaan en resulteren in 
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genetisch mozaïcisme. In hoofdstuk 4 gebruiken we verschillende NGS 
technieken om een aantal ogenschijnlijke de novo mutaties te onderzoeken, en 
te bepalen wat het aandeel is van post-zygotische gebeurtenissen hierin. In deze 
studie vonden we dat 7% van de novo mutaties die ogenschijnlijk aanwezig 
waren als constitutieve gebeurtenissen in het nageslacht, feitelijk aanwezig 
waren als mozaïeke mutaties, suggererend dat deze post-zygotisch waren 
ontstaan. Bovendien was het zo dat een aantal de novo mutaties die we vonden 
in individuen in ons cohort, ook werd teruggevonden in het bloed van de ouders 
als laaggradige mozaïeke mutaties. Dit bevestigde dat deze mutaties niet nieuw 
ontstaan waren in het nageslacht, maar waren ontstaan gedurende de 
embryonale ontwikkeling in één van de ouders. Samenvattend geven deze 
resultaten aan dat het ontstaan van de novo mutaties niet beperkt is tot de 
gametogenese maar dat een belangrijk deel van de novo mutaties post-zygotisch 
ontstaat. Genetisch mozaïcisme dat ontstaat door mutaties in gedurende de 
embryogenese komt veel voor en kan afhankelijk van het moment van ontstaan 
doorgegeven worden aan het nageslacht. Dit suggereert dat onze genomen veel 
dynamischer zijn dan eerder gedacht. 
Het ontstaan van nieuwe mutaties in mensen is niet beperkt tot de vroege 
stadia van het leven and mutaties ontstaan ook na de geboorte en gedurende het 
volwassen leven. In hoofdstuk 5 onderzoeken we de timing van nieuwe mutaties 
in weefsels gedurende het leven door middel van het onderzoeken van 
somatische mutaties in menselijke hematopoiese. In dit onderzoek richten we 
onze aandacht op mutaties die leiden tot positieve selectie van hematopoiese 
stamcellen die de uitbreiding van klonen met bepaalde mutaties voortdrijven. 
Deze mutaties staan bekend als klonale hematopoiese sturende mutaties en zijn 
vaak aanwezig als laaggradige mozaïeke mutaties in bloed. Om deze somatische 
mutaties te kunnen detecteren ontwikkelden we een test die twee zaken 
combineerde: toepasbaarheid op grote hoeveelheden mutaties en zeer grote 
gevoeligheid. Hiermee testen we het bloed van individuen met leeftijden tussen 
de 20 en 69 jaar op genetische veranderingen. Klonale hematopoiese sturende 
mutaties werden gevonden in het bloed van 3% van de individuen met een 
leeftijd tussen 20 en 30 jaar. Bovendien vonden we een exponentiële toename 
van de frequentie van klonale hematopoiese sturende mutaties in het bloed van 
meer dan 20% van de individuen met een leeftijd tussen de 60 en 69 jaar. De 
bevindingen van dit onderzoek ondersteunen het idee dat het ontstaan van 
somatische mutaties in stamcellen, zoals hematopoiese  stamcellen, samen met 
positieve selectie en de klonale evolutie van stamcellen met mutaties, een 
universeel mechanisme is dat plaatsvindt gedurende het menselijk leven. 
Het moment waarop nieuwe mutaties ontstaan is van invloed op de 
gevolgen die deze mutaties hebben. Dezelfde mutaties kunnen bijvoorbeeld 
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leiden tot volledig verschillende fenotypes, afhankelijk van het moment waarop 
de mutatie ontstaat, zoals aangetoond in hoofdstuk 6. Dit hoofdstuk verkent de 
functionele gevolgen van overeenkomende kiembaan en somatische mutaties in 
het gen SETBP1, resulterend in Schinzel-Giedion syndroom, een zeldzame 
ontwikkelingsaandoening en myeloïde leukemie, respectievelijk. In dit onderzoek 
vonden we overeenkomsten tussen de uiteindelijke effecten van identieke 
kiembaan en somatische mutaties in SETBP1, inclusief biochemische en cellulaire 
consequenties. Bovendien bleek het mutatie spectrum verschillend tussen beide 
aandoeningen, ondanks dat er overeenkomstige mutaties zijn tussen kiembaan 
en somatische SETBP1 mutaties in Schinzel-Giedion syndroom en myeloïde 
leukemie. Dit komt voort uit het feit dat ondanks dat SETBP1 mutaties met 
geringe functionele effecten veel worden waargenomen als kiembaan 
gebeurtenissen in Schinzel-Giedion syndroom, ze maar zelden worden gevonden 
als somatische gebeurtenissen in myeloïde leukemie. Dit suggereert dat er 
verschillende functionele grenswaarden bestaan voor kiembaan en somatische 
mutaties waarbij kwaadaardige tumoren uitsluitend worden aangedreven door 
zeer verstorende mutaties in SETBP1, terwijl prenatale ontwikkeling wordt 
verstoord in Schinzel-Giedion syndroom door sterke dan wel milde mutaties in dit 
gen.  
Tot slot, biedt hoofdstuk 7 een gedetailleerde discussie over de 
bevindingen van dit proefschrift, inclusief het gebruik van NGS voor het 
detecteren en bestuderen van de novo kiembaan en somatische mutaties en de 
bijdrage van timing van nieuwe mutaties voor hun consequenties.  
Het werk in dit proefschrift laat zien dat mutaties continue ontstaan, 
tussen generaties maar ook gedurende het leven. Dit continue ontstaan van 
mutaties leidt tot buitengewone genetische diversiteit tussen individuen maar 
staat ook aan de basis van het ontstaan van genetisch verschillende cel populaties 
in een enkele persoon. Alhoewel het ontstaan van nieuwe mutaties een belangrijk 
biologisch proces is in mensen met een belangrijke rol binnen prenatale 
ontwikkeling, fysiologie en evolutie, dragen nieuwe mutaties ook bij aan 
verschillende vormen van humane ziektes, van zeldzame ernstige 
ontwikkelingsaandoeningen tot aandoeningen die op volwassen leeftijd 
optreden zoals kanker. In de afgelopen jaren heeft NGS een centrale rol gespeeld 
in het identificeren en bestuderen van nieuwe mutaties, en heeft daarmee de 
humane genetica en de vertaling van resultaten naar klinische toepasbaarheid 
voortgestuwd. Het werk in dit proefschrift ondersteunt dat naast het identificeren 
van mutaties, NGS ook kan worden gebruikt als een instrument om het moment 
van het ontstaan van mutaties te vinden om zo de dimensie tijd toe te voegen 
aan de interpretatie van mutaties en hun mogelijke gevolgen. De novo mutaties 
hebben bijvoorbeeld een verschillend risico op herhaling, afhankelijk van het 
precieze moment waarop ze zijn ontstaan, wat kan worden vastgesteld door 
nauwkeurige analyse met NGS technieken. Bovendien, heeft het moment van 
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ontstaan van een mutatie ook gevolgen voor het uiteindelijke fenotype omdat 
dezelfde mutatie betrokken kan zijn bij verschillende aandoeningen afhankelijk 
van het ontstaansmoment. Toekomstig werk gericht op de rol en timing van 
somatische en kiembaan mutaties zal ons beter inzicht geven in het effect van de 
uiting van een mutatie in de dynamische context van een cel, een weefsel en een 
volledig organisme.  
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Toda la información necesaria para el desarrollo, crecimiento, vida y 
reproducción de una persona se encuentra codificada en el genoma humano y se 
transmite de padres a hijos. Las diferencias en la secuencia de ADN entre 
individuos se conocen como variantes genéticas. La mayoría de las variantes 
genéticas en el genoma de cualquier persona proviene del genoma de sus padres, 
quienes heredan estas variantes a su descendencia. Sin embargo, una pequeña 
parte de las variantes genéticas de cualquier persona aparecen por primera vez 
en el genoma de este individuo y se consideran por lo tanto mutaciones nuevas, 
llamadas de novo. Al igual que cualquier mutación genética, las mutaciones de 
novo pueden ser benignas, neutrales o dañinas y juegan un papel importante en 
la evolución, diversidad y enfermedad en el ser humano. En esta tesis, he 
estudiado en qué momento a lo largo de la vida humana aparecen nuevas 
mutaciones y qué consecuencias tiene una mutación dependiendo del momento 
en el que aparece. 
 
El Capítulo 2 de esta tesis ofrece una revisión detallada de los 
mecanismos tras la aparición de nuevas mutaciones y su distribución en el 
genoma. Una mutación surge cuando se produce un daño en el ADN que no se 
repara de forma exitosa, lo cual puede suceder en cualquier momento y en 
cualquier célula del organismo. Como resultado, las mutaciones pueden aparecer 
a lo largo de toda la vida humana, desde mutaciones en el espermatozoide o el 
óvulo durante la formación de los gametos dando lugar a mutaciones de novo en 
la línea germinal de la progenie, hasta mutaciones en el tejido somático durante 
la vida adulta. 
 
Las mutaciones nuevas son una causa frecuente de afecciones genéticas 
en el ser humano, en especial de enfermedades genéticas de aparición 
esporádica que causan alteraciones graves que afectan la adaptabilidad de un 
organismo o su fertilidad, como por ejemplo ciertas enfermedades pediátricas. El 
Capítulo 3 de esta tesis es un estudio en el que identificamos mutaciones de novo 
en la línea germinal en el gen THRA como la causa de un síndrome de resistencia 
a la hormona tiroidea caracterizado por alteraciones en el desarrollo y 
crecimiento. Los resultados de este estudio sirven como ejemplo del papel que 
desempeñan las mutaciones de novo en las enfermedades pediátricas severas y 
de aparición esporádica. Identificamos las mutaciones responsables de este 
síndrome de resistencia a la hormona tiroidea por medio de la secuenciación de 
exomas, seguido de un análisis comparativo de variantes genéticas entre dos 
individuos sin parentesco, afectados por esta enfermedad. Este estudio subraya 
la importante contribución del desarrollo de Next Generation Sequencing (NGS) 
a nuestra comprensión del papel de las mutaciones de novo en las enfermedades 
del ser humano. 
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Aunque la mayoría de las veces las mutaciones de novo aparecen durante 
la formación de los gametos o antes de la primera división celular del cigoto, 
también pueden ocurrir después de esta primera división celular, dando lugar a 
mosaicismo genético. De hecho, algunas enfermedades del desarrollo humano 
son causadas exclusivamente por mutaciones de novo postcigóticas. En el 
Capítulo 4, usamos diferentes técnicas de NGS para estudiar un grupo de más de 
cien mutaciones de novo y determinar qué proporción de las cuales corresponde 
a mutaciones de origen postcigótico. Descubrimos que el 7% de las mutaciones 
de novo que aparentaban ser mutaciones de línea germinal, corresponden en 
realidad a mutaciones de origen postcigótico. Además, encontramos varias 
instancias en las que mutaciones identificadas en sujetos de nuestra cohorte 
como mutaciones de novo de línea germinal, fueron posteriormente encontradas 
en ADN extraído de la sangre de uno de los padres. Este hallazgo sugiere que, 
contrario a lo que pensábamos, estas mutaciones no ocurrieron de novo en el 
sujeto estudiado sino antes, durante el desarrollo embrionario del padre en el que 
la mutación fue detectada. En conjunto, nuestros resultados indican que la 
aparición de mutaciones de novo no se limita a la etapa de formación de gametos, 
sino que una porción considerable de las mismas ocurre de forma postcigótica en 
el embrión en desarrollo. Por lo tanto, el mosaicismo es un fenómeno común y, 
en función del momento en el que aparecen, las mutaciones postcigóticas 
pueden transmitirse a la siguiente generación. Estos hallazgos sugieren que 
nuestros genomas serían más dinámicos de lo que se habría considerado 
anteriormente. 
La aparición de nuevas mutaciones no se limita únicamente a los estadios 
más tempranos de vida en el ser humano, sino que pueden seguir apareciendo a 
lo largo de toda la vida. En el Capítulo 5, usamos la hematopoyesis como modelo 
de estudio para investigar cuándo ocurren nuevas mutaciones en tejidos 
somáticos a lo largo de la vida humana. En este capítulo, nos enfocamos a estudiar 
mutaciones que promueven la selección positiva de células madre 
hematopoyéticas, causando así la expansión de clones de células madre 
hematopoyéticas con mutaciones. A las mutaciones que provocan este efecto se 
les conoce como mutaciones causantes de hematopoyesis clonal y su presencia 
se detecta en sangre frecuentemente como bajos niveles de mosaicismo. Para 
poder detectar la presencia de estas mutaciones en sangre, desarrollamos un 
método que combina alto rendimiento con secuenciación ultra-sensible y 
estudiamos individuos entre los 20 y los 69 años de edad. Detectamos mutaciones 
de este tipo en sangre en 3% de la población entre los 20 y 30 años de edad. 
Además, observamos que con la edad se produce un aumento exponencial en la 
frecuencia de estas mutaciones en sangre, llegando a sobrepasar el 20% de la 
población entre 60 y 69 años de edad. Los hallazgos de este estudio sugieren que 
la aparición de mutaciones somáticas en células madre y la subsiguiente selección 
positiva y evolución de clones de células con mutaciones es un mecanismo 
universal que ocurre a lo largo de toda la vida en el ser humano. 
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El momento de aparición de una mutación determina las consecuencias 
que puede llegar a tener esta mutación. Por ejemplo, mutaciones iguales pueden 
dar lugar a fenotipos completamente distintos, en función de cuándo ocurren, 
como mostramos en el Capítulo 6. Este capítulo explora las consecuencias 
funcionales de mutaciones en un gen llamado SETBP1 dependiendo de si ocurren 
como mutaciones en la línea germinal causando el síndrome de Schinzel-Giedion, 
una enfermedad rara del desarrollo, o si ocurren como mutaciones somáticas 
como sucede en la leucemia mieloide. En este estudio identificamos similitudes a 
nivel bioquímico y celular, entre las consecuencias de mutaciones de línea 
germinal y mutaciones somáticas que se sobreponen. Además, a pesar del 
traslape, el espectro de mutaciones es distinto en cada condición. Esto se debe a 
que las mutaciones en SETBP1 que tienen consecuencias funcionales leves, se 
observan con frecuencia en el síndrome de Schinzel-Giedion pero no tan 
frecuentemente en la leucemia mieloide. Las mutaciones que ocurren en la 
leucemia mieloide son casi exclusivamente mutaciones con consecuencias 
funcionales graves, mientras que en el síndrome de Schinzel-Giedion se detectan 
mutaciones con consecuencias funcionales tanto leves como intensas. Esto da pie 
a la posibilidad de que los umbrales de patogenicidad de las mutaciones 
somáticas involucradas en cáncer y de las mutaciones de línea germinal 
involucradas en enfermedades del desarrollo sean diferentes 
 
Finalmente, el Capítulo 7 contiene una discusión detallada de los 
hallazgos de esta tesis, incluyendo el uso de NGS para la detección de mutaciones 
nuevas tanto en la línea germinal como somáticas, así como para estudiar cómo 
el momento de aparición de una mutación influye sobre sus posibles 
consecuencias. 
 
El trabajo presentado en esta tesis muestra que las mutaciones aparecen 
de forma constante entre una generación y la siguiente pero también a lo largo 
de toda la vida. Esta aparición constante de mutaciones está detrás de la 
extraordinaria diversidad genética entre individuos, pero es también el origen de 
la existencia de poblaciones de células genéticamente distintas en una misma 
persona. La aparición de mutaciones nuevas representa un fenómeno biológico 
crucial en el ser humano, con un rol en el desarrollo embrionario, en la fisiología 
y en la evolución. Sin embargo, también contribuye a la aparición de distintas 
formas de enfermedad, incluyendo graves enfermedades congénitas y 
enfermedades de inicio tardío como el cáncer. En los últimos años, el NGS ha 
tenido un papel crucial en la identificación y el estudio de nuevas mutaciones, 
promoviendo el avance de la investigación en el campo de la genética humana y 
permitiendo de forma temprana la traducción de resultados al mundo clínico. El 
trabajo contenido en esta tesis propone que, además de utilizarse para la 
detección de mutaciones, es posible emplear el NGS como una herramienta para 
identificar el momento de aparición de una mutación y así poder incluir la 
dimensión del tiempo en la interpretación de las mutaciones y de sus posibles 
consecuencias. Por ejemplo, el riesgo de recurrencia de las mutaciones de novo 
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difiere en función del momento exacto en el que ocurren, lo cual puede 
detectarse por medio de un análisis meticuloso basado en NGS. Adicionalmente, 
el momento de aparición de una mutación también puede moldear sus 
consecuencias, ya que la misma mutación puede estar involucrada en distintas 
enfermedades en función de su momento de aparición. A futuro, la investigación 
sobre el papel que desempeña el momento de aparición de las mutaciones en la 
línea germinal y de las somáticas, nos proporcionará una mejor comprensión del 
efecto que tienen en el contexto dinámico de una célula, un tejido y un organismo 
completo. 
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Curriculum vitae 
 
Rocío Acuña Hidalgo was born in Buenos Aires, Argentina on February 
14th 1985. Her childhood was spent wandering around the world until her family 
decided to settle in Mexico City, Mexico. After graduating from the Lycée Franco-
Mexicain in 2003, Rocío began her studies in medicine at La Salle University in 
Mexico City. As part of her medical degree, she completed one year of mandatory 
social service performing basic research under the supervision of Dr. Gerardo 
Gamba at the Instituto Nacional de Ciencias Médicas y Nutrición, where she 
characterized the functional consequences of rare mutations in sodium co-
transporters linked to low blood pressure. Rocío received her Medical Degree with 
Honors in 2010 and, shortly after, was awarded a Huygen’s scholarship from the 
Dutch Minister of Education, Culture and Science to study a Master’s in Molecular 
Mechanisms of Disease at Radboud University in Nijmegen, The Netherlands. 
Interested in Next Generation Sequencing, she completed an internship at the 
Department of Human Genetics under the supervision of Joris Veltman and 
Alexander Hoischen where she performed whole exome sequencing to identify 
disease-causing genes in severe developmental disorders and prenatal lethal 
phenotypes. She was subsequently awarded a personal grant from the Radboud 
University Medical Centre (UMC) to pursue a PhD and, after receiving her Master’s 
degree cum laude, Rocío joined Joris Veltman’s group in 2012. Here, she worked 
on several projects studying the timing of novel mutations and the genetic 
overlap between developmental disorders and cancer. Rocío took part in the first 
edition of the Radboud DaVinci Challenge, a talent development programme 
from Radboud UMC. In 2015, Rocío visited Jay Shendure’s research group at the 
University of Washington in Seattle to learn Saturation Genome Editing, a novel 
technique for massive parallel mutagenesis. For this, she was awarded a Frye 
stipend, a travel grant for promising female scientists. Rocío received the Young 
Investigator Award for Outstanding Science at the European Society for Human 
Genetics conference in 2016, after which she completed her PhD the following 
year. 
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RIMLS portfolio 
Activity ECs Year(s) 
Courses & Workshops 
Graduate course (Radboud Institute for Molecular Life Sciences, 
RIMLS) 
Academic writing (Radboud Unversity) 
Technical forums and workshops (RIMLS) 
 
 
 
2 
3 
0.9 
 
 
2013 
2013-14 
2013-16 
Seminars & lectures 
Seminars and lectures (RIMLS) 
Seminars and lectures (Washington University, Seattle, WA, USA) 
 
 
3.7 
0.3 
 
2012-17 
2015 
National congresses  
New Frontiers in Genetics – Nijmegen, NL 
Rolduc Genetica retraite* – Kerkrade, NL 
New Frontiers in synthetic life – Nijmegen, NL 
Rolduc Genetica retraite** – Kerkrade, NL 
RIMLS PhD retreat** – Wageningen, NL 
New Frontiers in regenerative medicine – Nijmegen, NL 
RIMLS PhD retreat** – Veldhoven, NL 
RIMLS PhD retreat* – Veldhoven, NL 
 
International congresses  
European Society for Human Genetics – Paris, France 
European Society for Human Genetics** – Milan, Italy 
Genomics of Rare Disorders* - Hinxton, UK 
Rare Diseases, crossing borders together§ - Białobrzegi, Poland 
American Society for Human Genetics* – Baltimore, USA 
European Society for Human Genetics* – Barcelona, Spain 
American Society for Human Genetics** - Vancouver, Canada 
European Society for Human Genetics* – Copenhaguen, 
Denmark 
 
 
0.5 
0.75 
0.5 
0.75 
0.75 
0.5 
0.75 
0.75 
 
 
1 
1.5 
1.25 
1.5 
1.75 
1.75 
1.5 
 
1.75 
 
2012 
2013 
2013 
2014 
2014 
2014 
2015 
2016 
 
 
2014 
2015 
2015 
2015 
2015 
2016 
2016 
 
2017 
 
Student supervision 
Nehir Kurtas –Master’s in Molecular mechanisms of disease 
Hilal Sengül– Master’s in Molecular mechanisms of disease 
 
 
2 
2 
 
2014 
2016 
Other activities 
Literature discussion (RIMLS) 
Literature discussion (Washington University, Seattle, WA, USA) 
Member of the RIMLS PhD committee 
Chair of Genomic Disorders meeting 
 
 
3.5 
0.5 
1 
2 
 
2012-16 
2015 
2013-15 
2014-15 
Total 38.15 
 
* oral presentation; ** poster presentation; § invited presentation
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We shall not cease from exploration 
And the end of all our exploring 
Will be to arrive where we started  
And know the place for the first time. 
T.S. Elliot 

